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In patients undergoing ruptured and non-ruptured AAA repair, major cardiac events,
multiple organ failure and haemorrhage are responsible for the majority of the morbidity
and mortality.
Hypothesis
Deranged coagulation, fibrinolysis and endothelial activation contribute to the
thrombotic and haemorrhagic complications associated with AAA repair.
Aims
1. To determine the true hospital-based and overall community-based mortality rate for
ruptured AAA within the catchment area served by a regional vascular surgical unit.
2. To examine coagulation, fibrinolysis and endothelial activation in patients undergoing
ruptured and non-ruptured AAA repair.
3. To examine the relationship between coagulation, fibrinolysis and endothelial
activation and morbidity and mortality in these patients.
4. To investigate possible pathogenetic mechanisms for haemostatic derangement.
Methods and Results
A retrospective study identified 741 patients with ruptured AAA admitted to a regional
vascular unit over a 14-year period. Of these, 616 patients underwent attempted repair
with an operative mortality rate of 37%. The 'intention to treat' mortality rate was 42%.
During the study period, a greater proportion of patients underwent attempted repair
11
with an associated increase in operative mortality rate but no change in overall mortality.
Cardiac events, renal and respiratory failure, haemorrhage and coagulopathy, limb
ischaemia, stroke and pulmonary embolism were the major factors contributing to peri¬
operative mortality.
Of 972 patients diagnosed with ruptured AAA within the catchment area of a regional
vascular unit over a 7-year period, only 39% of patients were admitted to the regional
unit. Overall only 35% of patients underwent operation, 90% of operations being
performed in the regional unit. The overall community-based mortality rate was 79%,
similar to that where centralisation of vascular services has not occurred.
Markers of coagulation and fibrinolysis were examined in 10 patients undergoing repair
of ruptured and nine patients undergoing repair of asymptomatic non-ruptured AAA. All
patients survived to at least 24 hours after operation. Ruptured AAA repair was
associated with peri-operative thrombin generation and inhibition of systemic
fibrinolysis. Prolonged duration of symptoms before admission was associated with
increased thrombin generation; and increased operative blood loss was associated with
reduced fibrinogen and platelet count, and prolonged clotting times. In patients
undergoing non-ruptured AAA repair, the majority exhibited increased peri-operative
thrombin generation and a proportion demonstrated increased systemic fibrinolysis.
Increased operative blood loss and prolonged aortic clamp times were associated with
reduced fibrinogen and platelet count, prolonged clotting times and inhibition of
systemic fibrinolysis.
Haemostatic markers were examined pre-operatively in 22 patients with asymptomatic,
seven patients with acutely symptomatic and 37 patients with ruptured AAA. The study
confirmed the above findings. Haemostatic markers were not significantly different
between normotensive and hypotensive patients with rupture. Acutely symptomatic AAA
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was associated with reduced thrombin generation and increased systemic fibrinolysis
compared with rupture. There were significant differences in haemostatic markers
between symptomatic AAA and normotensive patients with ruptured AAA, such that
elevated PAI activity was more accurate than previous experience with emergency
computed tomography.
The endothelial marker, von Willebrand Factor, and platelet count were examined in 20
patients undergoing repair of ruptured and 10 patients undergoing repair of
asymptomatic AAA. Endothelial activation was present pre-operatively in 60%, and
post-operatively in almost 100% of both groups of patients. There was a significant
positive association between peri-operative vWF levels and platelet count in both
groups. In ruptured AAA, increased operative blood loss was associated with reduced
intra-operative vWF levels. In non-ruptured AAA, prolonged aortic clamp time was
associated with reduced intra-operative vWF levels and platelet count.
Eight patients with ruptured AAA who developed peri-operative coagulopathy and
haemorrhage were studied. All patients had increased thrombin generation but, unlike
those who survived to 24 hours, there was evidence of increased systemic fibrinolysis on
admission and/or before aortic declamping in five patients, all of whom died, four
within the first 24 hours after surgery.
The relationship between haemostasis and myocardial injury was examined in 10
patients undergoing ruptured AAA repair and nine patients undergoing repair of
asymptomatic AAA. Cardiac troponin I levels demonstrated peri-operative myocardial
injury in 80% of patients with ruptured and 33% with non-ruptured AAA. In ruptured
AAA, increased intra-operative inhibition of systemic fibrinolysis was associated with
increased post-operative cardiac troponin I levels.
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Markers of haemostasis and the endothelial vasopressor agent, endothelin, were
examined in 14 patients undergoing ruptured AAA repair. Patients who developed acute
renal failure and fatal organ dysfunction had significantly lower peri-operative
endothelin levels. Increased peri-operative endothelin levels were associated with
reduced thrombin generation.
Markers of haemostasis, endothelial activation and soluble TNF receptors were
examined in 16 patients undergoing repair of ruptured and 10 patients undergoing repair
of asymptomatic AAA. Ruptured AAA repair was associated with elevated levels of
soluble TNF receptors, and elevated levels during early reperfusion were associated with
increased post-operative mortality. Increased soluble TNF receptors were associated
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Outcome of ruptured AAA
In the UK, infrarenal AAA greater than 4cm in diameter is present in 2.3% ofmen aged
65 to 74 years (1), and aneurysm rupture is responsible for 1.7% of all deaths in this
group (2). The natural history of aortic aneurysms is that they will rupture unless the
patient dies from another cause or the aneurysm is repaired. Once rupture has occurred,
death inevitably follows unless the aneurysm is successfully repaired.
The true mortality rate for ruptured AAA in hospital-based studies varies considerably
and results are often difficult to interpret. Many published series, for example, do not
report patients who survive to reach the hospital only to be denied repair, or who
succumb during transfer from the resuscitation room to the operating theatre (3).
Furthermore, many series, particularly those from North America, describe small
numbers of highly selected patients operated upon over long time periods. For example,
in a 26-year period, Crawford's group in Houston (4) operated upon 60 patients with
ruptured AAA achieving an impressive 30-day mortality rate of 23%. Lawrie et al (5)
and Cooley and Carmichael (6) are responsible for the lowest published operative
mortality rates for ruptured AAA repair; respectively, 15% in 61 patients over a 14-year
period, and 21% in 75 patients over a 10-year period. While there are several large
multicentre studies reporting operative mortality rates of between 38% and 64% (7-11),
there are few reports from single centres which describe experience with more than 100
patients (3,12-23) (Table 1.1).
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TABLE 1.1
Single centre experiences with more than 100 patients undergoing ruptured AAA repair.
Author Study period Number of patients Operative
undergoing operation mortality rate
DeBakey (12) 1952 - 1963 117 34%
Shumacker (20) 1953 - 1972 158 55%
Hildebrand (21) 1955 - 1973 131 51%
DiGiovanni (22) 1953 - 1974 107 68%
Gaylis (23) 1963 - 1977 105 58%
Wakefield (13) 1964- 1980 116 52%
Fielding (14) 1960- 1981 198 43%
Jenkins (15) 1974- 1984 174 33%
Shackleton (16) 1975 - 1985 106 41%
Johansen (17) 1980 - 1989 180 69%
Gloviczki (3) 1980 - 1989 214 45%
McCready (18) 1980 - 1989 208 49%
Nasim (19) 1979 - 1991 317 58%
2131 50%
21
Population studies show that a significant proportion of patients with rupture will either
not survive to reach hospital or will not undergo attempted repair, such that the overall
community-based mortality rate is between 79% and 94% (24-29).
It is widely believed that surgical and anaesthetic sub-specialisation leads to better patient
outcomes. As a result of clinical, political and economic factors, there is an increasing
tendency in the UK to centralise vascular surgical services within large regional vascular
units. The effect of such centralisation of vascular surgical services on individual patient
outcome and the overall prognosis from ruptured AAA remains unknown.
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1.2
Complications of ruptured AAA repair
Cardiac events, respiratory failure and renal failure are responsible for the majority of
the morbidity and mortality associated with ruptured AAA repair.
Myocardial infarction
Complications of coronary artery disease are the most common causes of early mortality
in vascular surgical patients. In patients operated for rupture, MI occurs in 6-24%
(3,14,15,30) with a mortality rate of 60-100% (3,10,14,15,30). Myocardial injury is
discussed in more detail in section 1.8.
Respiratory failure
This is reported in 25-48% of patients operated for rupture (3,13,14,23) with an
associated mortality rate of 34-70% (3,14). Patients at increased risk include the elderly,
cigarette smokers and those with chronic obstructive airways disease. Respiratory
complications are more frequent in association with emergency procedures, prolonged
general anaesthesia, thoracic and upper abdominal incisions, prolonged peri-operative
whole body hypoperfusion and massive blood transfusion.
There are several pathophysiological processes which may contribute to peri-operative
respiratory failure in patients undergoing aortic surgery. Increased pulmonary capillary
permeability secondary to aortic cross-clamping, cytokinaemia secondary to lower torso
ischaemia and reperfusion, and excessive peri-operative fluid resuscitation lead to an
increase in extravascular lung water and ARDS. Coagulopathy leads to pulmonary
microvascular thrombosis and haemorrhage, identical to that seen in ARDS (31).
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Myocardial injury and left ventricular dysfunction lead to pulmonary oedema. Post¬
operative pain and impaired consciousness may lead to shallow tidal breathing and
alveolar collapse, with sputum retention and secondary bacterial pneumonia. Impaired
consciousness and post-operative ileus may also lead to the aspiration of gastric contents
and subsequent pneumonitis.
Acute renal failure
The incidence of ARF in ruptured AAA repair is 18-33% (3,14,30) but may be as high
as 72% (13). The associated mortality is 33-76% (3,14). ARF in isolation is associated
with a mortality rate of 25-70%. When it occurs in association with MOF involving
three or more organ systems, ARF is almost universally fatal.
The patients' age, pre-morbid renal function and the presence of renal artery occlusive
disease are important risk factors for the development of ARF. There are several
pathophysiological processes which may contribute to the development ofARF in aortic
surgery (32). A massive shift of body water from the circulation to the extracellular and
third spaces occurs as a consequence of operative dissection, inadequately replaced
blood loss, altered acid-base balance in ischaemic tissues, increased inflammatory
mediators due to ischaemia and reperfusion, and low cardiac output during aortic
declamping. Acute tubular necrosis may occur secondary to renal ischaemia caused by
renal hypoperfusion during prolonged suprarenal aortic clamping, whole body
hypoperfusion during haemorrhagic shock, and myocardial dysfunction secondary to
arrhythmia or MI. Aortic clamping is associated with reduced renal cortical blood flow
during the period of ischaemia and immediately on reperfusion, and furthermore,
inflammatory mediators released on aortic declamping may damage renal parenchyma.
Renal athero-embolism may occur secondary to suprarenal aortic manipulation or
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clamping if there is atheroma in the proximal aorta. Finally, post-operative complications
such as sepsis and coagulopathy lead to ARF secondary to haemodynamic instability
and deposition of fibrin thrombi in the microvasculature.
Stroke
This may occur in approximately 5% of patients and is associated with a mortality rate
of 50% (3). The presence of pre-existing carotid artery occlusive disease is an important
risk factor. Possible mechanisms include cerebral hypoperfusion secondary to
haemorrhagic shock and haemodynamic changes which occur during aortic clamping
and declamping, as well as embolisation from intra-cardiac clot secondary to MI or
arrhythmia. A procoagulant state has been shown to be associated with CVA (33).
Venous thrombo-embolism
This is a multifactorial condition which occurs as a result of venous stasis and/or vessel
wall damage in the presence of a hypercoagulable state. A hypofibrinolytic state has
been demonstrated in approximately 30-40% of patients with DVT. Risk factors in patients
operated for AAA include age, prolonged surgery and cardiovascular complications.
Pulmonary embolism may lead to progressive or sudden cardiorespiratory failure.
Lower extremity ischaemia
Lower limb ischaemia occurs in 1-10% of patients following AAA repair (23,34). This
may occur for three principal reasons: distal micro- or macroscopic embolisation of
atheromatous debris or thrombus due to aortic manipulation; thrombotic occlusion of
pre-existing arterial occlusive disease or popliteal aneurysm secondary to low flow or a
hypercoagulable state; and embolisation of intra-cardiac clot secondary to MI or
25
arrhythmia. Microembolisation obstructing small arterioles leads to a reactive obliterative
endarteritis and subsequent tissue ischaemia and infarction. It affects not only the lower
extremities (when it is colloquially called 'trash foot') but may involve the kidney, colon
and spinal cord.
Bowel ischaemia
This most commonly affects the left colon owing to its precarious blood supply and poor
collateral circulation if arterial occlusive disease is present. Transmural infarction may
occur in up to 5-10% ofpatients undergoing ruptured AAA repair and is associated with
a mortality rate of approximately 70% (3). Lesser degrees of ischaemia may be present in
over 50% of patients. Bowel ischaemia may occur occur due to hypovolemic shock,
local pressure effects from retroperitoneal haematoma, traction on the small bowel
mesentery, ligation of the inferior mesenteric artery, bypass or ligation of the internal
iliac arteries, reduced cardiac output, ischaemia and reperfusion injury, and the presence of
a hypercoagulable state (35).
Multiple organ failure
MOF may account for up to 37% of post-operative deaths (17,35) in ruptured AAA.
Failure of two or more organ systems is associated with a mortality rate approaching
100%. Factors contributing to the development of MOF include: a) blood loss,
transfusion and malnutrition leading to depressed immune function; b) tissue ischaemia
and reperfusion leading to leucocyte activation and the production of cytokines. This
results in endothelial, platelet and leucocyte activation, and increased expression of
endothelial adhesion molecules, which are involved in the recruitment of leucocytes
across the endothelium and into adjacent tissues. Oxygen-derived free radicals and
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proteases then damage the endothelium and surrounding tissues; c) bowel ischaemia
leading to endotoxaemia, bacterial translocation, and peritoneal contamination and
sepsis, all of which lead to further cytokine production; d) generalised procoagulant
state and coagulopathy leading to macro- and microvascular thrombosis which
compromises end organ perfusion (35-38).
Haemorrhage
This may occur for technical reasons and/or because of abnormal haemostasis.
Excessive haemorrhage may occur in 17-33% of patients (3,10,22) and is associated
with a mortality rate of 89-100% (3,10,30).
Coagulopathy is an important cause of haemorrhage in ruptured AAA repair. Wakefield
et al (13) demonstrated coagulopathy in 15 of 24 (63%) patients who died intra-
operatively, and 8 of 92 (9%) patients who died post-operatively. Marsh (39) reported
coagulopathy during and after operation in 9 of 29 (31%) patients, eight of whom died;
and haemorrhage secondary to coagulopathy was a major contributory factor in 25% of
all post-operative deaths. The incidence of post-operative haemorrhage due to abnormal
haemostasis is 0.8-3.7% (30,40) in elective surgery for non-inflammatory AAA. In
thoraco-abdominal aortic aneurysm repair, the incidence of re-operation for bleeding
may be as high as 9% in specialist centres with haemorrhage responsible for 12-38% of
early deaths (41,42). In ruptured AAA repair, re-exploration for haemorrhage is not
uncommon (10,11,14,15) and is associated with poor outcome. For example, Milne et al
(43) reported re-operation for bleeding in 12 of 262 (4.6%) patients after ruptured AAA
repair in the ERVSU with a mortality rate of 50%. An abnormal coagulation screen at
the end of the primary operation was a universal finding.
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Clinico-pathological variables associated with mortality
Many studies have attempted to identify variables which predict mortality in patients
presenting to hospital with rupture, but no single variable has been shown to be 100%
predictive in isolation (Table 1.2). Coagulopathy has been reported by several
investigators to be associated with poor outcome. Coagulopathy and bleeding requiring
re-operation or transfusion are as significant predictors of poor outcome as major
cardiac events, respiratory failure, ARF requiring supportive therapy, CVA and distal
embolisation (7). More recently, Davies et al (44) and Bradbury et al (45) have
demonstrated a significant association between peri-operative haemostatic derangement


















1982 Hypotension; abnormal blood urea nitrogen and creatinine;
volume of blood and fluid administered
1984 Volume of blood administered
1985 Age > 76 years; haematocrit <0.30; persistent hypotension;
acute ECG changes; technical complications; organ failure
1987 Reduced level of consciousness; cardiac failure
1988 Volume ofblood administered
1989 Age > 72 years; hypotension
1990 Haemodynamically unstable; renal insufficiency;
chronic pulmonary disease
1991 Renal failure
1991 Loss of consciousness; hypotension;
symptom duration > 1 day; delay from emergency to
theatre > 2 hours; intraperitoneal rupture
1991 Male gender; unstable blood pressure;
pre-operative cardiac arrest; volume of blood administered
> 15 units
1992 Hypotension; low haematocrit; chronic lung disease;
high APACHE II score
1994 Abnormal creatinine; suprarenal aortic clamping;




Under normal conditions, blood circulates through the vasculature without appreciable
thrombus formation or haemorrhage. Normal haemostasis acts to minimise haemorrhage
and maximise perfusion. Vascular injury leads to temporary vasoconstriction and
increased tissue tension due to blood loss into adjacent tissues. Subsequent formation of
a platelet-fibrin plug (predominantly in the extravascular space) at the site of vessel injury
restores the integrity of the circulation. Inhibition of thrombus formation in intact areas
ensures that this occurs with minimal interruption to blood flow. The end result is healing
of the vascular injury, removal of the blood clot and restoration of function. Normal
haemostasis is a dynamic balance between fibrin formation and resolution, and is
dependent on interactions between endothelium, platelets, coagulation and fibrinolysis.
Endothelial cells
The vascular endothelium forms the physical interface between blood and the underlying
tissues, allows exchange and active transport of substances across the vessel wall, and
has an important role in the regulation of haemostasis and the maintenance of vascular
tone. Injured, denuded endothelium initiates thrombus formation by exposing the
subendothelial surface to platelets and coagulation factors.
Healthy intact endothelium is negatively charged and forms a physical barrier which
prevents the interaction between platelets and clotting factors, and subendothelial TF
and collagen. Healthy endothelial cells also contain an endogenous heparin-like factor
called heparan sulphate which acts to increase the rate of thrombin inactivation by the
antithrombins. Thrombin also binds to TM expressed on the surface of endothelial cells,
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and the resultant thrombin-TM complex activates protein C which, together with the
endothelial product protein S, inactivates coagulation factors Va and Villa, and the
tenase and prothrombinase complexes. Endothelial cells are the main site of synthesis of
TFPI, the principal inhibitor of TF. Endothelial cells also express t-PA which activates
fibrinolysis and ensures that coagulation is confined to areas of vessel injury.
Endothelial cells play an important role in the regulation of vascular tone. This is
determined, in part, by certain vasodilator and vasoconstrictor substances that control
vascular smooth muscle function. Thrombin, aggregating platelets, and increased shear
stress stimulate production ofNO which maintains arterial relaxation at rest and inhibits
platelet aggregation and monocyte and leucocyte adhesion. Prostacyclin is a vasodilator
and an inhibitor of platelet activation. The endothelins are the most potent endogenous
vasoconstrictors known and expression is induced by thrombin, shear stress and
hypoxia. ET-1 is the major isoform in blood vessels and is synthesized by endothelial
cells, macrophages and vascular smooth muscle cells. It is mainly secreted abluminally
but may enter the circulation if concentrations are high at the endothelial cell-vascular
smooth muscle interface (51).
Endothelial cell activation involves a change in function and morphology (52) and
consists of; change in phenotype from anticoagulant to procoagulant; loss of vascular
integrity; cytokine production; expression of leucocyte adhesions molecules; and
upregulation of human leucocyte antigen molecules. Type 1 endothelial cell activation
occurs rapidly and does not involve de novo protein synthesis. Examples include
endothelial cell retraction, and expression of P-selectin and vWF. Type II activation
requires protein synthesis. An example is expression of cytokines. Endothelial cell
activation is induced by a wide range of agents including ischaemia, endotoxaemia and
cytokines, such as IL-1 and TNF (52,53). In vitro, these cytokines induce TF expression
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by endothelial cells (and leucocytes) and upregulate the release of vWF into plasma
(53,54) resulting in a procoagulant state. The procoagulant effects of endothelial cell
activation consist of increased PAI release which inhibits fibrinolysis; increased platelet
activating factor expression; diminished platelet anti-aggregatory effects due to reduced
prostacyclin expression; vasodilation secondary to increased NO production; increased
TF expression; and shedding of heparan sulphate. There is debate about the significance
of shedding of TM from endothelial cells. Unlike vWF, increased soluble TM levels may
occur independent of cytokines and reflect endothelial injury rather than activation (55).
Endothelial cell activity may be assessed by monitoring plasma levels of its specific
products. vWF is the most commonly used endothelial marker. It is synthesised by
vascular endothelial cells and megakaryocytes (56). It mediates platelet adhesion to the
subendothelium which is essential for the formation of occlusive platelet thrombi at
sites of arterial injury; it also acts as a co-factor for factor VIII (57,58). The vWF-
mediated adhesion of platelets to exposed subendothelial collagen is irreversible and of
considerable importance in conditions of high shear stress (59). Endothelial cell vWF
accounts for 40% of total platelet adhesion, with the remaining 60% provided by plasma
vWF (59). Circulating vWF is stored intracellularly in the Weibel-Palade bodies (60),
the contents of which are released upon stimulation by factors such as thrombin, fibrin,
TNF, IL-1 and vasopressin (54,58,61). Platelet vWF contributes little if any to plasma
levels (62). Elevated levels of circulating vWF have been demonstrated as part of the
acute phase response (63), and in association with risk factors for atherosclerosis. There
is an increased thrombotic tendency with increased platelet adhesion in association with
elevated plasma vWF, and elevated plasma levels have been demonstrated in patients
with peripheral (64,65) and coronary artery disease (66-68).
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Platelets
Activated platelets orchestrate all of the components of the haemostatic system leading
to the formation of a stable clot; specifically, they adhere to subendothelial collagen,
form aggregates by chemotaxis, promote thrombin generation by releasing factors, and
provide negatively charged phospholipid for the prothrombinase and tenase complexes.
Endothelial cell injury induces several biochemical mechanisms which lead to platelet
activation (adhesion, aggregation, and secretion) (69). Plasma vWF binds to exposed
subendothelial collagen and elastin in the damaged vessel wall and undergoes a
conformational change to expose binding sites for platelets. Platelet adhesion to vWF
occurs via the platelet membrane glycoprotein (GP) lb, and is dependent on
subendothelial fibronectin, and ionised calcium and magnesium. The adherent platelets
form pseudopodia and flatten and spread over the injured endothelium. They express
glycoprotein receptor sites for coagulation factors, the most significant of which is GP
Ilb/IIIa which facilitates the binding of other platelets via fibrinogen. The release of
platelet components and platelet recruitment are stimulated not only by platelet
adhesion, but also by agonists in the vicinity of the injury such as adenosine diphosphate
(ADP), adrenaline, platelet activating factor and thrombin. Adherent platelets release
ADP, ionised calcium, serotonin and thromboxane A2 which provide a positive
feedback pathway for platelet aggregation. They also release large quantities of factor V
which increases thrombin generation; and expose large areas of negatively charged
phospholipids which are essential for the formation of the tenase and prothrombinase
complexes and further increased thrombin generation.
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Coagulation
Tissue injury, endothelial activation and injury, and monocyte activation leads to TF
expression which triggers the extrinsic coagulation cascade (70) (Figure 1.1). Vessel
wall injury leads to the exposure of subendothelial collagen and exposure and release of
TF. TF forms a complex with coagulation factor VII on endothelial cells and monocytes
which leads to activation of factor VII itself. The TF-activated factor VII complex
activates factor X directly when TF concentrations are high, and indirectly via activation
of factor IX. Activated factor IX, X and XII act in a positive feedback pathway to
increase activation of factor VII. The activation of factor X by activated factor IX (via
the intrinsic coagulation pathway) requires calcium ions and is increased almost 1000
times in the presence of activated factor VIII and negatively charged phospholipid. The
combination of activated factor IX, vWF, activated factor VIII, calcium and
phospholipid constitutes the tenase complex which is present on activated platelets and
endothelial cells.
All of the components of the intrinsic coagulation pathway are present in the plasma.
When it comes into contact with a foreign surface, the pre-kallikrien-high molecular
weight (HMW) kininogen complex is activated to release kallikrien. This serine protease
inhibitor stimulates the production of bradykinin from HMW kininogen, and activates
coagulation factor XII. Activated factor XII acts in a positive feedback to increase
kallikrien release and activate factor XI. Sufficient amounts of thrombin are generated to
induce fibrin formation before TFPI is released. Most thrombin formation occurs within
the fibrin clot by the activation of factor XI by thrombin via the intrinsic coagulation
cascade. Activated factor XI in turn activates factor IX and the extrinsic and intrinsic
coagulation pathways unite by the activation of factor X. Activated factor X converts
prothrombin to thrombin which, through another positive feedback pathway, activates
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factor V (large amounts of which are released from platelets). Activated factor X,
activated factor V and calcium bind to phospholipid to form the prothrombinase complex
on platelets. This increases the conversion of prothrombin to thrombin at over 300,000
times the rate of activated factor X alone. Thrombin also acts in a positive feedback by
increasing the release and activation of factor VIII from its complex with vWF. The
serine protease inhibitor TFPI, present in plasma and on the surface of endothelial cells,
binds and inhibits activated factor X when small amounts are generated by the extrinsic
coagulation cascade. This, in turn, rapidly inhibits the TF-activated factor VII complex.
This negative feedback pathway inhibits activation of factor X unless there is massive
expression and release of TF.
The conversion of prothrombin to thrombin leads to the release of PF 1+2. Once
produced, thrombin cleaves fibrinopeptides A and B from fibrinogen in platelets and
plasma, converting it into fibrin monomer. The fibrin monomer polymerises to form
strands and thrombin activates factor XIII which, in the presence of calcium, stimulates
the formation of a dense open mesh of insoluble cross-linked fibrin. This binds platelets
via GP Ilb/IIIa to form the platelet-fibrin plug, and also allows plasmin to enter the clot
to initiate fibrinolysis.
Thrombin generation adjacent to normal intact endothelium is inactivated by a number of
antithrombins, the most important of which is AT III. Thrombin binds to AT III, which is
concentrated by intact endothelium, and splits it to form the inactive TAT complex. TM
is expressed on the surface of the endothelium and binds thrombin. The thrombin-TM
complex inhibits fibrin formation and platelet activation, and activates protein C which
inactivates factors V and VIII and decreases thrombin generation. Protein C activity is
increased 10 times in the presence of protein S. Coagulation is localised to areas of
tissue injury by the fact that damaged endothelium is incapable of neutralising thrombin
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whereas adjacent intact endothelium continues to express agents such as AT III, TM and
protein C.
Thrombin has anticoagulant properties at low concentrations by increasing the activation
of protein C. At high concentrations, thrombin has a procoagulant and antifibrinolytic
effect by overcominf the effect of activated protein C and activating TAFI.
Thrombin cannot be measured directly as, under pathological conditions, less than 1%
of circulating prothrombin is transformed to thrombin, and it is rapidly inactivated by
AT III. Thrombin generation can, however, be measured indirectly by assessing levels of
the cleavage products released in the conversion of prothrombin to thrombin, namely PF
1+2; the activation products of the substrates of thrombin, namely fibrinopeptide A and
fibrin monomer; the products generated by secondary fibrinolysis, namely FDPs and D-
dimer; or more directly by measuring the amount of thrombin inactivated, namely TAT.
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FIGURE 1.1
Extrinsic and intrinsic coagulation systems.
Extrinsic pathway
Tissue injury

























Fibrinolysis is a physiological consequence of fibrin deposition anywhere in the body. At
the same time as thrombin generation and fibrin deposition are taking place, the
fibrinolytic system is secondarily activated in order to limit clot formation to the site of
vessel wall injury and recanalise blood vessels after repair has taken place.
t-PA is the principal endogenous activator of plasminogen (Figure 1.2) and is rapidly
released from vascular endothelial and smooth muscle cells in response to thrombin,
endotoxin, cytokines and ischaemia (71-77). Plasminogen is concentrated into the
forming clot and t-PA binds to the fibrin surface to form the t-PA/plasminogen/fibrin
complex. t-PA activates plasminogen to the enzyme plasmin. Plasmin activity is maximal
in the clot where it is protected from the circulating plasmin inhibitor, a-2 antiplasmin.
Plasmin causes lysis of fibrin, fibrinogen and cross-linked fibrin clot to produce split
products including FDP and D-dimer which further stimulate plasmin formation.
Plasmin acts specifically in areas of excessive fibrin deposition as tPA is a poor
plasminogen activator in the absence of fibrin (78).
The availability and activity of t-PA is dependent, not only on its release from
endothelium, but also on neutralisation by its inhibitors, a-2 antiplasmin and PAIs, and
first-pass PAI-independent hepatic clearance. PAI is the principal fast-acting inhibitor of
t-PA. It is synthesised by vascular endothelial and smooth muscle cells, hepatocytes and
is found in the alpha granules of platelets and in normal plasma. PAI is an acute-phase
protein produced in response to sepsis, endotoxin, cytokines, thrombin, ischaemia,
surgery and trauma (71,76-83). The main role of PAI would appear to be in the
regulation of plasma tPA activity. PAI rapidly complexes with tPA to reduce its activity
in plasma, prevent excessive plasmin formation and thus localise fibrinolysis to fibrin
deposits. The binding of PAI to clot-bound tPA however is much slower. High plasma
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levels of t-PA antigen reflect inactive t-PA/PAI complexes rather than free active t-PA.
If there is a large excess of PAI activity, then the plasma levels of t-PA/PAI complex
and t-PA antigen are raised but t-PA activity is reduced. Increased PAI activity and
increased t-PA antigen levels reflect reduced fibrinolytic activity. High concentrations of
thrombin activate TAFI which acts on partially degraded fibrin to prevent formation of
the t-PA/plasminogen/fibrin complex and thus limit plasmin formation.
Under resting conditions, platelets do not appear to contribute to plasma PAI levels.
Plasma PAI has a short half-life (2 hours) and so, to maintain constant levels, there must
be rapid synthesis and release into the circulation (84). Stimulation and aggregation of
platelets can lead to a transient and rapid increase in PAI levels (78,85). High
concentrations of platelets in blood clot may provide high PAI levels which prevent
fibrinolysis. PAI's short half-life, its inactivation by activated protein C and thrombin,
and the diffusion of t-PA into fibrin clot all favour fibrinolysis.
Elevated fibrinogen is a risk factor for the development of cardiovascular (86-88) and
peripheral arterial disease (64,89,90), and predicts death in patients with intermittent
claudication (91,92). Elevated fibrinogen may disrupt the normal equilibrium between
coagulation and fibrinolysis (93). Increased FDP levels are associated with peripheral
vascular disease and are predictive of coronary thrombosis in patients with peripheral
vascular disease (92). Low fibrinolytic activity is associated with ischaemic heart disease
and thromboembolic disease (94-99). t-PA antigen levels predict risk ofMI and stroke
(100,101), elevated PAI levels occur in young survivors of MI (102,103), and patients

























Abnormal haemostasis or coagulopathy occurs due to a disturbance in the physiological
balance between coagulation and fibrinolysis. It is a consequence of inappropriate and
excessive activation of the extrinsic and/or intrinsic coagulation pathway in the general
circulation rather than within the confines of an area of tissue damage.
Causes
Coagulopathy has a large number of underlying causes which may be acute or chronic
(Table 1.3). TF release is the responsible for the majority of acute coagulopathies.
Hypothermia and acidosis have a major impact on haemostasis as coagulation factors
are enzymes which function optimally within a narrow range of temperature and pH. A
chronic sub-clinical 'compensated' coagulopathy may exist in patients with aortic
aneurysms. Decompensation may occur if the haemostatic system is stressed by, for
example, the development of renal or hepatic impairment, rapid aneurysm expansion,




Causes of abnormal haemostasis.
Acute Chronic
Ischaemia and acidosis Carcinomatosis (esp. adenocarcinoma)




(esp. Gram -ve bacteraemia, endotoxaemia)
Massive blood transfusion
ABO incompatible blood transfusion
(immune complex formation)
Massive head injury
Placental abruption, amniotic fluid embolism
Hepatic failure
(hypersplenism, reduced vitamin K
absorption, reduced clotting factor and





As platelets are consumed at sites of endothelial injury and form procoagulant surfaces
and/or express TF, thrombocytopenia coincides or precedes activation of the coagulation
cascade. Activated coagulation factors are relatively protected from endogenous
inhibitors while they are attached to procoagulant surfaces, and therefore excess
thrombin generation spreads proximally and distally from the site of injury. Fibrin
microthrombi lodge within the vascular beds of end organs (especially kidney, lung,
adrenals and brain) and polymerisation of fibrin monomer occurs. This stimulates
secondary fibrinolysis which acts to restore microvascular patency. Secondary
fibrinolysis, however, results in the production of FDPs and D-dimer which are
anticoagulants, potentiate fibrinolysis and interfere with formation of fibrin clot. Excess
fibrinolytic activation overcomes the endogenous inhibitors and leads to the destruction
of coagulation factors themselves. Unrestricted activation and destruction of fibrin,
fibrinogen and coagulation factors VII and VIII occur until the reserves are exhausted
and de novo synthesis is inadequate. This is known as consumptive coagulopathy.
Primary systemic fibrinolysis occurs when excess plasmin saturates PAI and a-2
antiplasmin leading to increased free circulating plasmin. Free plasmin consumes
coagulation factors, and plasmin within clot and on endothelial cells and platelets causes
lysis of haemostatic plugs. Compensatory thrombin generation and platelet activation
occur in an attempt to restore haemostasis. In both consumptive coagulopathy and
primary fibrinolysis, microvascular thrombosis and haemorrhage occur once the
reticulo-endothelial system and the phagocyte system are overwhelmed.
The primary mechanism in most cases of coagulopathy is considered to be widespread
deposition of fibrin thrombi within the microvasculature with consumption of
43
coagulation factors and platelets. There is considerable debate, however, as to whether
fibrinolysis and fibrinogenolysis in coagulopathy is a primary phenomenon or secondary
to thrombin generation and intravascular fibrin deposition. Hyperfibrinolysis, however,
remains the major cause of haemorrhage in patients with coagulopathy. Depletion of
coagulation factors and platelets, and the inhibitory effect of FDPs and D-dimer further
contribute to haemorrhage.
There is evidence to suggest that endothelial activation and injury has a key role in the
development of MOF and mortality in patients with coagulopathy. Wada et al (36)
demonstrated that elevated plasma levels of TAT, PAP and D-dimer predicted the
development of coagulopathy. Furthermore, MOF and/or death were associated with a
hypofibrinolytic state as demonstrated by elevated plasma t-PA antigen, PAI antigen and
soluble TM, and reduced PAP:TAT ratio.
Clinical presentation
Coagulopathy is a syndrome of clinical and laboratory findings. The clinical presentation
is variable and dependent on the haemostatic stimulus; the activity of the coagulation and
fibrinolytic pathways; bone marrow function; and liver and reticulo-endothelial system
function. Coagulopathy may be asymptomatic or it may cause severe bleeding or
thrombosis, or both simultaneously. Haemorrhage, however, is the commonest
presentation and manifests clinically as; spontaneous bleeding from multiple sites with
petechiae, ecchymoses, mucosal oozing, prolonged bleeding from puncture sites, and
excessive secondary haemorrhage into wounds during and after procedures;
hypovolemia, hypotension and haemorrhagic shock; and organ dysfunction, particularly
affecting lung, kidney and liver. Haemorrhage is associated with hypovolemia,
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hypotension and shock due to activation of the intrinsic coagulation pathway and
bradykinin production and interaction between IL-1 and TNF (53). ARF is typical in
patients with coagulopathy and occurs due to hypotension and reduced renal blood flow,
and also deposition of fibrin thrombi in the microvasculature. Respiratory failure occurs
due to microvascular thrombosis and haemorrhage and is identical to that seen in
patients with ARDS; 20% of patients with coagulopathy and ARDS share the features of
both (31).
Laboratory findings
The diagnosis of coagulopathy consists of thrombocytopenia, prolonged clotting times
(PT, aPTT), hypofibrinogenaemia and elevated levels of FDPs. Thrombocytopenia due
to platelet consumption consequent on thrombin generation is almost universal.
Prolonged clotting times occur in 50-70% of patients and are due to consumption of
prothrombin and the tenase and prothrombinase complexes. Hypofibrinogenaemia
occurs in less than 50% of patients and elevated FDPs occur in 85% of patients. PT
assesses the extrinsic and aPTT the intrinsic coagulation pathway with the exception of
factor VII. These tests must be interpreted with caution in hypothermic patients as they
are performed in the laboratory at 37 C. If the clotting times are normal, however, then it




Abnormal haemostasis or coagulopathy occurs due to a disturbance in the physiological
balance between coagulation and fibrinolysis in the general circulation as well as within
the confines of an area of tissue damage. Stimuli include hypotension, ischaemia,
acidosis, hypoxia, hypothermia and massive blood transfusion. Coagulopathy may be
asymptomatic or manifest as severe bleeding or thrombosis, or both simultaneously. The
primary mechanism in most cases is considered to be widespread deposition of fibrin
thrombi within the microvasculature of end organs with resultant consumption of
coagulation factors and platelets. Haemorrhage is the commonest presentation and
occurs due to depletion of coagulation factors and platelets secondary to thrombus
formation, (primary or secondary) hyperflbrinolysis and the inhibitory effect of FDPs.
Organ dysfunction occurs due to haemorrhage, reduced blood flow secondary to
hypotension and deposition of fibrin thrombi within the microvasculature. The
laboratory diagnosis consists of a) thrombocytopenia which is almost universal, b)
prolonged clotting times which occur in 50%-70% of patients, c) hypofibrinogenaemia




Abnormal haemostasis and aortic aneurysmal disease
Previous studies
Siebert and Natelson (106) proposed four criteria to ensure that intact AAA was the
cause of any coagulopathy after exclusion of other possible causes: 1) presence of a
chronic acquired bleeding diathesis; 2) laboratory evidence of coagulopathy; 3)
correction of the abnormality by aneurysm repair; and 4) maintenance of normal
coagulation for a minimum of three months after repair. If adhered to, these criteria
effectively exclude patients who do not undergo aneurysm repair from having the
diagnosis of coagulopathy secondary to non-ruptured AAA. Despite this, several
interesting studies suggest that platelet activation and increased fibrinolysis may be
responsible for coagulopathy associated with intact non-operated aortic aneurysms.
In 1971, Biegler and colleagues (107) were the first to report a case of coagulopathy
associated with a thoracic aortic aneurysm. A 73 year old patient with an aortic arch
aneurysm presented with haematuria, abdominal pain, and dyspnoea with opacification
of the left hemithorax on chest x-ray presumed secondary to haemothorax. The patient
had laboratory evidence of coagulopathy and his condition improved spontaneously
without operation. In 1973, Schnetzer and Penner (108) reported the first case of chronic
coagulopathy (of two and a half years duration) secondary to a large thoraco-abdominal
aortic aneurysm which responded to heparin therapy without repair.
Fouser et al (109) demonstrated laboratory evidence of coagulopathy as well as acquired
platelet dysfunction in an 82 year old man with an 8cm diameter AAA and a one year
history of a bleeding disorder. Booth et al (110) demonstrated increased systemic
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fibrinolysis, rather than platelet or coagulation cascade activation, in two patients with
large AAAs who developed major haemorrhage after minor surgery. More recently,
Micallef-Eynaud and Ludlam (111) reported three patients with non-ruptured abdominal
(n=2) and thoracic aortic aneurysm (n=l) who presented with bleeding and laboratory
evidence of coagulopathy. Bone marrow aspirate in one patient revealed large numbers
of megakaryocytes suggesting that the thrombocytopenia was due to excessive
peripheral destruction of platelets. Indium-labelled platelet scanning in two patients
demonstrated increased uptake in the region of the aneurysm indicative of increased
platelet destruction. Mamiya et al (112) reported one patient with a thoraco-abdominal
aneurysm and coagulopathy which responded to antifibrinolytic therapy without repair.
Proposed mechanisms
Many patients with AAA take regular antiplatelet or anticoagulant medication, or non¬
steroidal anti-inflammatory drugs. All of these medications may lead to clinically
significant haemostatic derangement and bleeding.
Straub and Kessler (113) were the first to demonstrate an accumulation of labelled
fibrinogen within AAA before operation and in the resected aneurysm tissue, and ten
Cate reported a similar finding in a patient operated for rupture (114). Fibrin thrombus
within the aneurysm sac may lead to increased fibrin turnover and elevated levels of
FDPs (115) which, in turn, may stimulate fibrinogen synthesis leading to
hyperfibrinogenaemia (116). The finding of focal fibrinolytic activity and fibrinolytic
gene expression within the aortic wall of patients with asymptomatic AAA (117,118)
suggests that the fibrinolytic system is inappropriately activated in this group.
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Fouser et al (109) were the first to report abnormal platelet function associated with
AAA and proposed that this may occur due to; inhibition of platelet retention and
aggregation by FDPs; mechanical damage to platelets due to turbulent blood flow
adjacent to the aneurysm thrombus; or prolonged survival of platelets which have
already underwent aggregation and partial/complete storage granule release in response
to exposure to thrombin within the aneurysm. Using platelet scintigraphy, several
authors (111,119,120) have demonstrated increased radio-activity over the aortic
aneurysm suggesting that increased platelet destruction may occur due to incorporation
in the aneurysm thrombus (111).
Several early studies in the 1960s and early 1970s demonstrated that the aortic
adventitia had high fibrinolytic activator activity, that the aortic media and intima had
weak prothrombotic properties (121), and that ulcerated atheromatous aorta and aortic
subendothelial tissues induced platelet adhesion and thrombin activation (122,123). ten
Gate et al (114) hypothesised that damage to the aortic wall might lead to; exposure of
subendothelial collagen and induction of the intrinsic coagulation pathway; TF exposure
and induction of the extrinsic coagulation pathway; exposure of aortic adventitia and




Abnormal haemostasis and aortic aneurysm surgery
Thrombotic and haemorrhagic complications are responsible for the majority of the
major morbidity and mortality associated with aortic aneurysm surgery, and in particular
ruptured AAA repair. There is increasing evidence that haemostatic derangement is
central to the pathogenesis of these complications. Many studies have examined
haemostasis in animal models of aortic surgery, some have included patients who have
and have not undergone operation, and others have studied patients undergoing
reconstruction for aneurysmal and occlusive disease but have not differentiated between
the two. Haemostasis before and after aortic surgery has been the subject of several
studies, but there are few detailed investigations of peri-operative changes in the
haemostasis in patients undergoing elective AAA repair. To our knowledge, there are no
previously published reports in patients undergoing ruptured AAA repair.
Previous studies ofthoraco-abdominal aneurysm repair
While coagulopathic bleeding is a common problem during and after surgery for
thoracic and thoraco-abdominal aortic aneurysm (41,42), there are few studies
examining the pathophysiology of this complication. Cohen et al (124-126) studied peri¬
operative haemostasis in a canine model of supracoeliac aortic cross clamping.
Increasing duration of aortic cross-clamping was associated with a significant decrease
in platelet count and fibrinogen and significantly prolonged clotting times possibly due
to ischaemic hepatic damage and intestinal bacterial translocation.
50
Previous studies ofnon-ruptured and ruptured AAA repair
As early as 1955, Krevans and Jackson (127) reported two patients who received
massive blood transfusions during elective AAA repair and developed fatal post¬
operative bleeding with laboratory evidence of coagulopathy. Since then, there have
been many case reports of abnormal coagulation in patients undergoing abdominal
aortic surgery, and of patients with AAA and coagulopathy who have undergone
successful repair (106, 112, 114, 119, 120, 127-136).
In a retrospective study, Mulcare et al (137) reported laboratory evidence of
coagulopathy and increased fibrinolysis in blood sampled within 12 hours of operation
in five patients who received massive blood transfusion and developed excessive
bleeding during or after repair of ruptured (n=4) and non-ruptured AAA (n=l). Getaz
and Louw (138) demonstrated an abnormal standard coagulation screen in 10 of 18
patients presenting with ruptured AAA, of whom 10 had thrombocytopenia and two had
coagulopathy. Thrombocytopenia alone was present in 11 of 39 patients with non-
ruptured AAA. Fisher et al (139) performed coagulation studies in 76 patients with
aortic aneurysm. Elevated FDPs alone were present in 8 of 22 patients with infrarenal
AAA, and 14 of 32 patients with thoraco-abdominal aortic aneurysm. Elevated FDP
levels were not useful in diagnosing coagulopathy and were not associated with
increased operative blood loss.
Mulcare et al (140) performed coagulation studies pre-operatively, and immediately and
24 hours post-operatively in 32 patients with non-ruptured AAA and/or aorto-iliac
occlusive disease. All patients received intra-aortic heparin before aortic cross clamping.
As a function of time, there was a significant increase in clotting times and levels of fibrin
monomer and FDPs; and a significant decrease in platelet count, fibrinogen, plasminogen
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and fibrinolytic inhibitors. The authors suggested that elective aortic surgery may
produce low-grade local or disseminated coagulopathy with secondary fibrinolysis. In
33 patients undergoing aorto-bifemoral bypass, Mashiah et al (141) also reported a
significant fall in fibrinogen and plasminogen levels intra-operatively but were unable to
demonstrate laboratory evidence of increased coagulation or fibrinolysis. Although the
authors suggested that fibrinogen and plasminogen may have been removed by physical
means, this may have occurred secondary to peri-operative haemodilution. De Mol Van
Otterloo et al (142) demonstrated increased platelet activation and increased FDPs
before and after operation in patients undergoing aorto-iliac reconstruction for
aneurysmal and occlusive disease. Brothers et al (143) also reported post-operative
increased fibrinolysis as demonstrated by elevated FDPs in 10 patients which was
confirmed by TEG in only 25% of samples. In 10 patients undergoing elective aorto-
bifemoral bypass for occlusive disease (n=8) and non-ruptured (n=2), von Sommoggy et
al (144) reported a significant increase in ECLT and decrease in AT III and oo -
antiplasmin before aortic clamping which was possibly secondary to haemodilution.
During aortic clamping, there was a significant increase in FDPs suggesting increased
fibrinolysis. Interestingly, there authors reported no significant difference in clotting
tests from femoral and central venous blood suggesting that lower limb ischaemia does
not contribute directly to haemostatic derangement.
In 19 patients undergoing elective aortic surgery for aneurysmal and occlusive disease,
Gibbs et al (145) demonstrated an early post-operative hypercoagulable state with
elevated levels of fibrinogen, factor VIII and vWF and reduced levels of protein C, AT
III and co-macroglobulin. The authors were the first to speculate that this procoagulant
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state might contribute to peri-operative MI. The same authors later confirmed this
hypercoagulable state using TEG in 30 patients (146) and failed to demonstrate a
beneficial effect of epidural and general anaesthesia on this procoagulant state over
general anaesthesia alone in 20 patients undergoing elective abdominal aortic surgery
(147). Aramato et al (148) measured FDP, D-dimer, TAT and PAP levels in 41 patients
undergoing elective surgery for AAA and 30 patients for aorto-iliac occlusive disease.
Levels of all markers were elevated in AAA patients. Intra-operatively, the levels of
conventional haemostatic markers fell suggesting consumption, and post-operatively
returned to normal or increased consistent with a hypercoagulable state.
Gomez et al were the first to report the results of detailed investigation of the fibrinolytic
pathway in aortic surgery. In a study comparing patients undergoing thoracic, abdominal
and peripheral vascular surgery, the authors demonstrated peri-operative inhibition of
fibrinolysis in patients undergoing aortic surgery with a significant increase in PAI levels
(80). The same authors (78) measured PAI activity in 25 patients undergoing aortic
surgery for aneurysmal (n=14) or occlusive disease (n=l 1). Plasma PAI levels were not
elevated before, but increased during, the operation. Levels peaked at 8 hours post¬
operatively and returned to baseline by 48 hours. Eriksson and Rosberg (149) confirmed
post-operative inhibition of systemic fibrinolysis, as demonstrated by significantly
elevated PAI levels and undetectable t-PA activity, in 12 patients undergoing infrarenal
aortic reconstruction for occlusive disease. In a study of 31 patients operated for AAA
(n=18) and aorto-iliac occlusive disease (n=13), Welch et al (150) reported low PAI
activity before and during surgery which increased post-operatively to peak 6 hours after
declamping. In a rat model of infrarenal aortic cross clamping and isolated lower body
ischaemia, Schneiderman et al (71) demonstrated a significant increase in plasma t-PA
53
activity and decrease in PAI activity after 30 minutes of ischaemia with a further increase
in both PAI and t-PA activities after 90 and 120 minutes of ischaemia, respectively.
Although PAI synthesis increased during ischaemia there was a greater elevation in t-PA
synthesis leading to a net increase in fibrinolytic activity. The first rise in t-PA activity
was due to release of stored t-PA from the ischaemic vascular bed, and the second rise in
t-PA and PAI was associated with increased expression of t-PA and PAI mRNA in non-
ischaemic viscera, muscle and fat presumably due to the effect of humoral mediators.
In a prospective study, Davies et al (44) reported an abnormal coagulation screen on
admission to the resuscitation room in 20 of 43 patients who underwent attempted repair
of ruptured AAA. The coagulation screen was abnormal in 13 of 15 patients who died in
the peri-operative period from haemorrhage, MI, cardiac arrest, cardiac failure, MOF
and CVA. Thrombocytopenia, prolonged PT and hypofibrinogenaemia were individually
and collectively associated with significantly increased risk of peri-operative death. More
recently, Bradbury et al (45) demonstrated a significant relationship between low pre¬
operative platelet count and mortality, and low post-operative platelet count and
mortality, development of MOF, days of ventilatory support, and days spent in the ITU
in 65 patients operated for ruptured AAA. Platelet count remained low after operation in
non-survivors who died from continuing haemorrhage. Almost 40% of survivors
developed post-operative thrombocytosis which was strongly associated with the
development of venous thrombo-embolism.
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Proposed mechanisms
The pathophysiology of haemorrhage and thrombosis in patients with aortic aneurysm is
multifactorial. It has been suggested by many investigators that, in most patients with
non-ruptured AAA, there exists a compensated state between the production and
localised consumption of platelets, fibrinogen, and clotting factors within the aneurysm
sac which amounts to a low-grade and subclinical form of coagulopathy (45,137). This
may render the patient particularly sensitive to the effects of profound or prolonged
hypotension, hypothermia, ischaemia, acidosis, endothelial cell damage, haemodilution
and depressed reticulo-endothelial cell function (45,79,137), such that the consumptive
process overwhelms production and clinically apparent coagulopathy occurs (139). As a
result, the degree of coagulopathy may be out of proportion to the degree of hypotension
and blood loss.
Several mechanisms have been proposed for the abnormalities in coagulation and
fibrinolysis associated with AAA repair. Mild platelet dysfunction, prolonged bleeding
times and moderate thrombocytopenia occur due to platelet activation and consumption
in surgical wounds and on the prosthetic graft (151,152). Coagulation factor and platelet
consumption within the haematoma in ruptured AAA (39). Coagulopathy in sepsis,
endotoxaemia and atherosclerosis is associated with TF expression (153-155) and, in a
similar manner, the pathophysiology of ruptured AAA repair may be thrombogenic by
the increasing TF exposure on endothelial cells and monocytes. Patients with rupture
have higher levels of elastase in the aortic wall than patients with non-ruptured AAA
(156,157). Although no significant difference in circulating elastase activity has been
demonstrated between AAA patients and controls (158), it is possible that aortic wall
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disruption in ruptured AAA may release elastase and other proteases into the circulation
leading to deranged coagulation and fibrinolysis (144).
Consumption of coagulation factors and activation of the fibrinolytic system have been
reported in patients with septic shock (82,159), and bacterial translocation has been
implicated in the development of coagulopathy (160). Endotoxaemia occurring due to
increased intestinal permeability consequent on bowel ischaemia (150) may stimulate the
procoagulant effects of endothelial and leucocyte activation, either directly or indirectly,
through the synthesis and release of cytokines (52-54,72-75,77,82,83,150). Intestinal
ischaemia and bacterial translocation may contribute to the increased incidence of
coagulopathy in patients undergoing thoracoabdominal aortic aneurysm repair (124,125).
Elevated levels of cytokines such as TNF have been demonstrated in human and animal
studies of infrarenal aortic cross-clamping (161-164), and it has been suggested that TNF
and IL-1 may be responsible for fibrinolytic activation in lower torso ischaemia (71).
Coagulopathy has been linked to neutrophil activation and endothelial dysfunction (165).
Whole body or local hypoperfusion with reperfusion of large ischaemic areas leads to
acidosis, hyperkalemia and myoglobinaemia which contribute to abnormal haemostatic
function. Hypoxia combined with reperfusion induces procoagulant activity in vascular
endothelium (166). Prolonged supracoeliac aortic cross-clamping is associated with an
increased incidence of coagulopathy suggesting that the greater the ischaemic insult, the
greater the haemostatic derangement (42,124). The exposure of endothelial cells in vitro
to hypoxia is associated with a procoagulant state (167) and stimulation of the synthesis
of PAI-1 (168). Morphological evidence of endothelial cell activation has been
demonstrated before operation in patients with ruptured AAA (169). Increased PAI
synthesis occurs during isolated lower torso ischaemia but a greater elevation in t-PA
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synthesis leads to a net increase in fibrinolytic activity (71). Similar findings have been
demonstrated in humans and animals exposed to endotoxin, where an early increase in t-
PA activity was associated with increased t-PA and PAI mRNA expression (72-74).
Others investigators, however, have demonstrated increased PAI release and down-
regulation of t-PA release in animal studies and in cultured endothelial cells (83).
Platelet activation may also lead to the release of PAI (78).
In patients undergoing elective aortic surgery, blood loss and crystalloid/colloid
replacement may have a dilutional effect on levels of coagulation factors and platelets
(144). Massive transfusion of RCC leads to critically low levels of circulating fibrinogen,
platelet and clotting factors such that dilutional coagulopathy invariably occurs. The
degree and length of shock, as well as the number of units of RCC transfused are strong
predictors of outcome in patients with massive blood loss. Hypothermia occurs as a
consequence of whole body hypoperfusion, prolonged complicated surgery, increased
blood loss and resuscitation with large volumes of non-warmed intravenous fluid. It is a
common finding in patients undergoing aortic surgery (43,170). Hypothermia may itself
cause further blood loss by both potentiating platelet activation by plasmin (171) and
causing reversible platelet dysfunction (117,172). In patients undergoing elective AAA
repair, Kahn et al (172) demonstrated a significant association between change in body
core temperature and bleeding time suggesting a marked effect on platelet function
which was greater than the effect of intra-operative heparinisation.
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Summary
The pathophysiology of haemorrhage and thrombosis in patients with aortic aneurysm is
multifactorial. Antiplatelet and anticoagulant medication are associated with an
increased incidence of bleeding and impaired platelet function. Mural thrombus within
the aneurysm sac leads to increased consumption of fibrin, platelets and coagulation
factors. Increased secondary fibrinolysis consequent on increased thrombin generation
within the aneurysm leads to elevated FDP levels that may, in turn, stimulate fibrinogen
synthesis leading to hyperfibrinogenaemia. A compensated state may exist between the
production and localised consumption of haemostatic components within the AAA sac.
Focal fibrinolytic activity and fibrinolytic gene expression have also been demonstrated
within the aortic wall of patients with AAA suggesting that the fibrinolytic system is
inappropriately activated. Disruption of the aortic wall secondary to rupture might
release proteases and TF into the circulation and trigger the coagulation pathways, and
stimulate fibrinolysis and platelet consumption. Further consumption of coagulation
factors and platelets occurs within the retroperitoneal haematoma.
Operative factors are important in the development of coagulation disorders. Whole
body or local hypoperfusion with reperfusion of large ischaemic areas leads to acidosis,
hyperkalaemia and myoglobinaemia which contribute to abnormal haemostatic function.
Prolonged duration of aortic cross-clamping is associated with an increased incidence of
coagulopathy. While lower torso ischaemia and endotoxaemia have been reported to be
associated with increased fibrinolytic activity, others have demonstrated inhibition of
fibrinolysis. Blood loss, massive blood transfusion and resuscitation with large volumes
of crystalloid and/or colloid may have a dilutional effect on levels of coagulation factors
and platelets. Hypothermia may cause blood loss by both potentiating platelet activation
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by plasmin and causing reversible platelet dysfunction. Mild platelet dysfunction,
prolonged bleeding times and moderate thrombocytopenia may also occur due to
platelet activation and consumption in surgical wounds and on the aortic prosthetic
graft. Bacterial translocation and endotoxaemia, which occur secondary to bowel
ischaemia and increased intestinal permeability, may stimulate the procoagulant effects
of endothelial and leucocyte activation, either directly or indirectly through the synthesis
and release of cytokines. Cytokines have been shown to contribute to fibrinolytic system
activation in lower torso ischaemia and endotoxaemia. Morphological evidence of
endothelial cell activation has been demonstrated in patients with ruptured AAA. As in
sepsis and endotoxaemia, haemostatic derangement in ruptured AAA repair may occur
secondary to neutrophil and endothelial cell activation and TF expression.
59
LZ
Prevention and management of haemostatic complications
Surgical bleeding occurs for two main reasons; inadequate surgical haemostasis due to a
large defect in a vessel and where the treatment is surgical; and failure of the
physiological mechanisms of haemostasis where there is microvascular bleeding and the
treatment is correction of the underlying disorder. Vascular patients may have a number
of concomitant disorders responsible for increased bleeding such as pre-existing liver
and renal impairment, antiplatelet and anticoagulant therapy, dilutional coagulopathy
due to massive blood transfusion and fluid resuscitation, and coagulopathy secondary to
haemorrhagic and hypovolemic shock.
The definitive management of coagulopathy is removal of the underlying cause. In
addition the patient may require supportive therapy and regular laboratory assessment of





Treat the underlying cause
Circulatory and ventilatory support
including RCC transfusion, inotropic
support, IPPV, RRT
Replacement of deficient factors
including FFP, platelets, cryoprecipitate
Exogenous administration of













This will replete endogenous stores of red blood cells, coagulation factors and platelets.
a) RCC is used to restore the oxygen carrying capacity of the circulation
b) FFP is used if there are multiple coagulation factor deficiencies and consumptive
coagulopathy. It replaces most factors with the exception of factors V and VIII.
c) Platelets are transfused if there is active bleeding and thrombocytopenia. Pooled
platelets also contain FFP and coagulation factor V.
d) Cryoprecipitate is used in consumptive coagulopathy. It contains fibrinogen, vWF
and coagulation factor VII.
Administration ofasents which modify haemostasis
Thrombin inhibitors
Heparin is the most frequently used thrombin inhibitor. There are no prospective
randomised trials of the use of intravenous or low-dose heparin in patients with
coagulopathy and there is no conclusive evidence that it improves outcome. It may be
ineffective in patients with coagulopathy as it requires AT III for its action and this is
reduced due to binding with thrombin. Antithrombin (AT) III infusion, with or without
heparin, may be associated with some improvement in coagulopathy and reduced
mortality in patients with septic shock (173). Recombinant activated protein C inhibits
generation of thrombin and TAFI and has been shown to reduce mortality in patients
with severe sepsis. Gabexate mesylate is a synthetic inhibitor of thrombin and plasmin
and a non-randomised study has reported some improvement in coagulopathy (174).
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Plasmin inhibitors
£-aminocaproic acid (EACA), tranexamic acid and aprotinin inhibit plasminogen directly
or inhibit the action of plasmin on fibrinogen and fibrin. Aprotinin is the most frequently
used antifibrinolytic agent and much of the work on its applicability has occurred in the
context of cardiopulmonary bypass. Proposed mechanisms of action include; inhibition
of the intrinsic coagulation pathway and complement cascade; antifibrinolysis;
hypercoagulability; reduced endothelial adhesion molecule expression; and preservation
of platelet adhesion molecule expression. Antifibrinolytic agents are advocated in
primary systemic fibrinolysis and aprotinin may be beneficial in the treatment of aspirin-
induced platelet abnormalities. In consumptive coagulopathy, secondary fibrinolysis acts
to restore microvascular patency and should not be inhibited. Antifibrinolytic agents
may lead to a hypercoagulable state with increased microvascular thrombosis and organ
failure (31,175) and some have recommended that their use in aortic surgery is contra-
indicated (137,140) for this reason. In non-cardiac surgery, randomised clinical trials of
aprotinin have shown a reduction in bleeding and blood requirement in thoracic and
thoraco-abdominal aortic aneurysm surgery using left heart bypass (176) and orthotopic
liver transplantation (177).
Desmopressin (PDAVP)
This is a synthetic analogue of vasopressin which leads to an acute increase in circulating
coagulation factor VIII and vWF levels and increased platelet adhesiveness to injured
endothelium. It may have a role in the treatment of aspirin-induced platelet abnormalities.
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Specific management ofhaemostatic complications in association with AAA.
There are many reports of the use of blood product replacement and intravenous/low-
dose heparin (106-108,111,114,120,130,135,137,140,178), antifibrinolytic agents
(108,112) or warfarin (111) in patients with coagulopathy presumed secondary to AAA,
and in whom aortic surgery is not performed. Pre-operative heparin therapy
(119,128,132) and infusion of gabexate mesylate (119) have been used to correct the
underlying coagulation abnormalities and reduce intra-operative blood loss in patients
who have chronic coagulopathy and AAA.
In ruptured AAA, delaying fluid resuscitation until haemorrhage is controlled by aortic
cross-clamping may be associated with a reduction in requirement for blood product
replacement. Most of the blood loss incurred during aortic aneurysm surgery is due to
technical manoeuvres involving large vessels and can be minimised by careful and
minimal dissection, the use of blended electrocautery for dissection, avoidance of excess
heparin administration, selection of a woven or sealed prosthetic graft and the use of
deep sutures. There is no evidence that the retroperitoneal approach to AAA repair is
associated with less blood loss than the transperitoneal approach. Short aortic clamp
times may also reduce the risk of coagulopathy (42,124). If major intra-operative blood
loss is anticipated, the use of auto-transfusers has been advocated (131,139) but these
devices may wash platelets and coagulation factors from the blood and cause mechanical
trauma to these elements. Prevention of severe hypothermia may minimise blood loss and
can be achieved by resuscitation with warm intravenous fluids, short operating times,
maintenance of optimal tissue perfusion and the use of warming devices (43,172). If six
or more units of RCC are transfused or there is on-going bleeding, then FFP and platelet
transfusion are advocated to reduce the risk of dilutional coagulopathy. Cryoprecipitate
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may also be required if the fibrinogen level is less than lg/dl. Due to the increased
incidence of severe coagulopathy in ruptured AAA, transfusion of platelets and/or FFP
has been recommended either pre-operatively (179) or after aortic cross clamping
(45,138). Thrombocytopenia and deranged coagulation at the end of the operation
should prompt further transfusion of platelets and/or FFP to reduce the risk of continuing
haemorrhage. Mulcare et al (137) have also recommended heparin therapy and the
avoidance of re-operation in this situation. Intravenous DDAVP has no beneficial effect
on haemostatic function or clinical outcome in elective aortic surgery (180).
The high incidence of post-operative thrombotic events after ruptured AAA repair
prompted Bradbury et al (45) to recommend the use of post-operative low-dose heparin
therapy in the absence of an abnormal coagulation screen or continuing haemorrhage.
Intravenous heparinisation in patients undergoing elective aortic surgery is not
associated with increased blood loss and reduces peri-operative fatal and non-fatal acute
coronary events (181). In patients undergoing ruptured AAA repair, peri-operative
intravenous heparinisation is mentioned in only one larger multicentre study. Hoffman
et al (10) reported that over 40% of 152 patients operated for rupture were given
intravenous heparin and peri-operative haemorrhage was the principal cause of death.
These anecdotal data suggest that heparinisation may be detrimental, but as no other
studies of ruptured AAA repair mention the use of intra-operative heparinisation, no




Patients with peripheral arterial disease have a high prevalence of symptomatic and
asymptomatic coronary artery disease which is associated with a significantly increased
risk of post-operative MI (182,183). There are multiple patient- and procedure-related
factors that might contribute to the development of peri-operative cardiac events. Patient
factors include age over 70 years, previous MI, cigarette smoking, previous coronary
artery interventions and co-existing cardiac failure, cardiac valve disease, angina pectoris,
arrhythmia and diabetes mellitus. In patients undergoing elective aortic surgery, 75-95%
have significant double or triple vessel coronary artery disease (184,185). In aortic
surgery, cardiac events are considered to occur secondary to hypotension associated with
anaesthetic induction, blood loss, fluid shifts and declamping; during the period of lower
torso ischaemia; and secondary to acidosis and metabolic defects which occur during
reperfusion. Cardiac morbidity is often preceded by myocardial ischaemia. However, this
is often difficult to detect as it occurs frequently, is typically asymptomatic, and may
only be suggested by persistent tachycardia. Myocardial ischaemia occurs in up to 30%
of patients undergoing aortic surgery, and is clinically 'silent' in 98%.
Atherosclerotic plaque rupture with subsequent occlusive thrombus formation generally
results in Q-wave infarction on ECG (186). A generalised procoagulant state has been
shown to be associated with myocardial injury (68,95-100,102,103,187-189). Peri¬
operative MI in vascular and non-vascular patients is most often of the non-Q-wave type
(190,191) and is frequently preceded by periods of ST segment depression on ECG,
rather than ST segment elevation, indicating cyclical changes in coronary artery
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bloodflow. This implies that peri-operative MI is not solely attributable to main stem
plaque rupture and thrombotic occlusion. Although haemodynamic instability may result
in sustained subendocardial ischaemia, a procoagulant state may lead to macro- and
microvascular thrombosis of the coronary circulation.
In contemporary practice, the reported median (range) incidence of peri-operative MI
and fatal MI in patients undergoing elective infrarenal aortic surgery is 3% (range, 0-
10%) and 1.3% (range, 0-4.7%), respectively (192). The incidence of MI, however,
largely depends on how enthusiastically the clinician investigates the patient. The MI rate
in retrospective studies is approximately 3%, whereas in prospective studies using ECG
and CK-MB analyses, this approaches 10-15%. As a marker ofmyocardial injury, cTn I
has major advantages over CK-MB and cTn T in patients undergoing major peripheral
vascular surgery. CK-MB is a non-structural cardiac enzyme which is largely, but not
absolutely, specific for myocardial injury and is usually elevated only when myocardial
cell necrosis occurs. CK-MB persists in the circulation for 24-36 hours after myocardial
injury. cTn I is a structural myocardial protein which modulates the interaction of the
contractile proteins, actin and myosin. cTn I is found in larger quantities in the
myocardial cell than CK-MB. Thus, when the myocardial cell is injured due to ischaemia,
cTn I is liberated into the circulation in much larger quantities than CK-MB. It is
detectable between 2 and 6 hours after the injury and persists for up to 7-10 days. cTn I
levels usually begin to rise while the patient is asymptomatic and precedes clinically
significant cardiac events by 24-48 hours in 50% of patients. Although small areas of
myocardial injury, rather than actual necrosis, may liberate CK-MB in quantities too
small to be detected, cTn I is liberated in relatively greater quantities and is more likely
to be detectable. Unlike CK-MB and cTn T, cTn I is entirely cardiospecific, does not
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accumulate in patients with renal failure, has not been shown to be released from skeletal
muscle. Furthermore, cTn I can be detected after myocardial ischaemia and minor
myocardial injury whereas CK-MB is usually only elevated secondary to myocardial
necrosis. For these reasons, cTn I is currently the most specific and sensitive marker for
myocardial injury (193-197). The size of cTn I rise has been shown to be proportional to
the size of the area ofmyocardial injury (197). In patients with acute chest pain, cTn I is
highly sensitive for the early detection ofmyocardial cell injury (198) and can predict the




The vascular endothelium has an important role in the regulation of haemostasis and the
maintenance of vascular tone. Vasoconstriction in response to vascular injury is the initial
step in the process leading to haemostasis.
Endothelin (ET)-l is the most potent known vasoconstrictor. It is synthesized by
endothelial cells as well as macrophages and vascular smooth muscle cells. It is
principally secreted abluminally from vascular endothelial cells but may enter the
circulation if concentrations are high at the endothelial cell-vascular smooth muscle
interface (51). Expression is induced by haemorrhage, haemodilution, hypoxia, acidosis,
shear stress, catecholamines, cytokines, endotoxin and thrombin.
Big ET-1 is the immediate precursor of ET-1, and its conversion to biologically active
ET-1 by endothelin-converting enzymes occurs mainly in the vessel wall (202,203). Big
ET-1 is detectable in the plasma for considerably longer than ET-1 which has a half-life
of approximately five minutes (204), and increased plasma levels of big ET-1 are
considered to represent increased ET-1 generation rather than reduced clearance.
ET-1 leads to vasoconstriction in resistance vessels, especially the coronary, cerebral
and renal circulation by acting on ET^ receptors in vascular smooth muscle cells, and
ETg receptors on vascular smooth muscle and endothelial cells. ET-1 stimulates
thrombin generation in vitro as demonstrated by elevated TAT levels and reduced levels
of AT III and fibrin monomer (205,206). ET-1 leads to vasoconstriction and a local
inflammatory response both of which facilitate intravascular thrombosis (205-208).
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Elevated plasma ET levels may form part of a homeostatic response to maintain systemic
blood pressure (204), and have been demonstrated in critically ill patients with MI (209),
cardiogenic shock (210), septic shock (211), ARDS (212), cardiac failure (213,214), and
ARF (215). ET levels are increased in patients with coagulopathy, particularly if
associated with sepsis or MOF (208,216). To date, several animal and human studies of
septic shock have suggested that ET release may be pathological (217-222) or
homeostatic (222,223). Increased plasma ET levels have been demonstrated in patients
undergoing non-ruptured AAA repair with infrarenal (224,225) and supracoeliac aortic





The pro-inflammatory cytokine, tumour necrosis factor (TNF), has been implicated in the
pathophysiology of the systemic inflammatory response syndrome and MOF (35,228).
Increased levels of TNF, occurring directly or in response to endotoxaemia, have a
pivotal role in endothelial cell activation (52,53). TNF causes leucocyte activation,
increased phagocytosis, and neutrophil chemotaxis and tissue sequestration. TNF can
also induce a procoagulant and hypofibrinolytic state by stimulating TF expression by
endothelial cells (and leucocytes), upregulating the release of vWF into plasma (53,54),
and upregulating PAI and downregulating t-PA release (72-75,77,82,83,150).
TNF acts by binding to target cells at specific TNF receptors (TNF-R) of 55 kDa and 75
kDa molecular mass (p55 and p75), respectively. Binding of TNF leads to cleavage of
these receptors from target cells and their release into the circulation as soluble TNF
receptors (sTNF-Rs) (229). Circulating TNF is frequently difficult to demonstrate. This
may be because of its short half-life, or because of TNF binding to plasma proteins,
difficulties with the numerous methods ofmeasuring TNF in the circulation, or the fact
that it is mainly produced in tissues and only occasionally enters the circulation. It has
been suggested, therefore, that sTNF-R levels may better reflect the degree of TNF-
induced tissue injury (230,231). The finding that high concentrations of the sTNF-Rs act
as endogenous TNF antagonists, and that low concentrations may slow down TNF
clearance so prolonging its activity (231), has led to the suggestion that administration
of exogenous sTNF-Rs may ameliorate the adverse effects of TNF. Experimental data
suggest that administration of exogenous sTNF-R before aortic cross-clamping is
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associated with a reduction in circulating TNF and subsequent lung injury in an animal
model (232). However, human studies have shown that elevated levels of endogenous
sTNF-Rs are actually associated with the development of MOF and increased mortality
in sepsis (233), pancreatitis (234) and multiple trauma (235). Circulating TNF has been
demonstrated in elective and emergency aortic surgery (75,161,163,236-241). Elevated
levels of sTNF-Rs have also been detected in patients undergoing repair of non-ruptured





Activation of the coagulation cascade and the fibrinolytic system contribute to the
pathophysiology of haemorrhagic and micro- and macrovascular thrombotic events such
as coagulopathy, myocardial infarction and multiple organ dysfunction. Although
deranged haemostatic function has been described in patients with asymptomatic AAA,
careful review of the literature reveals that there are no detailed studies of peri-operative
haemostatic function in patients undergoing emergency AAA surgery for rupture.
The hypothesis of this thesis is that whole body hypoperfusion due to haemorrhagic
shock in ruptured AAA, and lower body ischaemia and reperfusion injury during AAA
repair all contribute to the development of abnormal haemostatic function. In turn, this
state of haemostatic derangement is responsible for haemorrhagic and thrombotic
complications which account for the majority of the morbidity and mortality associated
with elective and emergency AAA repair.
The principal aims of this thesis were four-fold. The first aim was to determine the
hospital-based and overall community-based mortality rate for patients with ruptured
AAA within the catchment area served by a regional vascular surgical unit in order to
assess whether advances in anaesthesia, surgical techniques and critical care, as well as
the centralisation of vascular surgical services have altered the outcome for patients with
ruptured AAA in the past two decades. In addition, the aetiology of fatal peri-operative
complications was examined to determine the contribution of haemostatic derangement
to outcome in this group of patients.
The second aim was to examine, for the first time, the pathophysiology of haemostatic
derangement in patients undergoing ruptured AAA repair by measuring peri-operative
changes in circulating markers of coagulation, fibrinolysis and endothelial cell activation.
The findings in patients with ruptured AAA were compared with patients undergoing
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repair of asymptomatic and symptomatic non-ruptured AAA to assess the effect of
haemorrhagic shock and other clinicopathological variables such as operative blood loss
and aortic clamp time on haemostastic function.
The third aim was to relate the observed peri-operative changes in coagulation,
fibrinolysis and endothelial cell activation to clinical end-points including death,
myocardial injury, haemorrhage and organ dysfunction.
The final aim of this thesis was to investigate possible pathogenetic mechanisms for the
observed changes in haemostatic function by determining the relationship between





Ethical and consent issues
Lothian Region Ethical Committee approval was obtained for all aspects of the work
within this thesis. Fully-informed consent was obtained from all patients or next of kin.
When a patient was admitted with ruptured AAA and written consent could not be
obtained, verbal consent was obtained from the patient or the next of kin. All patients
studied were admitted to the ERVSU between February 1996 and December 1997.
Patients
Sixty-six patients who underwent operation for infrarenal AAA were prospectively
studied. Twenty two patients (19 men and 3 women of median age 69, range 56 - 81,
years) underwent elective repair of asymptomatic AAA. Seven patients (7 men of median
age 68, range 65 - 74, years) underwent emergency repair of acutely symptomatic non-
ruptured AAA. Thirty seven patients (33 men and 4 woman of median age 74, range 63
- 87, years) underwent attempted repair of ruptured AAA. The overlap of patients studied
in chapters 6-12 are illustrated in Tables 3.1 and 3.2.
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TABLE 3.1
Patients with asymptomatic and symptomatic non-ruptured AAA.
Patient AAA Ch 6 Ch7 Ch8 Ch9 ChlO Chll Chl2
1 A Y Y Y Y Y





7 A Y Y Y Y Y










18 A Y Y Y Y Y
19 A Y Y Y Y Y
20 A Y Y Y Y Y
21 A Y Y Y Y Y








KEY: A = asymptomatic, S = symptomatic
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TABLE 3.2
Patients with ruptured AAA.
Patient Ch 6 Ch7 Ch8 Ch9 ChlO Chll Chl2
1 Y




6 Y Y Y Y Y
7 Y Y Y Y Y Y
8 Y Y Y
9 Y
10 Y Y Y Y Y
11 Y Y Y Y Y Y
12 Y Y Y Y Y
13 Y
14 Y Y Y Y Y Y
15 Y Y Y Y Y Y
16 Y




21 Y Y Y Y
22 Y Y Y Y
23 Y
24 Y
25 Y Y Y Y
26 Y Y Y Y Y Y
27 Y Y Y Y Y Y
28 Y Y Y Y Y Y
29 Y










The following clinicopathological and operative data were collected prospectively:
a) Patient demography - age and sex; co-morbidity and medications; type of presentation
(asymptomatic, acutely symptomatic non-ruptured or ruptured AAA); and antero¬
posterior diameter of the aneurysm measured by ultrasonography in asymptomatic AAA.
b) Pre-operative data - delay between the onset of symptoms of rupture and hospital
admission; documented episodes of hypotension, loss of consciousness and cardiac
arrest; and resuscitative measures.
c) Operative data - type of aneurysm (intraperitoneal and/or retroperitoneal rupture,
inflammatory AAA, suprarenal AAA); pharmacological intervention (including heparin,
protamine sulphate, mannitol, adrenaline and dopamine); aortic clamp time and
operation time; measured blood loss and fluid administration (including crystalloid,
colloid, RCC and blood products); intra-operative episodes of hypotension;
complications; and graft configuration (aorto-aortic, aorto-bi -iliac or aorto-bifemoral).
d) Post-operative data - duration of ITU stay, ventilatory support and hospital stay;
complications and mortality; and therapeutic intervention.
Operative methods
Ruptured AAA was defined by the presence of fresh retroperitoneal and/or
intraperitoneal blood in the presence of an aortic aneurysm with no other identifiable
cause for the findings at operation. Acutely symptomatic non-ruptured AAA was defined
by the acute onset of abdominal and/or back pain in the presence of a tender AAA which
was found to be intact at emergency operation. Sudden expansion or impending rupture
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were presumed to be responsible for the clinical findings as there were no other
identifiable causes.
Patients with rupture had general anaesthesia, and patients with non-ruptured AAA had
combined general and epidural anaesthesia. All patients underwent AAA repair through a
transverse supra-umbilical incision with infra-renal aortic clamping. No patients required
suprarenal or supracoeliac aortic clamping. No patients with ruptured AAA were
systemically heparinised. Patients with non-ruptured AAA were given an intravenous
bolus of 5000 units of heparin immediately before aortic clamp placement. The dose of
heparin was not varied according to the weight of the patient.
Definition ofperi-operative complications
1. Major peri-operative cardiac complications were defined as:
a) Acute MI diagnosed by two of the following three criteria: history of ischaemic-type
chest pain, evolving ECG changes, and a rise and fall in serial serum cardiac enzymes.
b) Cardiac failure associated with chest x-ray evidence of pulmonary oedema.
c) Cardiac arrhythmias requiring therapeutic intervention to maintain cardiovascular
stability.
2. Peri-operative organ failure:
a) Cardiac failure was defined as sustained periods of hypotension (mean arterial
pressure less than or equal to 60 mmHg) requiring fluid resuscitation and inotropic
support and/or cardiac arrhythmia requiring pharmacological treatment to maintain
cardiovascular stability
b) Respiratory failure was defined as hypoxia requiring mechanical ventilatory support
for more than four days.
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c) ARF was defined as elevated serum creatinine greater than or equal to 250 pmol/1
and/or the requirement for renal replacement therapy.
d) Coagulopathy was defined as clinical evidence of haemorrhage accompanied by
laboratory evidence of thrombocytopenia, prolonged clotting times, hypofibrinogenaemia
and elevated levels of D-dimer.
Blood sample collection
Arterial blood was sampled from an indwelling radial arterial line. The first 10ml of blood
were discarded. Blood was collected in a standard syringe without the application of
suction, and then transferred to specific tubes. After sampling, the arterial line was
flushed with heparinised saline. A 2.7 ml sample was collected into EDTA anticoagulant
(1.6mg/ml). A 3ml sample was collected into sodium citrate anticoagulant (0.106 mol/1).
A 9ml sample was collected into lithium heparin. A 9ml sample was collected into a tube
containing clot activator. All of the above tubes were manufactured by Monovette ®,
Sarstedt. A 4.5 ml sample was collected into strong acid citrate (Stabilyte ®, Biopool,
Sweden). Samples were placed immediately on ice and transferred to the laboratory
where they were centrifuged within 30 minutes of collection at 3,000 revolutions per
minute for 30 minutes at a temperature of 4 C (1400g). Plasma and serum were
separated and stored at - 70 C for later batch analysis.
Assay methods
All commercially available assays were performed according to the manufacturer's
instructions. Prior to each assay run, a standard reference curve was constructed from
standards provided by the supplier. All determinants were performed in duplicate.
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1. Standard coagulation screen
Haematocrit (normal range, 0.37 - 0.54) and whole blood platelet count (normal range,
150 - 350 x 10 /1) was determined on an EDTA sample using the fully-automated
Sysmex NE 8000 analyser. Fibrinogen (normal range, 1.5 - 4.0 g/1), PT (normal range,
10.5 - 14.5 seconds) and aPTT (normal range, 28 - 40 seconds) were determined on a
sodium citrate anticoagulant sample using the fully-automated Sysmex CA 6000
analyser.
2. Markers of thrombin generation
a) PF 1+2 (normal range, 0.4 - 1.1 nmol/1) was determined on a sodium citrate
anticoagulant sample by sandwich ELISA (Enzygnost ® F 1+2 micro, Behring
Diagnostics, USA). During the first incubation period (30 mins at 37C), PF 1+2 antigen
in a 50|ul serum sample binds to rabbit anti-human PF 1 +2 antibodies fixed to the surface
of a microtitration plate. Unbound constituents are removed by washing the plate and
100|Lll of peroxidase-conjugated rabbit anti-human prothrombin antibody is added to the
plate. During the second incubation period (15 mins at 37C), these enzyme-conjugated
antibodies bind to PF 1+2 antigen that was bound by the first layer of antibody. The
plate is rinsed to remove excess enzyme-conjugated antibodies and a chromogen
solution is added. The plates are incubated protected from light for 15 mins at 20-25C.
The enzymatic reaction between hydrogen peroxide and chromogen is terminated by
adding diluted sulphuric acid. The resulting colour intensity, which is proportional to the
concentration of PF 1+2, is determined photometrically against distilled water at 492nm.
The lower limit of detection is 0.04 nmol/1.
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b) TAT (normal range, 1.0-4.1 jag/1) was detennined on a sodium citrate anticoagulant
sample by sandwich ELISA (Enzygnost ® TAT micro, Behring Diagnostics, USA).
During the first incubation period (15 mins at 37C), TAT antigen in a 50pil serum
sample binds to rabbit anti-human thrombin antibodies fixed to the surface of a
microtitration plate. Unbound constituents are removed by washing the plate and 1 OOpl
of peroxidase-conjugated rabbit anti-human AT1II antibody is added to the plate. During
the second incubation period (15 mins at 37C), these enzyme-conjugated antibodies
bind to TAT antigen that was bound by the first layer of antibody. The plate is rinsed to
remove excess enzyme-conjugated antibodies and a chromogen solution is added. The
plates are incubated protected from light for 30 mins at 20-25C. The enzymatic reaction
between hydrogen peroxide and chromogen is terminated by adding diluted sulphuric
acid. The resulting colour intensity, which is proportional to the concentration of TAT,
is determined photometrically against distilled water at 492nm. The lower limit of
detection of the assay is 0.5 jU.g/1.
3. Markers of fibrinolysis
a) t-PA activity (normal range, 0.2 - 2.0 IU/ml) was determined on a strong acid citrate
sample by chromogenic assay (amidolytic method) (Coaset ® t-PA, Chromogenix,
Sweden). The blood sample for estimation of t-PA activity is collected into strong acid
citrate (Stabilyte ®, Biopool, Sweden) and this immediately stops the in vitro inhibition
of t-PA by PAI. The acidified plasma sample is thawed and 100pl is diluted with 3.5ml
sterile water. 200pl of this diluted sample is placed in a test tube to which 1 volume of
human plasminogen, 1 volume of chromogenic substrate S-2251 and 3 volumes of Tris
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buffer working solution are added. Human t-PA stimulator and Tris buffer solution are
then added and this markedly increases the conversion of plasminogen to plasmin by t-
PA in the plasma sample. The contents of the test tube are mixed and incubated at 37C
for 135-240 mins. The reaction is terminated by adding 20% acetic acid or 10% citric
acid. The amount of t-PA activity is determined by measuring the amidolytic activity of
plasmin on the chromogenic substrate and the release of p-nitroanaline is determined
photometrically against distilled water at 405nm. The lower limit of detection of the
assay is 0.1 IU/ml.
b) t-PA antigen (normal range, 1-12 ng/ml) was determined on a sodium citrate sample
by ELISA (Coaliza ® t-PA, Chromogenix, Sweden). During the first incubation period
(60 mins at 37C), t-PA antigen in the sample binds to two mouse anti-human t-PA
monoclonal antibodies fixed to the surface of a microtitration plate. Unbound
constituents are removed by washing the plate and 200pl of horseradish peroxidase-
conjugated anti-human t-PA monoclonal antibody is added to the plate. These enzyme-
conjugated antibodies bind to t-PA antigen that was bound by the first layer of antibody.
A further wash removes unbound peroxidase and the plates are incubated for a second
period (60 mins at 37C). The plates are then washed again and 200pl of
tetramethylbenzidine dissolved in dimethyl sulphoxide is added. This chromogen acts
on the peroxidase to form a blue colour. The plates are incubated for a third time for 30
mins at room temperature and the enzymatic reaction is terminated by adding dilute
sulphuric acid. The colour then turns yellow and the intensity is proportional to the
concentration of t-PA antigen in the sample. This is determined photometrically by a
microplate reader with 450nm and 620nm or 690nm filter. The lower limit of detection
of the assay is 0.5 ng/ml.
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c) PAI activity (normal range, < 15 AU/ml) was determined on a sodium citrate sample
by chromogenic assay (amidolytic method) (Coatest ® PAI, Chromogenix, Sweden). To
a 25pl sample of plasma, 25pl of 40IU/ml t-PA is added such that inactive t-PA:PAI
complexes form. The sample is mixed and incubated at 20-24C for 10 mins. The sample
is diluted with 4ml of sterile water and 200pl of this diluted sample is placed in a test
tube to which 1 volume of human plasminogen, 1 volume of chromogenic substrate S-
2403 and 3 volumes of Tris buffer working solution are added. Human fibrinogen
fragments stimulator and Tris buffer solution are then added and this markedly increases
the conversion of plasminogen to plasmin by residual t-PA in the plasma sample. The
contents of the test tube are mixed and incubated at 37C for 50 mins. The reaction is
terminated by adding 20% acetic acid or 2% citric acid. PAI activity is determined by
measuring the amidolytic activity of plasmin on the chromogenic substrate and the
release of p-nitroanaline is determined photometrically against distilled water at 405nm.
The amount of plasmin formed is proportional to the residual t-PA activity and inversely
proportional to the PAI activity. The lower limit of detection is 5 AU/ml.
d) FDP D-dimer (normal range, 630 - 850 ng/ml) was determined on a sodium citrate
sample by ELISA (Asserachrom ®, D-Di, Diagnostica Stago, France). During the first
incubation period (60 mins at 18-25C), D-dimer antigen in the sample binds to mouse
anti-human D-dimer monoclonal antibody fixed to the surface of a microtitration plate.
Unbound constituents are removed by washing the plate and 200pl of peroxidase-
conjugated rabbit anti-fragment D antibody is added to the plate and incubated for 60
mins at 18-25C. These enzyme-conjugated antibodies bind to D-dimer antigen that was
bound by the first layer of antibody. After incubation, a further wash removes unbound
peroxidase and the bound peroxidase acts on 200pl of ortho-phenylenediamine and
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hydrogen peroxide which is added. The plates are incubated for 3 mins at room
temperature and the enzymatic reaction is stopped with dilute sulphuric acid. The
intensity of the colour change is determined photometrically at 492nm and is
proportional to the D-dimer concentration. The lower limit of detection is 5 ng/ml.
4, Markers of endothelial cell activation
a) Big ET-1 (normal range, 10 - 60 pg/ml) and ET-1 (normal range, 1.5 - 4.5 pg/ml)
concentrations were determined on a lithium heparin plasma sample using an acetic acid
extraction technique and a modified commercial radio-immunoassay using rabbit anti-
human big ET-1 or ET-1 (Peninsula Laboratories Europe, UK). Sample extract was
incubated with either big ET-1 or ET-1 antibody for 24 hours at 4 C. Following
incubation, 125 I-labelled big ET-1 (Peninsula Laboratories Europe) or ET-1 (NEN Life
Science Products, Boston, MA, USA) was added and incubation was continued for an
additional 20 minutes at 4 C. Complexes were precipitated with Amerlex ® donkey anti-
rabbit antibody (Amersham Life Sciences Limited, UK) and counted for radioactivity.
The lower limit of detection for big ET-1 and ET-1 is 1 pg/ml and 0.25 pg/ml,
respectively.
b) vWF antigen (normal range, 0.42 - 1.22 IU/ml) was determined on a sodium citrate
sample by ELISA developed and validated in the Department of Haematology, Royal
Infirmary of Edinburgh. During the first incubation period (120 mins at room
temperature), vWF antigen in the sample binds to rabbit anti-human vWF monoclonal
antibodies fixed to the surface of a microtitration plate. Unbound constituents are
removed by washing the plate and 100pl of peroxidase-conjugated anti-human vWF
antibody is added to the plate. These enzyme-conjugated antibodies bind to vWF antigen
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that was bound by the first layer of antibody. The plates are incubated for 60 mins at
room temperature and a further wash removes unbound peroxidase. The plates are then
washed again the bound peroxidase acts on lOOpl of ortho-phenylenediamine and
hydrogen peroxide which is added. The plates are placed in the dark for 7 minutes and
the enzymatic reaction is terminated with dilute sulphuric acid. The colour intensity is
proportional to the concentration of vWF antigen in the sample. This is determined
photometrically by a microplate reader at 492nm. The lower limit of detection is 0.5
ng/ml.
c) Soluble thrombomodulin (sTM) (normal range, < 25 ng/ml) was determined on a
sodium citrate sample by ELISA (Asserachrom Thrombomodulin, Diagnostica Stago,
France). During the first incubation period (120 mins at 18-25C), sTM antigen in the
sample binds to mouse anti-thrombomodulin monoclonal antibody fixed to the surface of
a microtitration plate. Unbound constituents are removed by washing the plate and 200pl
of peroxidase-conjugated mouse anti-thrombomodulin monoclonal antibody is added to
the plate and incubated for 120 mins at 18-25C. These enzyme-conjugated antibodies
bind to sTM antigen that was bound by the first layer of antibody. After incubation, a
further wash removes unbound peroxidase and the bound peroxidase acts on 200pl of
ortho-phenylenediamine and urea peroxide which is added. The plates are incubated for
8 mins at room temperature and the enzymatic reaction is stopped with dilute sulphuric
acid. The intensity of the colour change is determined photometrically at 492nm and is
proportional to the sTM concentration. The lower limit of detection is 5 ng/ml.
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5. Markers ofmyocardial injury
a) CK (normal range, 30 - 150 U/l) and its myocardial iso-enzyme CK-MB were
determined on a clotted serum sample by colourimetric assay with dry slide technology
(Vitros CK and CK-MB slides, Johnson and Johnson, USA) using the fully-automated
Kodak 250 analyser. The lower limit of detection for CK is 20 U/l. If total CK was
elevated above the normal range, then CK-MB was measured. CK-MB level less than
16 U/l is negative for CK-MB. CK-MB greater than 16U/1 is positive and the proportion
of CK-MB relative to CK was calculated. A value for CK-MB between 4 and 25% of
the total CK is considered positive for myocardial infarction.
b) cTn I was determined on a clotted serum sample by ELISA (OPUS Troponin I, Dade
Behring Inc, USA) using the fully-automated OPUS II analyser. The lower limit of
detection is 0.5 ng/ml and a value greater than or equal to this is considered positive for
myocardial injury.
6. C-reactive protein
CRP (normal range, < 10 mg/1) was determined on a clotted serum sample by sandwich
ELISA using rabbit anti-human-CRP antibody and peroxidase-conjugated rabbit anti-
human-CRP antibody (DAKO Rabbit Anti-human CRP, High Wycombe, UK). Prior to
each assay run, a standard reference curve is constructed from standards provided by the
supplier. All determinants are performed in duplicate. The lower limit of detection is
0.39 mg/1.
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7. Soluble Tumour Necrosis Factor Receptors p55 and p75
Serum levels of sTNF-Rs p55 and p75 were determined on a clotted serum sample by
sandwich ELISA using polyclonal and monoclonal anti-sTNF-R55 and sTNF-R75
antibodies. The assays were developed and validated by Dr WA Buurman, University of
Maastricht, Netherlands who kindly donated them for use in this thesis. Prior to each
assay run, a standard reference curve is constructed from standards provided by the
supplier. All determinants are performed in duplicate. The lower limit of detection for
sTNF-R p55 and p75 is 0.2 ng/ml and 2 ng/ml, respectively.
Statistical analysis
2
The Mann-Whitney U test (MW), % test and Fisher's exact test were used to compare
groups of patients. The Kruskal-Wallis one-way analysis of variance was used to
examine whether assay levels changed significantly between sampling points. As the
data were not normally distributed, the Spearman rank test was used to correlate
clinicopathological variables and haemostatic data. A probability value of less than 0.05
was regarded as statistically significant.
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Chapter 4
Outcome of ruptured AAA in the Edinburgh
Regional Vascular Surgery Unit
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4.1 Introduction
Careful review of the literature reveals few reports from single centres which describe
the results of surgery for more than 100 patients with ruptured AAA (Table 1.1). Many
series describe relatively small numbers of highly selected patients operated upon over
long study periods, and patients who survive to reach the hospital only to be denied
repair, or succumb during transfer to the operating theatre, are often not included (3).
In 1983, three consultants with a special interest in vascular surgery combined formally
to create the ERVSU. At the time of writing, the ERVSU was the sole provider of 24-
hour, 365-day vascular surgical services for a population of 1.2 million living in an area
of approximately 4,500 square miles in south-east Scotland. In this unit, almost 50% of
all the AAA repairs are performed for rupture and this has resulted in considerable
experience in the management of this group of patients (15).
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4.2 Aims
To determine the operative mortality rate, and the incidence and aetiology of fatal
complications in patients who underwent ruptured AAA repair in the ERVSU during the
14-year period ending 31st December 1996. As patient selection impacts on operative
mortality, the characteristics of those patients who were admitted to this unit with
rupture and did not undergo attempted repair were also examined.
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4.3 Methods
The prospective Lothian Surgical Audit data-base was interrogated to identify all
patients admitted to the ERVSU with a diagnosis of ruptured AAA during the 14-year
period between 1st January 1983 and 31st December 1996. Hospital discharge
summaries were reviewed and cause of death recorded.
A patient was considered to have had an operation if an anaesthetic was administered
with the intention of repairing the ruptured AAA regardless of whether a graft was
successfully inserted. Ruptured AAA was defined by the presence of fresh
retroperitoneal and/or intraperitoneal blood in the presence of an aortic aneurysm and
with no other identifiable cause for the findings. Operative mortality has been defined as




The Mann-Whitney test (MW), test and Fisher's exact test were used.
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4.4 Results
A total of 1381 patients had surgery for AAA during the 14-year study period. Of these,
616 patients (45%) (505 men and 111 women of median age 72, range 46-86, years)
underwent operation for ruptured AAA. A tube graft was inserted in 311 patients and a
bifurcated graft in 240 patients. In 65 patients, no graft was inserted at operation and all
of these patients died. There was no significant difference in the age of patients who had
a graft inserted compared with those who did not. The operative mortality rate was 230
of 616 (37.3%) patients. Survivors were significantly younger than non-survivors
(median age 71, range 46-85 years vs. non-survivors: median age 74, range 46-86 years;
p<0.001, MW). One hundred patients died during attempted repair and 130 patients died
in the post-operative period. The factors contributing to the death of these 230 patients
are shown in Table 4.1. A further 125 patients (73 men and 52 women of median age
79, range 54-93 years) were admitted but did not undergo operation. Non-operated
patients were significantly older than operated patients (p<0.001, MW). There were
usually multiple factors which influenced the decision not to operate (Table 4.2).
During the study period, the operative mortality increased (Figure 4.1) but there was no
significant difference in the operative mortality for patients who had a graft inserted, or
the overall mortality rate (including operated and non-operated patients). A significantly
greater proportion of patients underwent operation (Figure 4.2) but a significantly
greater proportion did not have a graft inserted (Figure 4.3). Significantly more patients
had a tube graft (Figure 4.4) and there was no difference in mortality for patients who
underwent repair with a tube (88 of 310, 28%) or bifurcated graft (77 of 240, 32%).
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TABLE 4.1
Fatal complications in patients undergoing ruptured AAA repair.
Complication contributing to death No. of patients
Intra-operative death 100

















Ruptured thoracic aortic aneurysm 1
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TABLE 4.2
Reasons for patients with ruptured AAA not undergoing attempted repair
Reason No. of patients
Decision to operate had been reached but patient died
en route to the operating theatre 48
Poor clinical condition on admission to hospital
Unresponsive shock 32





Ischaemic heart disease 12
Chronic obstructive airways disease 8
Previous disabling CVA 5
Chronic renal failure 4
Co-existing inoperable malignancy 3
Dementia 3
Parkinson's disease 2
Co-existent severe acute pancreatitis 1
Paraplegia 1
Previously assessed by anaesthetist as unfit
for elective aneurysm repair 11
Known inoperable thoraco-abdominal aortic aneurysm 5
Patient declined the offer of operation 3
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FIGURE 4.1
Operative mortality rate (%) for ruptured AAA repair in the ERVSU between
1983 and 1996.
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FIGURE 4.2
Patients operated (%) for ruptured AAA in the ERVSU between 1983 and 1996.
Operated patients are represented by the red column, and non-operated patients




Proportion of operated patients who received a graft (%) in the ERVSU between
1983 and 1996.
Patients receiving a graft are represented by the red column, and those not
receiving a graft by the yellow column.
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FIGURE 4.4
Patients operated who received a tube or bifurcated graft in the ERVSU
between 1983 and 1996.
Patients receiving a tube graft are represented by the red column, and those
receiving a bifurcated graft by the yellow column.
No. of patients
p < 0.001
1983- 1987 1988-1992 1993- 1996
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4.5 Discussion
This study reports the largest single centre experience of ruptured AAA repair. Unlike
other reports, the present study also describes those patients who were admitted and did
not undergo operation. The operative mortality rate for rupture was 230 of 616 (37.3%)
patients. By including the 48 patients who died during transfer to the operating theatre,
the 'intention to treat' mortality rate was 278 of 664 (41.9%) patients. Those patients
who did not undergo an operation were significantly older than those who were operated
upon, and survivors of operation were significantly younger than non-survivors.
Over time, attempted repair was undertaken in an increasing proportion of patients, but
an increasing proportion did not have a graft inserted. This, combined with the fact that
there was no improvement in the outcome for patients who had a graft inserted, appears
to explain the increase in operative mortality rate during the study period. A more
aggressive surgical approach in recent years has not had a positive impact on the overall
mortality rate (operated and non-operated patients) in this unit.
Cardiac events, ARF, respiratory failure and haemorrhage contributed to the majority of
the peri-operative mortality. Major cardiac events contributed to 48%, and ARF and
respiratory failure to 41% and 22% of post-operative deaths, respectively. Coagulopathy
was recorded in 19% of intra-operative deaths. Intra-abdominal haemorrhage occurred
in 23% of post-operative deaths but coagulopathy was present in only 15%. This may be
an underestimate as coagulopathy is present in almost all patients with rupture who are
re-operated for bleeding (43). Lower limb ischaemia, CVA and pulmonary embolism
contributed to 11%, 9% and 4% ofpost-operative deaths, respectively.
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Despite advances in anaesthesia, surgical techniques and critical care, there has been no
improvement in the outcome for patients presenting with ruptured AAA and admitted to
the ERVSU in the past two decades. This study did not include patients who died from
rupture at home or in hospital, or patients in whom the diagnosis was reached in other
hospitals in our catchment area but were not referred, transferred or operated upon.
While centralisation of vascular surgical services has not been associated with an
improvement in mortality rate for patients presenting to this unit, the effect on the overall




• The operative mortality rate for ruptured AAA was 37%.
• The 'intention to treat' mortality rate was 42%.
• Attempted repair was undertaken in an increasing proportion of patients over time.
• This was associated with an increase in the operative mortality rate.
• Thrombotic and haemorrhagic events (MI, ARF, coagulopathy, CLI, CVA and PE)
contributed to the majority of the peri-operative mortality.
• Centralisation of vascular surgical services has not been associated with an
improvement in mortality for patients presenting to this unit. Further study is required




Community outcome from ruptured AAA in the




As a result of clinical, political and economic factors, there is an increasing tendency in
the UK to centralise vascular surgical services within large regional units. However, to
concentrate vascular expertise within a small number of individuals at limited
geographical sites inevitably leads to depletion, even an absence, of expertise elsewhere.
For example, at the time of writing only one of eight peripheral hospitals conducting
'general' surgery in the catchment area of the ERVSU is staffed by vascular surgeons.
While specialisation may improve individual patient outcomes for specific procedures
performed within specialist units, it is equally important to demonstrate that
centralisation does not prejudice equality of access to specialist care and, therefore, the
overall, community-based, outcome for the underlying condition. Ruptured AAA is a
major problem in the UK and decisions on how vascular services are to be distributed
must be based, at least in part, upon consideration of how these unstable, high risk
patients are most appropriately managed.
106
5.2 Aims
To examine the patterns of referral, management and outcome of patients identified as
having ruptured AAA within the catchment area served by this regional vascular unit.
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5.3 Methods
This study period was 1st January 1989 to 31st December 1995 (the most recent year for
which complete population data were available). All residents of the catchment area of
the ERVSU who were admitted to any hospital in the catchment area with a diagnosis of
ruptured AAA (International Classification of Diseases ninth revision (ICD-9) codes
441.3, 441.5, and 441.1 if coded in addition to 441.3 or 441.5), or who were certified
deceased as a result of ruptured AAA, either in hospital or in the community, were
identified through the Information and Statistics Division (ISD) of the National Health
Service in Scotland using the Scottish Morbidity Records 1 (SMR1) (hospital discharge
records) and General Registrar Office (Scotland) (GRO (S)) mortality records. SMR1
records are linked to each other, and to the GRO (S) mortality records by ISD using
probability matching and provide a patient database that includes hospital admission and
mortality data. The prospective Lothian Surgical Audit data-base was interrogated to
identify all residents from the catchment area who were admitted to this unit with
ruptured AAA. Residents of the catchment area who were admitted to hospitals outwith
the catchment area (n=32), and residents of other catchment areas who were admitted to
hospitals within the area (n=20), were excluded from analysis. Patterns of referral and
management, as well as outcome data and post-codes were retrieved for each patient.
As in most instances it was not possible to ascertain the patient's precise location at the
time of rupture, it was assumed that rupture had occurred near to their home address
rather than at a distant site. Travelling distance for patients admitted directly to this unit
was, therefore, defined as the distance by land from the centre of the individual's
postcode region of residence to this unit. For those admitted indirectly, travelling
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distance was defined as the distance from the centre of the individual's postcode region
of residence to the referring hospital and then onto this unit. All patients in the present
study were transferred by land ambulance.
Statistical analysis
2
The Mann-Whitney test (MW), x test and Fisher's exact test were used.
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5.4 Results
The patterns of referral, management and outcome for 972 patients who were identified
as having ruptured AAA during the 7-year study period are shown in Figure 5.1. Two
hundred and nineteen (22.5%) patients were certified dead in the community without
being admitted to hospital, 551 (56.7%) were certified dead in hospital, and 202 (20.8%)
survived. The community mortality for ruptured AAA was, therefore, 770 of 972 (79%)
patients. The diagnosis was confirmed at operation in 340 (35%) patients, and at post¬
mortem examination in 268 (28%), of whom 175 died in the community, and 93 died in
hospital without transfer to the ERVSU. In the remaining 364 patients, ruptured AAA
was diagnosed and recorded on the death certificate on the basis of clinical examination
and/or investigation.
Three hundred and seventy two (38%) patients were admitted to other units within or
outwith Edinburgh and were not transferred to the ERVSU. Of these, 24 (6.4%) patients
underwent operation of whom 14 (3.8%) survived. No data are available to explain the
decisions to transfer, operate or treat conservatively this group of patients. Three
hundred and eighty one (39%) patients (304 men and 77 women of median age 73,
range 46 to 93 years) were admitted to this unit. Of these, 65 (17%) patients did not
undergo operation because they were considered unfit for surgery due to severe co¬
morbidity and/or extreme age, their clinical condition had deteriorated such that they
were considered unfit for repair, a decision was made to operate but death occurred
before surgery could commence, or the offer of operation was declined. Of 316 (83%)
patients who were operated, a graft was inserted in 277 (88%). The overall mortality for
all patients admitted to the ERVSU was 193 of 381 (51%), and the operative mortality
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was 128 of 316 (41%). There was no significant difference in the overall mortality
between patients transferred from units outwith Edinburgh (25 of 43, 58%), those
transferred from units within Edinburgh (16 of 28, 57%), and those admitted directly to
the ERVSU (152 of 310, 49%) (p=0.41, %2). Overall, 316 operated patients travelled
significantly further than 65 non-operated patients (p<0.001, MW). There was no
significant difference in travelling distance between 188 (59%) operated patients who
survived and the 128 who did not (Table 5.1). Of 310 patients who were admitted
directly to this unit, 262 who were operated travelled significantly further than 48 who
were not (pO.OOl, MW), and there was no significant difference in travelling distance
between 160 operated patients who survived and 102 (40%) who did not.
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FIGURE 5.1



































Transfer distance and outcome in patients with ruptured AAA admitted (directly

















0-5 152 41 95 16 44/111 (40) 85/152 (56)
5 - 10 74 9 58 7 26/65 (40) 35/74 (47)
10- 15 48 9 34 5 19/39 (49) 28/48 (58)
15-20 44 3 39 2 14/41 (34) 17/44 (39)
20-25 32 1 27 4 14/31 (45) 15/32 (47)
25+ 31 2 24 5 11/29 (38) 13/31 (42)
381 65 277 39 128/316 (41) 193/381 (51)
Values in parentheses are percentages
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5.5 Discussion
The first principal finding of the present study was that there was no significant
difference in travelling distance between the operated patients who survived and those
who did not; but that patients who were not operated travelled significantly shorter
distances to hospital than those who were. One explanation for this may be the pre¬
selection of 'good risk' patients for transfer over longer distances. In addition, a
proportion of patients sustaining rupture in the immediate vicinity of the Edinburgh
Vascular Unit may have been moribund on arrival and thus not operated.
Several studies have attempted to determine whether travelling distance and transfer
time has an effect on operative mortality in ruptured AAA. Butler et al (243) showed no
significant difference in operative mortality between patients admitted from the local
catchment area (28 of 48, 58%) and those transferred from other centres (13 of 24,
54%). In 183 patients, Fielding et al (244) reported no significant difference in operative
mortality between those transferred less than five miles (43 of 85, 50.5%) and those
transferred farther than five miles (39 of 97, 40.2%) and, similarly, Barros D'Sa (245)
demonstrated no significant correlation between travelling distance and outcome in 187
operated patients. While Yashar et al (246) reported a mortality rate of 27% for patients
operated within four hours of onset of symptoms compared with 80% for those operated
beyond four hours, van Heeckeren (247) was unable to demonstrate a significant
correlation between duration of symptoms and mortality in 57 operated patients, and
Amundsen et al (248) failed to demonstrate any correlation between transport time and
overall mortality for 114 patients (including 30 who were not operated). Meyer et al
(249) compared 48 patients admitted to a community hospital and 49 admitted to a
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municipal hospital, and demonstrated that while significantly more stable patients were
operated more than two hours after diagnosis in the community hospital, significantly
more shocked patients underwent immediate operation, and consequently mortality was
significantly higher, in the municipal hospital. Ouriel et al (49), however, demonstrated
no significant difference in the delay from the onset of symptoms to hospital arrival for
patients admitted to a university or community facility, as well as no significant
relationship between operative mortality and the delay between arrival in hospital and
the start of the operation. In a study of 122 patients, Farooq et al (250) also
demonstrated no relationship between operative mortality and duration of symptoms and
delay between hospital arrival and the start of the operation. Although more hypotensive
patients were operated upon within two hours of onset of symptoms, this was not
associated with a significant increase in mortality.
At first sight, these and present data suggest that centralisation does not prejudice the
community outcome for ruptured AAA. However, in this 7-year study, 93% of survivors
were operated upon in this regional vascular unit, fewer than 40% were transferred to
this unit, and only 6% of those treated outwith this unit underwent operation. The
operative mortality outwith the ERVSU was a very acceptable 14 of 24 (58%).
However, almost all of these operations were performed in one peripheral hospital by
two general surgeons with a major vascular interest. None of the other seven hospitals
were staffed by surgeons with vascular expertise which presumably explains the very low
operation rate outside the Edinburgh Vascular Unit and the other peripheral hospital.
The present study, indeed all community studies of ruptured AAA, have limitations. The
diagnosis of rupture was confirmed by operation or post-mortem examination in only
63% of patients. It is not known what proportion of patients who were not operated
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upon were diagnosed as having ruptured AAA in life. It is likely that there were patients
who died suddenly from rupture in whom the diagnosis was not made, and perhaps a
few who did not die from rupture but in whom this was the certified cause of death.
The important question raised by these data is whether a broader provision of vascular
surgical expertise would have increased the proportion of patients offered and surviving
surgery and whether this, in turn, would have positively impacted the community
survival from the condition. Although the community outcome in the present series is
similar to that reported in earlier studies from regions where centralisation has not
occurred (Table 5.2), centralisation of vascular surgical services may be associated with
an inappropriately low operation and survival rate for the majority of patients who are
not transferred to the regional centre.
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TABLE 5.2
Reported studies estimating the community outcome from ruptured AAA
Author No. of Died outside Died in hospital Survivors
patients hospital not operated operated
Armour (24) 25 11 (44) 9 1 4(16)
Ingoldby (25) 260 158(61) 1 49 52 (20)
Johansson (26) 88 24 (27) 51 8 5(6)
Mealy (27) 265 169(64) 18 48 30(11)
Thomas (28) 183 64 (35) 44 41 34(19)
Semmens (29) 873 379(43) 211 102 181 (21)
Present study 972 219(23) 413 138 202 (21)
Values in parentheses are percentages
117
5.6 Summary
• There was no significant difference in overall mortality between patients who were
admitted directly to this unit, and those who were transferred from elsewhere.
• Operated patients travelled significantly further than non-operated patients, but there
was no significant difference in travelling distance between operated patients who
survived and those who did not.
• The overall community-based mortality rate was 79%, similar to that reported from
where centralisation of vascular surgical services has not occurred.
• Despite considerable expertise in the management of ruptured AAA, centralisation of
vascular surgical services has not been associated with an improvement in individual
patient or community-based outcome. By contrast, this situation is associated with an
inappropriately low operation and survival rate for patients who are not transferred
to the regional centre.
• Fundamental basic science research into the pathophysiology of ruptured AAA repair
is required to improve patient care and clinical outcome.
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Chapter 6
Serial peri-operative markers of coagulation




Repair of ruptured and non-ruptured abdominal aortic aneurysm (AAA) is associated
with an operative mortality rate of 33% to 69% (Table 1.1), and 3% to 15%
(4,6,9,30,251), respectively. The great majority of the morbidity and mortality is due to
MI and MOF, which may be related to micro- and macrovascular thrombosis developing
as a result of a procoagulant state (Chapter 1.2). It is perhaps surprising, therefore, that
previous workers have suggested that supracoeliac aortic cross-clamping and thoraco¬
abdominal aortic aneurysm repair (252,253), as well as animal studies of infrarenal aortic
clamping and isolated lower body ischaemia (71), are associated with increased
fibrinolysis. Studies of elective infrarenal aortic reconstruction are few and contradictory
(78,80,140,141,144,149,150,254,255). Although data such as these have been used to
support the use of antifibrinolytic agents in patients undergoing operation for ruptured
AAA (256), careful review of the literature reveals that the precise nature of the
haemostatic derangement in such patients has not previously been studied.
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6.2 Aims
To examine serial markers of thrombin generation and fibrinolysis during the course of
emergency surgery for ruptured AAA and to compare this with patients undergoing




Ten patients (8 men and 2 women of median age 76, range 71-86, years) operated for
ruptured and 9 patients (8 men and 1 woman of median age 69, range 58-80, years)
operated for asymptomatic non-ruptured infrarenal AAA were prospectively studied.
In patients operated for rupture, the median (range) delay between the onset of
symptoms of rupture and hospital admission was 5 (3-14) hours. All patients had at least
one documented episode of hypotension (systolic blood pressure less than lOOmmHg)
prior to surgery. In patients undergoing non-ruptured AAA repair, the median (range)
antero-posterior diameter of the aneurysm measured by ultrasonography was 6.5 (5.5-
8.0) cm. No patient had liver disease. Co-morbidity data are shown in Table 6.1.
Operative methods
The operations were performed as previously described. Rupture was retroperitoneal in
all patients. No patient received protamine sulphate. A dacron tube graft was inserted in
13 patients (9 rupture, 4 non-rupture), an aorto-bi-iliac graft in five (1 rupture, 4 non-
rupture) and an aorto-bifemoral graft in one patient with non-ruptured AAA.
Definition ofperi-operative complications
These were defined as described above.
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Assays ofhaemostatic function
The extrinsic coagulation and fibrinolytic systems are summarized in Figure 6.1 and 6.2,
respectively. Plasma levels of PF 1+2 and TAT were assayed as markers of thrombin
generation, and t-PA activity, t-PA antigen, PAI activity, and fibrin degradation product
D-dimer as markers of fibrinolysis. Haematocrit, platelet count, fibrinogen, PT, aPTT,
and CRP were also measured. Assays were performed as described above.
Sample collection
The pathophysiology of ruptured AAA repair can be divided into three phases (Figure
6.3). Firstly, there is a period of whole body hypoperfusion due to hypovolemic shock.
Secondly, there is a period of lower body ischaemia following aortic clamp placement.
Finally, if repair is successful, there is a period of reperfusion. The sampling points were
chosen to reflect the maximum effect of each of the three phases. Blood was sampled
from an indwelling arterial line immediately prior to the induction of anaesthesia
(sample A); immediately before aortic clamp release (sample B); five minutes (sample
C) and 24 hours (sample D) after aortic clamp release; and on post-operative days 2, 3
and 5. t-PA antigen, D-dimer and TAT were measured at sample point A. Haematocrit,
platelet count, fibrinogen, PT, aPTT, CRP, t-PA activity, PAI activity and PF 1+2 were
measured at all sample points. Samples were prepared as described above.
Statistical analysis
The Mann-Whitney U test (MW) and Spearman rank tests were used.
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TABLE 6.1
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Overview of the extrinsic coagulation system.
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Schematic view of the pathophysiology of ruptured AAA repair.
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Clinical and operative data for both groups of patients are summarized in Table 6.2.
During operation, no patients with non-ruptured AAA received inotropic support. Three
patients with rupture received adrenaline, and five received dopamine, infusion. All
patients with rupture were admitted to the Intensive Therapy Unit (ITU) post-operatively
for ventilatory support. All patients operated for non-ruptured AAA were admitted to
the High Dependency Unit post-operatively and no patient was admitted to ITU or
required ventilatory support. Seven patients operated for rupture and four operated for
non-ruptured AAA developed major post-operative complications (Table 6.3). All
patients survived to 24 hours after repair. Two patients with rupture died in hospital
from acute respiratory distress syndrome and ARF on post-operative day 10, and from
pneumonia and critical lower limb ischaemia on post-operative day 21. There were no
deaths after repair of non-ruptured AAA.
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TABLE 6.2












Crystalloid administration (1) 0.5 (0.1 -4.0) -
Colloid administration (1) oo -
Intra-operative
Operation time (minutes) 105 (70-205) 160 (85 -285) NS
Aortic clamp time (minutes) 60 (30- 125) 70 (25 - 150) NS
Measured blood loss (1) 2.3 (1.0-6.4) 2.8(1.0-6.0) NS
Crystalloid administration (1) 2.0 (0.5-3.5) 2.0(1.0-4.0) NS
Colloid administration (1) 1.5 (0-2.3) 2.0 (0.5 - 3.8) NS
RCC administration (units) 1 8(6-11) 4(0- 10) 0.02
2
FFP administration (units) 2 (0 - 6) 0 (0 - 2) NS
3
Platelet administration (bags) 1(0-1) 0(0-1) NS
Post-operative
Duration of ITU stay (hrs) 72 (13-244) -
Duration of IPPV (hrs) 19(9-142) -
KEY: * Mann-Whitney U test, 1 RCC = 300 ml, 2 FFP = 300ml, 3 one bag of platelet
transfusion = 4 pooled units (250 ml)
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TABLE 6.3
Post-operative complications and procedures in ruptured and non-ruptured AAA.
Ruptured AAA Non-ruptured AAA









Chest infection 6 2
Respiratory failure 3 0
ARDS 1 0
Acute Renal Failure 2 1
Coagulopathy 1 0
Sepsis syndrome 1 0
Colon ischaemia 1 0
Total parenteral nutrition 3 0
Inotropic support
Adrenaline 3 0
Renal dose dopamine 6 0
Re-operation 1 1 1
KEY: 1 = laparotomy for intra-abdominal hemorrhage, femoral thrombectomy,
Hartmann's procedure for colon ischaemia, drainage of infected pelvic
?
haematoma, = popliteal embolectomy and fasciotomies
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Haematocrit, platelet count, fibrinogen, PT, aPTT and CRP
The median (range) values for haematocrit, the standard tests of haemostasis (platelet
count, fibrinogen, PT and aPTT) and CRP to 24 hours post-operatively are shown in
Table 6.4. There was no significant difference between rupture and non-rupture with
regard to any of the assays on post-operative days 2,3 and 5.
In ruptured AAA, there was a significant negative correlation between operative blood
loss and fibrinogen level immediately before (r = - 0.694, p = 0.026) and five minutes
after aortic clamp release (r = - 0.75, p = 0.012), and also platelet count five minutes
after aortic clamp release (r = - 0.726, p = 0.018). There was a significant positive
correlation between operative blood loss and PT immediately before aortic clamp
release (r = + 0.823, p = 0.003) and aPPT immediately before (r = + 0.787, p = 0.007)
and five minutes after aortic clamp release (r = + 0.64, p = 0.046).
In non-ruptured AAA, there was a significant negative correlation between operative
blood loss and fibrinogen immediately before (r= -0.678, p= 0.045) and 5 minutes after
aortic clamp release (r= -0.711, p= 0.032); and platelet count immediately before aortic
clamp release (r= -0.728, p= 0.026). There was a significant positive correlation
between operative blood loss and PT 5 minutes after aortic clamp release (r= +0.728, p=
0.026). There was a significant negative correlation between clamp time and fibrinogen
immediately before (r= -0.812, p= 0.008) and 5 minutes after aortic clamp release (r= -
0.711, p= 0.032), and platelet count immediately before aortic clamp release (r= -0.678,
p= 0.045). There was a significant positive correlation between aortic clamp time and




Haematocrit, platelet count, fibrinogen, PT, aPTT and CRP to 24 hours post-operatively.
Assay Sample Ruptured Non-ruptured p value
(normal range) point AAA AAA *
median (range) median (range)
(n=10) (n=9)
Haematocrit A 0.31 (0.13-0.34) 0.42 (0.33 - 0.47) 0.0004
(0.37-0.54) B 0.27 (0.18-0.44) 0.30 (0.25 - 0.37) NS
C 0.28 (0.22 - 0.42) 0.30(0.23 -0.35) NS
D 0.34 (0.26 - 0.42) 0.34 (0.25 - 0.39) NS
Platelet count A 230 (119-303) 182 (75 - 744) NS
(150-350 x 109/l) B 120 (81 - 189) 132 (103 - 541) NS
C 108 (59- 146) 135 (91 - 577) NS
D 97 (50- 133) 127 (85 - 604) NS
Fibrinogen A 2.27 (0.86 - 3.75) 2.80(1.59- 6.02) NS
(1.5-4.0 g/1) B 1.12(0.88-2.51) 1.68 (0.72 -5.39) NS
C 0.97 (0.46- 1.82) 1.45 (0.36 - 5.44) NS
D 3.29(1.76-4.63) 3.70 (2.50- 8.98) NS
PT A 14(11 -35) 12(11 - 14) 0.009
(10.5-14.5 s) B 20 (15 -26) 17(15-26) NS
C 20(17-31) 20(14-23) NS
D 16(13-18) 14(12-21) NS
aPTT A 32 (28 - 126) 31 (25 -49) NS
(28-40 s) B 50 (34-210) 176 (56-240) 0.006
C 55 (42 -210) 210(79-240) 0.008
D 39 (32 - 76) 36 (29 - 39) 0.02
CRP A 6.7(2.6- 178.3) 4.3 (0.3 - 18.6) NS
(less than 10 mg/1) B 3.0 (0.9- 116) 5.0(1.1 - 13.4) NS
C 3.8(1.9- 11.4) 2.0(1.3 - 8.2) NS
D 105 (41.8 - 141.8) 92.4 (41.5 - 180.8) NS
KEY: * = Mann-Whitney U test
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Markers ofthrombin seneration
The median (range) values for PF 1+2 to 24 hours post-operatively are shown in Table
6.5. Before operation, TAT levels were elevated above the normal range in all patients.
Levels were significantly higher in patients with ruptured AAA than in those with non-
ruptured AAA (p<0.02, Mann-Whitney U test) (Figure 6.4). Before operation, 7 of 9
patients with non-ruptured AAA had elevated PF 1+2 levels. Before and during
operation, PF 1+2 levels were significantly higher in patients undergoing repair of
ruptured AAA when compared to those undergoing repair of non-ruptured AAA. At 24
hours and beyond, there was no significant difference in PF 1+2 levels between the
groups (Figure 6.5).
In ruptured AAA, there was no significant relationship between operative blood loss or
aortic clamp time and any of the markers of thrombin generation. There was, however, a
significant positive correlation between the duration of symptoms of rupture and pre¬
operative PF 1+2 (r= +0.717, p= 0.02).
In non-ruptured AAA, there was no significant relationship between operative blood
loss or aortic clamp time and any of the markers of thrombin generation.
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TABLE 6.5


















B 6.7 (3.3 - 8.9)










KEY: * = Mann-Whitney U test
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FIGURE 6.4
Individual data points for pre-operative TAT level.
Patients with ruptured AAA are represented by the red squares and
patients with non-ruptured AAA by the yellow circles.
The upper limit of the normal range for TAT (1-4.1 microg/1) is shown by the
horizontal line.


















Individual data points for PF 1+2 immediately before induction of anaesthesia
(sample A), immediately before release of the aortic clamp, (sample B), and
five minutes (sample C) and 24 hours (sample D) after aortic clamp release.
Patients with ruptured AAA are represented by the red squares and patients
with non-ruptured AAA by the yellow circles.
The upper limit of the normal range for PF 1+2 (0.4-1.1 nmol/1) is shown by
the horizontal line.
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The median (range) values for t-PA activity and PAI activity to 24 hours post¬
operatively are shown in Table 6.6. Before operation, t-PA antigen levels were
significantly higher in patients with ruptured AAA compared with those with non-
ruptured AAA (p<0.005, Mann-Whitney U test) (Figure 6.6). Before operation, there
was no significant difference in the D-dimer levels between ruptured and non-ruptured
AAA (Figure 6.7). Before and during operation, t-PA activity was significantly lower in
patients undergoing repair of ruptured AAA when compared to those undergoing repair
of non-ruptured AAA (Figure 6.8). At 24 hours and beyond, there was no significant
difference in t-PA activity between the groups. During the operation, four patients with
non-ruptured AAA had elevated t-PA activity. Before and during operation, PAI activity
was significantly higher in patients undergoing repair of ruptured AAA when compared
to those undergoing repair of non-ruptured AAA. At 24 hours and beyond, there was no
significant difference in PAI activity between the groups (Figure 6.9). Coagulation and
fibrinolytic data for two patients who died after ruptured AAA repair compared with
eight who survived are shown in Table 6.7. In ruptured AAA, there was no significant
relationship between the duration of symptoms, operative blood loss or aortic clamp
time and any fibrinolytic markers. In non-ruptured AAA, there was a significant
negative correlation between operative blood loss and t-PA activity 5 minutes after
aortic clamp release (r= -0.753, p= 0.019). There was a significant negative correlation
between aortic clamp time and t-PA activity immediately before (r= -0.837, p= 0.005)
and 5 minutes after aortic clamp release (r= -0.72, p= 0.029); and a significant positive
correlation with PAI activity 5 minutes after aortic clamp release (r= +0.686, p= 0.041).
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TABLE 6.6
t-PA and PAI activity to 24 hours post-operatively.
Assay Sample Ruptured Non-ruptured p value
(normal range) point AAA AAA *
median (range) median (range)
(n=10) (n=9)
t-PA activity A 0.12(0.06-0.43) 0.49 (0.14-3.2) 0.009
(0.2-2.0 IU/ml) B 0.27 (0.08 - 0.8) 0.91 (0.34-4.65) 0.0014
C 0.32 (0.09-4.53) 1.06 (0.19 - 5.62) 0.034
D 0.41 (0.15-2.1) 0.46 (0.21 - 1.45) NS
PAI activity A 36.5 (20.6 - 38.8) 8.2 (3.2-21.7) 0.0003
(less than 15 AU/ml) B 38.6(13.0-39.4) 10.8(2.8-38.9) 0.0042
C 37.2 (10.6 -39.4) 12.6 (2.2 - 28.7) 0.0055
D 18.1 (5.0-35.3) 14.7(5.7-22.3) NS
KEY: * = Mann-Whitney U test
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FIGURE 6.6
Individual data points for pre-operative t-PA antigen.
Patients with ruptured AAA are represented by the red squares and
patients with non-ruptured AAA by the yellow circles.



















Individual data points for pre-operative D-dimer
Patients with ruptured AAA are represented by the red squares and patients
with non-ruptured AAA by the yellow circles.















Individual data points for t-PA activity immediately before induction of
anaesthesia (sample A), immediately before release of the aortic clamp,
(sample B), and five minutes (sample C) and 24 hours (sample D) after aortic
clamp release.
Patients with ruptured AAA are represented by the red squares and patients
with non-ruptured AAA by the yellow circles.
The upper limit of the normal range for t-PA activity (0.2-2.0 IU/ml) is shown
by the horizontal line.
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FIGURE 6.9
Individual data points for PAI activity immediately before induction of
anaesthesia (sample A), immediately before release of the aortic clamp, (sample
B), and five minutes (sample C) and 24 hours (sample D) after aortic clamp
release.
Patients with ruptured AAA are represented by the red squares and patients with
non-ruptured AAA by the yellow circles.
The upper limit of the normal range for PAI activity (< 15 AU/ml) is shown by
the horizontal line.
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TABLE 6.7











Platelet count A 119 178 249 (156 -303)
(150-350 x 109/1) B 81 116 125 (96 - 189)
C 66 84 117 (59 - 146)
D 86 72 102 (50- 133)
Fibrinogen A 2.18 1.87 2.52 (0.86 - 3.75)
(1.5-4.0 g/1) B 1.2 0.94 1.20 (0.88 -2.51)
C 0.77 0.85 1.20 (0.46 - 1.82)
D 1.87 2.57 3.35 (1.76 -4.63)
PT A 16 14 14(11 -35)
(10.5-14.5 s) B 23 18 20(15 -26)
C 27 24 20(17-31)
D 18 15 16 (13 - 18)
aPTT A 40 35 30 (28 - 126)
(28-40 s) B 120 52 53 (34-210)
C 108 210 55 (42 - 123)
D 51 49 39 (32 - 76)
PF 1+2 A 10.1 9.3 7.7(5.4- 11.6)
(0.4-1.1 nmol/1) B 7.0 8.9 6.2 (3.3 - 8.4)
C 4.8 9.6 6.5 (4.2 - 8.0)
D 11.4 4.8 3.4(1.9-4.4)
t-PA activity A 0.13 0.11 0.17(0.06-0.43)
(0.2-2.0 IU/ml) B 0.8 0.12 0.27 (0.08-0.41)
C 4.53 0.43 0.28 (0.09 - 1.27)
D 2.1 0.25 0.41 (0.15-2.08)
PAI activity A 31.0 36.4 36.7(20.6 -38.8)
(< 15 AU/ml) B 13.0 38.9 38.6 (29.4 - 39.4)
C 10.6 38.2 37.2 (19.4 - 39.4)
D 5.9 22.2 18.1 (5.0-35.3)
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6.5 Discussion
The principal finding of the present study is that emergency repair of ruptured AAA is
associated with intense thrombin generation (as demonstrated by elevated TAT and PF
1+2 levels) and inhibition of systemic fibrinolysis (as demonstrated by elevated t-PA
antigen, reduced t-PA activity and elevated PAI activity). This procoagulant state is
present prior to surgery, persists throughout the period of operation, but has largely
resolved 24 hours post-operatively. The majority of patients undergoing elective repair
of non-ruptured AAA also exhibit increased thrombin generation, but this is of a much
lesser magnitude than in rupture. Furthermore, a proportion have evidence of increased
systemic fibrinolysis associated with ischaemia and early reperfusion.
Previous studies examining coagulation and fibrinolysis in aortic surgery are
contradictory. Mulcare et al (140) were the first to demonstrate a significant peri¬
operative decrease in platelet count, fibrinogen, plasminogen and fibrinolytic inhibitors in
patients undergoing elective aortic reconstruction for non-ruptured AAA and aorto-iliac
occlusive disease. Mashiah et al (141) later confirmed an intra-operative fall in fibrinogen
and plasminogen, but were unable to demonstrate evidence of increased coagulation or
fibrinolysis in patients undergoing aortic reconstruction. Gomez and colleagues (78,80),
however, demonstrated peri-operative inhibition of fibrinolysis in patients undergoing
elective aortic surgery for aneurysmal and occlusive disease by demonstrating a gradual
increase in PAI levels during operation, peaking 8 hours post-operatively. Eriksson and
Rosberg (149) confirmed elevated PAI levels in patients undergoing aortic
reconstruction for occlusive disease, and Welch et al (150) demonstrated minimal intra¬
operative PAI activity with post-operative increase peaking 6 hours after declamping in
patients undergoing elective surgery for AAA or occlusive disease. By contrast, in an
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animal model of infrarenal aortic cross clamping and isolated lower body ischaemia,
Schneiderman et al (71) demonstrated a net increase in fibrinolytic activity during
ischaemia. Two studies have demonstrated the confounding effect of haemodilution in
the interpretation of coagulation studies in elective infrarenal aortic surgery. In a study by
von Sommoggy et al (144), almost 2 litres of intravenous crystalloid were administered
before aortic clamping, which was sufficient to cause a fall in haematocrit and total
protein levels. Vahl et al (254) reported a decrease in fibrinogen, plasminogen, 0C2-
antiplasmin and antithrombin III during the operation; after correction for the effects of
blood loss and haemodilution, there was no significant change in fibrinogen or
plasminogen levels but a significant decrease in a2-antiplasmin and antithrombin III, the
latter of which may have been due to heparinisation. There was, however, an increase in
PF 1+2 levels indicating thrombin activation. The authors concluded that haemodilution
was an important variable as it reduced coagulation and fibrinolytic factors by 50% while
subsequent activation reduced the loss to 25% overall. In the present study, patients with
ruptured AAA received a median of 500ml of intravenous crystalloid and/or colloid
before induction of anaesthesia and both groups of patients received a median of 3.5-4.0
litres of crystalloid and/or colloid intra-operatively. The haemodilution effect may have
contributed to the intra-operative fall in platelet count and fibrinogen, but it is unlikely to
have had been responsible for the elevated levels of markers of thrombin generation and
fibrinolytic inhibition. Furthermore, given the fact that there was no significant difference
in the volume of crystalloid and/or colloid transfusion or intra-operative haematocrit
between patients with ruptured and non-ruptured AAA, haemodilution cannot be
responsible for the differences in coagulation and fibrinolysis between the groups.
Gertler et al (253) compared coagulation studies in 19 patients undergoing supracoeliac
aortic clamping for thoraco-abdominal aortic aneurysm and four patients undergoing
infrarenal AAA repair. After 30 minutes of ischaemia, coagulation factors and fibrinogen
were significantly lower and D-dimer and PF 1+2 levels were significantly higher in the
supracoeliac group compared with infrarenal group, and compared with pre-operative
levels. Transfusion of blood products returned levels of coagulation factors and
fibrinogen toward baseline levels by the end of surgery, but D-dimer and PF 1+2 levels
did not return to normal levels. Changes in coagulation were similar in both groups of
patients but more dramatic in the supracoeliac group, and the authors suggested that
bacterial translocation due to hepatic and mesenteric ischaemia and/or the total ischaemic
tissue burden were responsible. In 23 patients undergoing non-ruptured AAA repair,
Holmberg et al (255) recently demonstrated a significant increase in levels of PF 1+2 and
TAT during aortic clamping with PF 1+2 and TAT levels increasing further after aortic
declamping. In control patients undergoing spinal surgery, TAT levels increased during
operation and PF 1+2 levels were increased post-operatively. All three coagulation
markers, however, were significantly higher in AAA patients before and during
operation. Illig et al (252) recently examined coagulation and fibrinolysis in 10 patients
who underwent elective supracoeliac aortic clamping for AAA (n=8) or occlusive disease
(n=2) and eight patients who underwent infrarenal clamping for AAA. There was no
significant difference in peri-operative thrombocytopenia, hypofibrinogenaemia, D-
dimer levels, and coagulation factor consumption between the groups. During and early
after supracoeliac clamping, however, there was evidence of deranged liver function, a
significant increase in the levels of FDPs, a significant increase in t-PA antigen and a
significant fall in Ob-antiplasmin levels compared with the infrarenal group and baseline
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levels. PAI antigen levels were similar in both groups and did not increase until the post¬
operative period, but t-PA:PAI ratio was significantly higher during operation in the
supracoeliac group. The authors speculated that increased t-PA production due to
ischaemia and reduced hepatic degradation due to hepatocellular injury were responsible
primary systemic fibrinolysis in supracoeliac clamping, and hepatic ischaemia may have
contributed to the delay in PAI increase as in patients undergoing orthotopic liver
transplantation. The authors further advocated factor replacement and antifibrinolytic
therapy for bleeding in supracoeliac aortic clamping. At first sight, the findings of the
present study appear to contradict the study by Illig's group (252). One reason for this
apparent discrepancy may be due to the measurement of t-PA antigen as opposed to the
measurement of t-PA activity. This failure to measure activity as well as antigen, as in
the present study, might have led to the erroneous conclusion that ruptured AAA was
also associated with enhanced fibrinolysis. It is increasingly apparent that t-PA antigen
levels primarily reflect the level of inactive circulating t-PA/PAI complexes. This
contention is demonstrated by the present study, where elevated t-PA antigen is, in fact,
associated with markedly elevated PAI activity and markedly depressed t-PA activity,
consistent with a procoagulant state (99,257).
Given that repair of ruptured aortic aneurysm, and a proportion of elective aneurysm
operations, are associated with a procoagulant state (78,150), two important questions
need to be addressed. Firstly, is the presence and the intensity of the procoagulant state
associated with poor outcome as a result of thrombotic events ? Although the changes in
coagulation and fibrinolysis observed in the present study have been associated with
myocardial injury (68,95-100,102,103,187-189), MOF (36-38) and CVA (33) in other
patient groups, it is not possible to answer this question directly from the present data for
two reasons. Only data for patients who survived for 24 hours are included in the present
147
analysis and the number of patients and adverse clinical outcomes is small. These issues
will be addressed in subsequent chapters. The second question is whether therapeutic
intervention may ameliorate the adverse effects of this procoagulant state and thus
improve outcome ? Apart from the fact that patients in this study with ruptured AAA
sustained a period of pre-operative hypovolaemic shock, the most obvious difference
between the groups relates to the use of systemic heparin during aneurysm repair.
Reported effects of heparin include: minimal reduction in platelet count in a small
proportion of patients; prolongation of the aPPT; marginal prolongation of the PTT in a
small proportion of patients; elevation of the fibrinogen and a reduction in D-dimer levels
due to a reduction in fibrin deposition; reduced PF 1+2 due to inhibition of thrombin
generation by antithrombin III; and increased binding of thrombin to antithrombin III but
no increase in TAT levels. Other than t-PA, no other fibrinolytic component appears to
be affected by heparin: while the majority of clinical and volunteer studies have shown
that repeated administration of unfractionated heparin over a number of days increases t-
PA antigen, short-term studies have shown increases in t-PA activity similar in magnitude
to what might be expected due to diurnal variation (258). Surgeons are naturally
reluctant to systemically heparinise a patient with ruptured AAA, but these data suggest
that following control of bleeding by aortic clamping judicious use of heparin may partly
reverse the procoagulant state and, may, therefore, improve outcome from thrombotic
complications (181). It is important to note, however, that patients with ruptured AAA
exhibited very elevated levels of TAT which indicate that there is already a considerable,
albeit ineffective, attempt by nature to inhibit thrombin activation. This may limit the
efficacy of heparin in this situation as AT III is required for its action and the present
study suggests that AT III levels may be low secondary to thrombin binding to form
TAT. Other possible therapeutic interventions include angiotensin converting enzyme
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(ACE) inhibitors (which may decrease PAI and increase t-PA levels) and specific
inhibitors of PAI activity (324). There have been suggestions that patients with ruptured
AAA might benefit from antifibrinolytic therapy, specifically with aprotonin. However,
the routine administration of aprotinin has failed to demonstrate clinical benefit in
elective and ruptured AAA repair (256,259), and may actually be associated with a
hypercoagulable phase (175). The findings of the present study suggest that such therapy
is contra-indicated in most patients undergoing operation for ruptured AAA.
The finding that the majority of patients undergoing elective repair of non-ruptured
AAA also have elevated levels of TAT and PF 1+2 (indicating pathological levels of
thrombin generation) even before operation may be related to the presence and volume
of thrombus within the aneurysm sac (148,260). Indeed, others have reported increased
levels of fibrinogen (261), D-dimer (136,148,260), soluble fibrin (255), TAT
(136,148,255,269), PF 1+2 (255) and plasmin-antiplasmin (136,148) in patients with
asymptomatic non-ruptured AAA. Milne et al (262) have also demonstrated
significantly lower platelet counts with elevated plasma glycocalicin levels in patients
with asymptomatic AAA. The authors speculated that their findings may represent
increased platelet destruction and/or activation of platelets within the aneurysm sac
leading to circulating dysfunctional platelets. These findings are in keeping with
previous studies demonstrating increased platelet and fibrinogen deposition within the
aneurysm sac (111,113,117,119,120).
Thus patients with AAA may have a low-grade coagulopathy which makes them
particularly sensitive to the effects of operative trauma, hypotension and ischaemia
(45,79,263). Increased duration of aortic cross-clamping, for example, may contribute to
increased platelet and clotting factor consumption (124) and post-operative
thrombocytopenia (263). The present study confirms the relationship between prolonged
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aortic clamp time and increased operative blood loss, and a reduction in fibrinogen and
platelet count and prolongation of clotting times. For the first time, prolonged aortic
clamp time and increased operative blood loss were shown to be associated with
increased inhibition of systemic fibrinolysis in non-ruptured AAA repair
Currently, the triggering mechanisms leading to the procoagulant state in ruptured AAA
are unknown but, as it is present prior to operation, it is presumably related to
haemorrhage and whole body hypoperfusion. There was no relationship between the
degree of pre-operative hypotension and any of the haemostatic parameters studied, but
there was a significant positive correlation between duration of symptoms and increased
thrombin generation, and increased operative blood loss was associated with reduced
intra-operative fibrinogen and platelet count, and prolonged intra-operative clotting
times. Previous work from this group has demonstrated morphological evidence of
endothelial cell activation before operation in patients with ruptured AAA, suggesting
that this may be an early event in this group of patients (169). TF expression is the
stimulus for thrombin generation and inhibition of fibrinolysis (264,265) and its role in
haemostatic derangement in AAA repair requires further investigation (260,266).
In conclusion, these novel data demonstrate that ruptured AAA repair is associated with
a procoagulant state. This may contribute to micro- and macrovascular thrombosis
which, in turn, lead to the common causes of peri-operative morbidity and mortality,
namely MI, MOF and thrombo-embolism.
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.6 Summary
In hypotensive patients who survive to 24 hours after repair, ruptured AAA repair is
associated with peri-operative intense thrombin generation and inhibition of systemic
fibrinolysis.
In patients undergoing elective repair of non-ruptured AAA, the majority exhibit
increased peri-operative thrombin generation, and a proportion demonstrate increased
systemic fibrinolysis during ischaemia and early reperfusion.
In ruptured AAA, prolonged duration of symptoms of rupture was associated with
increased thrombin generation; and increased operative blood loss was associated
with reduced fibrinogen and platelet count, and prolonged clotting times.
In non-ruptured AAA, prolonged aortic clamp time was associated with reduced
fibrinogen and platelet count, prolonged clotting times and hypofibrinolysis; and
increased operative blood loss was associated with reduced fibrinogen and platelet
count, prolonged clotting times and hypofibrinolysis.
This procoagulant state may contribute to micro- and macrovascular thrombosis
which lead to the common causes of peri-operative morbidity and mortality.
Antifibrinolytic therapy may be contra-indicated in most patients undergoing
ruptured AAA repair.
Further study is required to: a) confirm these findings in a larger cohort of patients, b)
examine haemostasis in patients with peri-operative coagulopathy, c) assess whether
the procoagulant state is associated with adverse clinical outcomes, and d) elucidate
the triggering mechanisms for this procoagulant state.
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Chapter 7
Pre-operative markers of coagulation and
fibrinolysis in asymptomatic, acutely
symptomatic and ruptured AAA
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7.1 Introduction
The previous chapter demonstrated, for the first time, that ruptured AAA repair is
associated with intense peri-operative thrombin generation and inhibition of systemic
fibrinolysis. Elective repair of non-ruptured AAA was also associated with increased
peri-operative thrombin generation, and a proportion of patients had increased intra¬
operative systemic fibrinolysis.
In the United Kingdom, over 50% of all AAA repairs are performed as an emergency
because the surgeon believes, or is unable to exclude the possibility, that rupture has
occurred. However, in approximately 20% of these patients the AAA is found to be
intact at operation and sudden expansion or impending rupture are presumed to be
responsible for the patient's symptoms (251). The operative mortality for this group of
patients is twice that of symptomatic patients in whom rupture is not suspected and who
are not operated upon as an emergency (251,267).
To date, there are no reports of haemostatic function in patients with acutely
symptomatic non-ruptured AAA. We hypothesised that, as acutely symptomatic non-
ruptured AAA is not associated with extra-mural haemorrhage, this group of patients
would not manifest the same pattern of haemostatic derangement as patients with
rupture. Further, haemostatic variables might therefore aid clinical decision-making
regarding the timing of surgery in patients with acutely symptomatic non-ruptured AAA.
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7.2 Aims
To corroborate the findings of the previous chapter in a larger cohort of patients
undergoing repair of asymptomatic and ruptured AAA. To examine whether patients
undergoing emergency repair of suspected ruptured but, in fact, intact AAA exhibit the
same haemostatic derangement as patients operated upon for rupture. To determine the




Sixty-six patients who underwent operation for infrarenal AAA were prospectively
studied. Twenty two patients (19 men and 3 women of median age 69, range 56 - 81,
years) underwent elective repair of asymptomatic AAA; 37 patients (33 men and 4
woman of median age 74, range 63 - 87, years) underwent attempted repair of ruptured
AAA; and seven patients (7 men of median age 68, range 65 - 74, years) underwent
emergency repair of acutely symptomatic non-ruptured AAA. Acutely symptomatic and
ruptured AAA were defined as described above. Thirty-one patients with rupture had at
least one documented episode of hypotension (systolic blood pressure less than
lOOmmHg) prior to surgery. Seven patients with acutely symptomatic and six patients
with ruptured AAA were not hypotensive. Co-morbidity data are shown in Table 7.1.
Sample collection
Blood was sampled from an indwelling arterial line immediately prior to the induction
of anaesthesia. Samples were prepared as described above.
Markers ofthrombin generation and fibrinolysis
t-PA activity, PAI activity, PF 1+2 and D-dimer were assayed as described above.
Statistical analysis
The Mann-Whitney U test (MW) was used. In symptomatic and ruptured AAA, the
sensitivity, specificity, and positive and negative predictive values of each assay (alone
and in combination) for the diagnosis of rupture were compared with operative findings.
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TABLE 7.1












Peripheral arterial occlusive disease
Venous thrombo-embolism
Chronic obstructive airways disease








































































There were no deaths after repair of asymptomatic or acutely symptomatic non-ruptured
AAA. The 30-day in-hospital mortality rate for repair of ruptured AAA was 16 of 37
(43%) patients; seven patients died intra-operatively or within 24 hours of repair, and
nine patients died in the late post-operative period. There were no deaths among the six
patients with rupture who were normotensive prior to the operation.
Markers offibrinolysis and thrombin seneration
The median (range) values for pre-operative t-PA activity, PAI activity, PF 1+2 and D-
dimer levels are shown in Table 7.2, and illustrated in Figures 7.1 to 7.4, respectively.
When compared with asymptomatic AAA, ruptured AAA was associated with
significantly increased PAI activity (pO.OOl), PF 1+2 (pO.OOl) and D-dimer
(pO.OOl), but there was no significant difference in t-PA activity. When patients with
ruptured AAA who survived to 24 hours after repair were compared with asymptomatic
AAA (as in Chapter 6), PAI activity (pO.OOl), PF 1+2 (pO.OOl) and D-dimer
(pO.OOl) remained significantly higher in the rupture group, and again there was no
significant difference in t-PA activity. Acutely symptomatic AAA was associated with
significantly increased t-PA activity compared with asymptomatic AAA (p=0.028) but
there was no difference in PAI activity, PF 1+2 and D-dimer.
When compared with ruptured AAA, acutely symptomatic non-ruptured AAA was
associated with significantly increased t-PA activity (p=0.023), reduced PAI activity
(p=0.005), reduced PF 1+2 (pO.OOl) and reduced D-dimer (p=0.005) compared with
ruptured AAA. When the seven normotensive patients with acutely symptomatic non-
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ruptured AAA were compared with the six normotensive patients with rupture, the
differences in t-PA activity (median 1.7, range 0.75-3.2 vs. rupture: median 0.22, range
0.11-1.0; p=0.01), PAI activity (median 6.3, range 3.2-15.4 vs. rupture: median 30.3,
range 12.1-37.6; p=0.004) and PF 1+2 (median 2.1, range 1.1-5.2 vs. rupture: median
5.3, range 2.5-6.8; p=0.01) persisted, but there was no significant difference in D-dimer
levels. When acutely symptomatic non-ruptured AAA was compared with patients with
rupture who survived to 24 hours after repair, the statistical differences in all four
markers persisted.
In ruptured AAA, there was no significant difference in any of the markers between
hypotensive and normotensive patients, or between patients with retroperitoneal or
intraperitoneal haemorrhage. There was no significant difference in pre-operative t-PA
activity, PAI activity or PF 1+2 between survivors and non-survivors, but D-dimer was
significantly higher in non-survivors (median 6329, range 1372-25947 vs. survivors:
median 3582, range 155-9518; p=0.046).
When all symptomatic and ruptured AAA patients were examined, PF 1+2 was the most
accurate assay for distinguishing non-ruptured from ruptured AAA. Using the upper
limit of the normal laboratory range for PF 1 +2 as a diagnostic cut-off (greater than 1.1
nmol/1), the test had a high sensitivity (36 of 37, 97%) and positive predictive value (36
of 41, 88%), but low specificity (1 of 7, 14%) and negative predictive value (1 of 2,
50%) for diagnosing ruptured AAA. When the cut-off for PF 1+2 was increased to
greater than or equal to 2.5 nmol/1, the test had a high sensitivity (33 of 37, 89%),
specificity (6 of 7, 86%) and positive predictive value (33 of 34, 97%), but low negative
predictive value (6 of 10, 60%).
When only normotensive symptomatic and ruptured AAA patients were examined, PAI
activity was the most accurate assay for distinguishing non-ruptured from ruptured AAA.
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PAI activity above the normal range (greater than 15 AU/ml) had a high sensitivity (5 of
6, 83%) and specificity (6 of 7, 86%), and a high positive (5 of 6, 83%) and negative
predictive value (6 of 7, 86%) for the diagnosis of rupture. When the cut-off for PAI
activity was increased to greater than or equal to 16 AU/ml, the sensitivity and
specificity was 5 of 6 (83%) and 7 of 7 (100%), and the positive and negative predictive
values were 5 of 5 (100%) and 7 of 8 (88%), respectively.
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TABLE 7.2
Pre-operative t-PA activity, PAI activity, PF 1+2 and D-dimer in asymptomatic,
symptomatic and ruptured AAA.
Median (range)
Assay Normal Asvmptomatic Symptomatic Rupture
range (n=22) (n=7) (n=37)
t-PA activity 0.2-2.0 IU/ml 0.53 1.7 0.28
(0.1 - 7.2) (0.8 - 3.2) (0.1 -9.6)
PAI activity < 15 AU/ml 8.3 6.3 31
(0.9 - 34.6) (3.2- 15.4) (0.1 -39.4)
PF 1+2 0.4 - 1.1 nmol/1 1.9 2.1 6.4
(0.7-7.1) (1.1-5.2) (1.1 - 13.3)
D-dimer 630 - 850 ng/ml 1377 1633 4108
(190- 5577) (753 - 3014) (155 -25947)
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FIGURE 7.1
Pre-operative t-PA activity in asymptomatic, symptomatic and ruptured AAA.
The upper limit of the normal range for t-PA activity (0.2-2.0 IU/ml) is shown































Pre-operative PAI activity in asymptomatic, symptomatic and ruptured AAA.








































Pre-operative PF1+2 level in asymptomatic, symptomatic and ruptured AAA.
The upper limit of the normal range for PF 1+2 (0.4-1.1 nmol/1) is shown by
the horizontal line.























Pre-operative D-dimer level in asymptomatic, symptomatic and ruptured AAA.



































The findings of this study corroborate the observations in the preceding chapter, provide
further insight into the pathophysiology of haemostasis in ruptured AAA and reveal
novel data regarding haemostasis in acutely symptomatic non-ruptured AAA.
Asymptomatic AAA was associated with increased thrombin generation in 17 of 21
(81%) patients, and increased systemic fibrinolysis in four (19%) patients, one of whom
had considerably elevated t-PA activity. Previous studies have reported increased
thrombin generation in asymptomatic AAA (148,254,255,260) in association with
essentially normal systemic fibrinolytic activity (78,150,252).
Ruptured AAA was associated with inhibition of systemic fibrinolysis (elevated PAI
activity), and intense thrombin generation. D-dimer is a marker of secondary fibrinolysis
which occurs in response to thrombus formation and acts to restore microvascular
patency. D-dimer levels were elevated in ruptured AAA, and this is secondary to
increased thrombin generation. Markers of coagulation and fibrinolysis were not
significantly different between normotensive and hypotensive patients with rupture, a
finding which suggests that haemorrhage rather than hypotension may be one of the
principal mechanisms which triggers the generalised procoagulant state in ruptured
AAA. Unexpectedly, intraperitoneal haemorrhage from ruptured AAA was not
associated with a significant difference in any of the haemostatic markers.
Acutely symptomatic non-ruptured AAA was associated with increased systemic
fibrinolysis compared with asymptomatic AAA; and increased systemic fibrinolysis,
reduced secondary fibrinolysis and reduced thrombin generation compared with ruptured
AAA. t-PA activity was higher in patients with acutely symptomatic non-ruptured AAA
compared with rupture but the median values were within the normal range in both
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groups. The lower t-PA activity in ruptured AAA was secondary to increased inhibition
of systemic fibrinolysis (as demonstrated by elevated PAI activity), a finding which was
not present in the patients with acutely symptomatic non-ruptured AAA. D-dimer is a
marker of secondary fibrinolysis which occurs in response to thrombus formation and
acts to restore microvascular patency. D-dimer and PF 1 +2 levels were elevated in both
groups of patients but to a greater extent in ruptured AAA. These differences in
haemostasis were also observed when normotensive patients with acutely symptomatic
AAA were compared with normotensive patients with rupture.
The findings of the present study may be explained if one considers that sudden
expansion or impending rupture of an aortic aneurysm is analogous to an aortic
dissection. Fibrinolytic gene expression and focal fibrinolytic activity have been
demonstrated within the aortic wall of patients with asymptomatic AAA (117,118), and
aortic adventitia is associated with elevated fibrinolytic activator activity (114,121,122).
Sudden aneurysm expansion may lead to bloodflow in the marginal thrombus adjacent to
the diseased aortic wall and as the surface area of aortic adventitia exposed to blood flow
increases there is increased local and systemic fibrinolysis (114). Such a process may
account for the abdominal CT findings of a sickle-shaped thrombus or 'crescent sign' in
aneurysms at risk of rupture. Aneurysm rupture and subsequent haemorrhage may
trigger a procoagulant and hypofibrinolytic state which acts to minimise local blood loss
but has the detrimental effect of contributing to micro- and macrovascular thrombosis.
At present, acutely symptomatic non-ruptured AAA are differentiated from ruptured
AAA primarily on the basis of history and examination, but even the most experienced
of vascular surgeons cannot always confidently exclude rupture on clinical assessment
alone. Many clinicians have advocated the use of emergency computed tomography (CT)
in this situation, but previous work from this group has shown that, in cases of true
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clinical uncertainty, this has an unacceptably low sensitivity (79%) and specificity (77%)
in haemodynamically stable patients (268). In the present study, there were significant
differences in t-PA activity, PAI activity and PF 1+2 between normotensive patients
with acutely symptomatic non-ruptured and ruptured AAA. Furthermore, pre-operative
elevation of PAI activity appeared more accurate than emergency CT. While this may
help to distinguish acutely symptomatic normotensive non-ruptured AAA from ruptured
AAA, currently, the time taken to prepare the plasma and perform the assay
(approximately 2 hours) precludes its use as diagnostic adjunct. The small numbers of
patients studied with non-ruptured AAA does not allow the authors to reach strong
conclusions or make firm clinical recommendations. However, should a rapid assay for
PAI activity become available then it may be of value in distinguishing rupture from
non-rupture in normotensive patients presenting with acute symptoms.
There were three reasons for measuring only pre-operative haemostatic markers in this
study. Firstly, in the preceding chapter, there was little or no change in the levels of the
haemostatic markers intra-operatively compared with pre-operatively. Secondly, if the
findings were to have any value in distinguishing acutely symptomatic non-ruptured AAA
from ruptured AAA, then only the pre-operative markers would be relevant. And finally,
at the time, the assays were novel and consequently almost prohibitively expensive.
In conclusion, these data confirm that ruptured AAA is associated with thrombin
generation and inhibition of systemic fibrinolysis, whereas asymptomatic AAA is
associated with thrombin generation and increased fibrinolysis in a small proportion of
patients. Patients with acute symptomatic non-ruptured AAA do not manifest the same
pattern of haemostatic derangement evident in patients with rupture.
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7.6 Summary
• Ruptured AAA is associated with thrombin generation and inhibition of systemic
fibrinolysis, and asymptomatic AAA is associated with thrombin generation and
increased fibrinolysis in a small proportion of patients.
• In ruptured AAA, there was no difference in markers of coagulation and fibrinolysis
between normotensive and hypotensive patients, suggesting that haemorrhage rather
than hypotension may trigger the procoagulant state.
• Acutely symptomatic non-ruptured AAA is associated with increased systemic
fibrinolysis, and reduced thrombin generation compared with rupture. These
differences were also observed when the normotensive patients with acutely
symptomatic non-ruptured AAA were compared with normotensive patients with
rupture.
• Pre-operative PAI activity above the normal range was more accurate than abdominal
CT in a previous study of patients with suspected rupture.
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Chapter 8




Approximately 40% of patients who fail to survive ruptured AAA repair die intra-
operatively or in the immediate post-operative period (251). Uncontrollable haemorrhage
is one of the principal causes of death in these patients and may occur due to technical
problems and/or coagulopathy (13,39,43). In the ERVSU, haemorrhage and
coagulopathy contributed to 30% and 17% of peri-operative deaths, respectively
(Chapter 4). Wakefield et al (13) reported coagulopathy in 63% of patients who died
during attempted repair of ruptured AAA. Peri-operative coagulopathy in patients with
ruptured AAA is associated with a poor prognosis (3,10,30,44) and is as significant a
predictor of poor outcome as major cardiac events, respiratory failure, ARF, CVA and
distal embolisation (7).
In patients undergoing early re-operation for haemorrhage after rupture, an abnormal
coagulation screen at the end of the primary operation is universal (43). Peri-operative
haemostatic derangement, as demonstrated by low pre-operative platelet count (44,45)
and prolonged clotting times (44), has been shown to be associated with major peri¬
operative morbidity and mortality mainly due to haemorrhage, and thrombotic events
including MI, MOF and CVA (43,44,45). Previous investigations of haemostasis in
ruptured AAA repair are few and have largely consisted of the measurement of the
standard laboratory markers of haemostatic function (44,45,114,137,138). As shown in
chapter 6, in patients who survive to 24 hours post-operatively, ruptured AAA repair is
associated with intense thrombin generation and inhibition of systemic fibrinolysis. The
pathophysiology of the haemostatic derangement which occurs in patients with peri¬
operative coagulopathy has not previously been studied.
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8.2 Aims
To examine serial peri-operative changes in markers of coagulation and fibrinolysis in





Eight patients (8 men of median age 74, range 69-87, years) operated upon for ruptured
infrarenal AAA were studied. All of these patients had clinical and laboratory evidence of
coagulopathy and haemorrhage and all had an aortic graft inserted in an apparently
technically adequate manner and the circulation restored to the lower extremities.
The median (range) delay between the onset of symptoms of rupture and hospital
admission was 7 (2-14) hours. All patients had at least one documented episode of
hypotension (systolic blood pressure less than lOOmmHg) prior to surgery. Two patients
with retroperitoneal and intraperitoneal rupture had a documented episode of loss of
consciousness prior to admission, and one patient was transferred from another hospital
wearing a pneumatic anti-shock garment. No patient had a history of liver disease. Co¬
morbidity data are shown in Table 8.1.
Operative methods
Six patients had retroperitoneal, and two intraperitoneal rupture. The operations were
performed as previously described. A dacron aorto-aortic graft was inserted in five
patients, an aorto-bi-iliac graft in two patients and an aorto-bifemoral graft in one
patient. Clinical and operative data are shown in Table 8.2.
Sample collection
Blood was sampled from an indwelling arterial line immediately prior to the induction of
anaesthesia (sample A); immediately before release of the aortic clamp (sample B); and
five minutes (sample C) and 24 hours (sample D) after aortic clamp release in those
patients who survived repair. The samples were prepared as described above.
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Assays ofhaemostatic function
Haematocrit, platelet count, fibrinogen, PT and aPTT were measured in the routine
haematology laboratory. Thrombocytopenia was defined as a platelet count less than 150
g
x 10 /1. Hypofibrinogenaemia was defined as a fibrinogen level less than 1.5 g/1. PF
1+2 was assayed as a marker of thrombin generation, and t-PA and PAI activities as
markers ofprimary systemic fibrinolysis. Assays were performed as described above.
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TABLE 8.1






















Clinical and operative data in patients with peri-operative coagulopathy.
Median (range)
Pre-operative
Crystalloid administration (1) 1.5 (0.3 - 2.6)
Colloid administration (1) 0.2 (0 - 2.0)
Intra-operative
Operation time (mins) 145 (110 - 250)
Aortic clamp time (mins) 80 (45 - 135)
Measured blood loss (1) 6.4 (1.7 - 11.0)
Crystalloid administration (1) 3.5 (2.0 - 7.5)
Colloid administration (1) 2.3 (0 - 5.0)
RCC administration (units) 1 14 (8 - 22)
FFP administration (units) 2 3 (2 - 12)
Platelet administration (bags) 3 1(1-2)





Three patients died intra-operatively from uncontrollable coagulopathy haemorrhage
after an aortic graft had been inserted. The remaining five patients had clinical and
laboratory evidence of on-going coagulopathy during the first 24 hours post-operatively.
One of these patients died in the early post-operative period from continuing
haemorrhage, and two patients died in the late post-operative period. Clinicopathological
and outcome data are shown in Table 8.3.
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TABLE 8.3
Clinicopathological and outcome data in patients with peri-operative coagulopathy.
Complications
Age Intra-operative Post-operative Outcome
1 71 Coagulopathy Coagulopathy (2 FFP, 10 cryo),
inotrope, respiratory







Coagulopathy (2 RCC, 4 FFP),





74 Coagulopathy Coagulopathy (8 RCC, 6 FFP,
2 PC, 20 cryo), inotrope, DVT,
respiratory failure, IPPV
261 hours, bilateral BKA
Death post-op.
day 40
75 Coagulopathy Coagulopathy (6 RCC, 1 PC),
CCF, inotrope, respiratory







8 87 Coagulopathy Coagulopathy (18 RCC, 9 FFP,
3 PC), inotrope, IPPV 18 hours
Death 18 hours
post-op.
KEY: Cryo = cryoprecipitate, PC = platelet concentrate,
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Haematocrit, platelet count, fibrinogen, PT and aPTT
The median (range) values for haematocrit, platelet count, fibrinogen, PT and aPTT are
shown in Table 8.4. Fibrinogen levels are shown in Figure 8.1. Pre-operative standard
haemostatic markers were within the normal range in three patients, two of whom
survived. Of the remaining patients, all five had thrombocytopenia, three had prolonged
clotting times, and one had hypofibrinogenaemia. Intra-operatively, all of the patients
had thrombocytopenia and prolonged clotting times, six had hypofibrinogenaemia and two
had fibrinogen levels near the lower limit of the normal range. At 24 hours, all patients




Haematocrit, platelet count, fibrinogen, PT and aPTT.
Assay Normal range Sample Median (range)
Haematocrit 0.37-0.54 A 0.276(0.140-0.342)
B 0.235 (0.194 -0.439)
C 0.236 (0.183 -0.420)
D 0.329 (0.329 - 0.357)
Platelet count 150- 350 x 109/1 A 131 (40- 321)
B 91 (48 - 127)
C 79 (44 - 114)
D 66 (23 - 102)
Fibrinogen 1.5 - 4.0 g/1 A 2.37 (0.74-6.31)
B 1.29 (0.1 - 1.64)
C 1.03 (0.24- 1.64)
D 4.0 (2.96 - 5.64)




aPTT 28 - 40 s A 37.1 (27.8 - 75.0)
B 104.1 (44.4->210.0)
C 86 (44.4->210.0)
D 41.3 (32.1 - 55.9)
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Markers ofthrombin generation and fibrinolysis
The median (range) values for PF 1+2, t-PA activity and PAI activity are shown in Table
8.5. All of the patients had evidence of intense thrombin generation (elevated PF 1+2
levels) before, during and after operation (Figure 8.2). Pre-operatively, three patients had
evidence of increased systemic fibrinolysis (elevated t-PA activity and reduced or normal
PAI activity) which persisted intra-operatively. All of these patients died, one intra-
operatively, one within 24 hours and one in the late post-operative period. In two further
patients, t-PA activity was normal pre-operatively but became elevated before aortic
declamping, and these patients also died intra-operatively (Figure 8.3). Pre-operatively,
five patients had evidence of inhibition of systemic fibrinolysis (reduced t-PA activity
and elevated PAI activity). PAI activity remained elevated intra-operatively and at 24
hours post-operatively in three patients, two ofwhom survived (Figure 8.4).
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TABLE 8.5
PF 1+2, t-PA activity and PAI activity.
Assay Normal range Sample Median (range)




t-PA activity 0.2 - 2.0 IU/ml A 0.86 (0.09 - 9.6)
B 7.0(0.19-13.7)
C 5.8(0.16-14.1)
D 0.72 (0.73 - 2.3)
PAI activity <15 AU/ml A 28.7 (0.1 -38.9)
B 7.9(0.1 -39.4)




Individual data points for fibrinogen level immediately before induction of
anaesthesia (sample A), immediately before release of the aortic clamp, (sample
B), and five minutes (sample C) and 24 hours (sample D) after aortic clamp
release.
Non-survivors of ruptured AAA are represented by the red squares and
survivors by the yellow circles.
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FIGURE 8.2
Individual data points for PF 1+2 immediately before induction of anaesthesia
(sample A), immediately before release of the aortic clamp, (sample B), and
five minutes (sample C) and 24 hours (sample D) after aortic clamp release.
Non-survivors of ruptured AAA are represented by the red squares and
survivors by the yellow circles.




Individual data points for t-PA activity immediately before induction of
anaesthesia (sample A), immediately before release of the aortic clamp,
(sample B), and five minutes (sample C) and 24 hours (sample D) after
aortic clamp release.
Non-survivors of ruptured AAA are represented by the red squares and
survivors by the yellow circles.
The upper limit of the normal range for t-PA activity (0.2-2.0 IU/ml) is
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FIGURE 8.4
Individual data points for PAI activity immediately before induction of
anaesthesia (sample A), immediately before release of the aortic clamp,
(sample B), and five minutes (sample C) and 24 hours (sample D) after aortic
clamp release.
Non-survivors of ruptured AAA are represented by the red squares and
survivors by the yellow circles.
The upper limit of the normal range for PAI activity (< 15 AU/ml) is shown
by the horizontal line.
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8.5 Discussion
The present study is the first to examine serial peri-operative changes in coagulation and
fibrinolysis in patients with ruptured AAA complicated by peri-operative coagulopathic
haemorrhage. In Chapter 6, it was demonstrated that, in patients who survive to 24
hours, ruptured AAA repair is associated with intense thrombin generation and
inhibition of systemic fibrinolysis. All of the patients in the present study were shocked
pre-operatively, two had intraperitoneal rupture in association with loss of
consciousness and cardiac arrest, and all received massive volumes of intravenous fluid,
RCC, and clotting factors intra-operatively. All of the patients had increased thrombin
generation but, unlike those who survived their operation, there was evidence of
increased systemic fibrinolysis in five patients, all of whom died, four within the first 24
hours after surgery. Mulcare et al (137) have previously reported increased post¬
operative fibrinolysis in four patients with rupture who developed excessive bleeding.
It has been suggested that, in patients with non-ruptured AAA, there exists a
compensated and subclinical form of coagulopathy which may render the patient
particularly sensitive to the pathophysiological effects of aneurysm rupture and repair
such that decompensation occurs and clinically apparent coagulopathy develops
(45,179,137,139). Several mechanisms may contribute to the development of
coagulopathy. Patients with vascular disease frequently have a number of concommitant
coagulation disorders such as pre-existing liver and renal impairment, and regular
antiplatelet and anticoagulant therapy. Increased levels of elastase have been
demonstrated within the aortic wall of patients with aortic aneurysms (156,157) and this
may lead to activation of the coagulation and fibrinolytic systems if released into the
circulation due to aortic wall disruption. Fibrinogen, fibrin, and platelet consumption
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occurs within the aneurysm thrombus (111), surgical wounds, the aortic graft (142,144),
and within the ruptured aneurysm haematoma (39). Blood loss, fluid resuscitation and
blood transfusion have a dilutional effect on the levels of clotting factors and platelets,
and hypothermia due to shock and prolonged and complicated surgery is associated with
adverse platelet effects (172). Intestinal ischaemia and endotoxaemia (72) may
contribute to the increased incidence of coagulopathy associated with supracoeliac aortic
clamping (124,125). Finally, the relationship between prolonged aortic cross-clamp
times and increased incidence of coagulopathy suggests that as the magnitude of the
ischaemic insult increases, then the risk of coagulopathy increases (42,124).
Based upon these data and the findings of Chapter 6, patients with ruptured AAA may be
classified into two categories. Those who have 'compensated' haemorrhagic shock
exhibit thrombin generation and inhibition of systemic fibrinolysis and appear likely to
survive to at least 24 hours post-operatively. By contrast, those with 'decompensated'
shock exhibit thrombin generation and increased systemic fibrinolysis and appear likely to
die intra-operatively or in the immediate post-operative period from coagulopathy
despite the apparently technically adequate insertion of a graft. Of practical importance is
the fact that those patients who die from peri-operative haemorrhage have a
hyperfibrinolytic state on admission to the resuscitation room and/or before aortic
declamping. There was no difference in the duration between the onset of symptoms of
rupture and hospital admission in these patients compared with those who survived to 24
hours. PAI is presumably consumed during the period of haemorrhagic shock resulting in
high levels of circulating free t-PA. This leads to high levels of circulating free plasmin
which leads to consumption of fibrinogen and fibrin. t-PA and PAI activities are of value
as a research tool, but it takes several hours to prepare the plasma and perform the
assays and this precludes their clinical use in identifying this hyperfibrinolytic state.
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There are two clinical methods which may identify those patients with coagulopathy
secondary to hyperfibrinolysis. Euglobulin clot lysis time (ECLT) measures the time for
a clot to lyse in a test tube. If fibrinolysis predominates there is early clot lysis, and if
coagulation factor consumption predominates then there is little or no clot formation in
the first place. Thromboelastography (TEG) measures the strength of the blood clot as it
forms and can determine the whole blood clotting time, coagulation factor and platelet
function, fibrinolysis and hypercoagulability. Using a whole blood sample, a result can
be obtained within 15-20 minutes. Given that the hyperfibrinolytic state may be
identified early during aneurysm repair, can therapeutic intervention improve outcome ?
Peri-operative administration of FFP and platelets have been advocated in patients with
ruptured AAA (45,138,179). The routine administration of the antifibrinolytic agent,
aprotinin, in elective and ruptured AAA repair has failed to demonstrate clinical benefit
(256,259). However, the present study suggests that the use of antifibrinolytic agents as
well as the administration of FFP and cryoprecipitate may prove more beneficial if
targeted at the selected group of patients with ruptured AAA who demonstrate
hyperfibrinolysis.
In conclusion, these data demonstrate that patients with ruptured AAA who develop
peri-operative coagulopathy secondary to hyperfibrinolysis have a poor prognosis. The
measurement of peri-operative fibrinolytic function may help to identify the select group
of patients with rupture who are at increased risk of developing life-threatening
coagulopathic haemorrhage, and thereby allow early aggressive therapeutic intervention.
Due to the limitations of such an observational study of a small and heterogenous group
of patients, it is not possible to conclude whether the hyperfibrinolytic state is a
contributory factor in the development of intra-operative coagulopathy or it is simply a
manifestation of severe and irreversible whole body hypoperfusion.
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8.6 Summary
• Patients with peri-operative coagulopathy haemorrhage have evidence of increased
thrombin generation but, unlike those who survive to 24 hours, a proportion
demonstrate hyperfibrinolysis on admission and/or before aortic declamping which is
associated with an extremely poor prognosis.
• Ruptured AAA may be classified into two categories, according to the pattern of
haemostatic derangement: 'compensated' shock leads to thrombin generation and
inhibition of systemic fibrinolysis and is associated with survival to at least 24 hours
post-operatively; 'decompensated' shock leads to thrombin generation and
hyperfibrinolysis and is associated with intra- or early post-operative death from
coagulopathy.
• Measurement of the fibrinolytic function may help to identify the patients who are at
increased risk of developing life-threatening coagulopathy, thereby allowing early
intervention with antifibrinolytic agents, FFP and cryoprecipitate.
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Chapter 9
von Willebrand factor and platelet count in
ruptured and non-ruptured AAA repair
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9.1 Introduction
Ruptured and non-ruptured AAA repair are usually associated with a generalised
procoagulant state with evidence of increased thrombin generation. This may be because
endothelial cell injury leads to the exposure of subendothelial collagen and elastin that
triggers the extrinsic coagulation cascade.
Endothelial cell activation and injury is also associated with the rapid release of vWF into
the circulation. vWF binds to exposed subendothelial collagen at sites of vessel injury;
platelets then irreversibly bind to vWF. Plasma vWF accounts for 60% of total platelet
adhesion with the remaining 40% provided by endothelial cell vWF (59). vWF is
essential for the formation of occlusive platelet thrombi at sites of arterial injury (56).
Previous work from this department has demonstrated that AAA repair is associated
with early peri-operative thrombocytopenia and late post-operative thrombocytosis
(45,263). Furthermore, in ruptured AAA, a strong association exists between platelet
count and mortality, MOF and thrombo-embolic events (45). Although the underlying
mechanisms remain ill-defined, vWF and its effect on platelets may have an important
role in the procoagulant state which occurs in patients undergoing AAA repair. To date,
however, there have been few studies examining endothelial cell activation in elective
aortic surgery (145,260) and none in patients with ruptured AAA.
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9.2 Aims
To examine peri-operative vWF, sTM and platelet count in patients operated for
ruptured and non-ruptured AAA, and to determine the relationship between these




Twenty patients (18 men and 2 women of median age 74, range 63-86, years) operated
for ruptured and 10 patients (8 men and 2 woman of median age 69, range 58-80, years)
operated for asymptomatic non-ruptured infrarenal AAA were prospectively studied.
Co-morbidity data are shown in Table 9.1.
In patients operated for ruptured AAA, the median (range) delay between the onset of
symptoms of rupture and hospital admission was 5 (2-14) hours. All patients with
rupture had at least one documented episode of hypotension (systolic blood pressure less
than 1 OOmmHg) prior to surgery. On admission to the resuscitation room or immediately
before anaesthetic induction, the median (range) peripheral body temperature of patients
with ruptured AAA was 35.4 (32.2-37.5) C. In patients undergoing operation for non-
ruptured AAA, the median (range) antero-posterior diameter of the aneurysm measured
by abdominal ultrasonography was 6.5 (5.5-8.0) cm.
Operative methods
The operations were performed as previously described. Fourteen patients had
retroperitoneal, and six intraperitoneal rupture. A dacron tube graft was inserted in 17
patients (13 rupture, 4 non-rupture), an aorto-bi-iliac graft in six (2 rupture, 4 non-
rupture) and an aorto-bifemoral graft in five (3 rupture, 2 non-rupture). Two patients
with rupture had no graft inserted and died intra-operatively.
Definition ofperi-operative complications
These were defined as described above.
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Sample collection
Blood was sampled from an indwelling arterial line immediately prior to the induction
of anaesthesia (sample A); immediately before release of the aortic clamp (sample B);
five minutes (sample C) and 24 (sample D) and 48 hours (sample E) after aortic clamp
release. Samples were prepared as described above.
Haemostatic and endothelial markers and C-reactive protein
Haematocrit, platelet count, fibrinogen, PT, aPTT, D-dimer, vWF antigen, soluble
thrombomodulin (sTM) and CRP were assayed as described above. D-dimer was
determined in all patients pre-operatively, and at all sample points in those who
developed post-operative coagulopathy.
Statistical analysis
The Mann-Whitney U test (MW) and Spearman rank test were used.
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TABLE 9.1
Co-morbidity in patients operated for ruptured and non-ruptured AAA.











Peripheral arterial occlusive disease
Venous thrombo-embolism
Chronic obstructive airways disease










Angiotensin converting enzyme inhibitor 1
Calcium-channel blocker 1





















Clinical and operative data for both groups of patients are summarized in Table 9.2.
Three patients with ruptured AAA died during attempted repair, and one died in the
recovery room immediately after graft insertion. Fifteen of 16 patients with rupture who
survived to leave the operating room subsequently developed major post-operative
complications, and five of these patients died in the post-operative period. There were
no deaths after repair of non-ruptured AAA and four patients developed major post¬
operative complications (Table 9.3). No patients with non-ruptured AAA required
admission to the ITU or assisted ventilation.
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TABLE 9.2
















Aortic clamp time (minutes)
Measured blood loss (1)
Crystalloid and
colloid administration (1)






Duration of ITU stay (hours)
Duration of IPPV (hours)
Duration of hospital stay (days)
129 (77 -233)
0.7 (0.1 - 5.5)
70 (30- 150)
4.0(1.0- 11.0)
3.5 (1.5 - 12.5)
8 (5 - 22)
2 (0- 12)
1(0-2)
73 (13 - 579)
22 (9 -451)
19(9-50)
92 (63 - 123)
75 (25 - 150)
2.4 (0.4 - 6.0)
3.8(2.0-7.1)
4(0 - 10)










9 (7 - 40)
KEY: * Mann-Whitney U test, 1 RCC = 300 ml, 2 FFP = 300ml, 3 one bag of platelet
transfusion = 4 pooled units (250 ml)
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TABLE 9.3
Post-operative complications and procedures in ruptured and non-ruptured AAA.
Ruptured Non-ruptured
AAA AAA









Chest infection 11 2
Respiratory failure 7 0
ARDS 1 0
Acute Renal Failure (receiving RRT) 8 (3) 1
Coagulopathy 3 0
Sepsis syndrome 3 0
Colon ischaemia 1 0
Inotropic support
Adrenaline 5 0
Renal dose dopamine 11 0
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Haemostatic and endothelial cell markers
The values of haemostatic markers are shown in Table 9.4. In ruptured AAA, platelet
count was significantly lower in non-survivors compared with survivors pre-operatively
(median 119, range 40-321 vs. survivors: median 224, range 144-303; p= 0.007),
immediately before (median 81, range 48-116 vs. survivors: median 123, range 86-189;
p= 0.009) and 5 minutes (median 74, range 44-93 vs. survivors: median 114, range 59-
146; p= 0.009) and 24 hours (median 72, range 23-86 vs. survivors: median 102, range
50-133; p= 0.02) after aortic clamp release. There was also a significant negative
correlation between platelet count at 48 hours post-operatively and duration of ITU stay
(r= -0.536, p= 0.039) but no significant relationship existed between platelet count and
duration of assisted ventilation, hospital stay or the number ofmajor complications.
The values of vWF, sTM and CRP are shown in Table 9.5. Pre-operative vWF was
elevated above the normal range in 6 of 10 patients with non-ruptured AAA, and 13 of
20 with ruptured AAA. Pre-operative levels of sTM were elevated above the normal
range in all patients in both groups, but there was no significant difference between the
groups. There was a significant positive relationship between pre-operative vWF and
sTM in all patients (r= +0.574, p= 0.001) and in patients with ruptured AAA (r= +0.492,
p= 0.032). At 24 hours, vWF was above the normal range in all patients operated upon
for non-ruptured AAA and 14 of 16 survivors of ruptured AAA.
There was no relationship between duration of symptoms of rupture and vWF, platelet
count or CRP. In ruptured AAA, there was a significant negative correlation between
CRP at 24 hours post-operatively and vWF pre-operatively (r= -0.593, p= 0.015), and
platelet count pre-operatively (r= -0.552, p= 0.027), immediately before (r= -0.657, p=
0.011) and 5 minutes after aortic clamp release (r= -0.552, p= 0.041).
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In non-ruptured AAA, there was a significant positive correlation between pre-operative
vWF and haematocrit (r= +0.721, p= 0.019). There was no correlation between vWF
and haematocrit or platelet count in ruptured AAA. There was no correlation between
pre-operative body temperature and vWF or platelet count in patients with ruptured
AAA. In ruptured AAA, there was a significant positive correlation between vWF and
platelet count pre-operatively (r= +0.477, p=0.033), immediately before (r = +0.467, p=
0.044) and 5 minutes after clamp release (r = +0.495, p=0.043). In non-ruptured AAA,
there was a significant positive correlation between vWF and platelet count pre-
operatively (r = +0.794, p= 0.006), immediately before (r = +0.648, p= 0.043) and 5
minutes after clamp release (r= +0.634, p= 0.048).
There was significant negative correlation between operative blood loss and vWF 5
minutes after aortic clamp release in all patients with ruptured AAA (r= -0.526, p= 0.03)
which became more significant when only patients who survived the repair were
examined (r= -0.662, p= 0.007). There was no significant relationship between aortic
clamp time and vWF. There was a significant negative correlation between operative
blood loss (r= -0.569, p= 0.027) and aortic clamp time (r= -0.574, p= 0.02) and platelet
count 5 minutes after aortic clamp release in all patients with ruptured AAA. The
relationship between blood loss and platelet count 5 minutes after clamp release became
more significant when only patients who survived the repair were examined (r= -0.622,
p= 0.023). In non-ruptured AAA, there was significant negative correlation between
aortic clamp time and vWF 5 minutes after aortic clamp release (r= -0.632, p= 0.05).
There was no relationship between blood loss and vWF, or blood loss or aortic clamp
time and platelet count.
Two patients with rupture had a post-operative MI. Both patients had significant cardiac
disease and were hypotensive before and during the operation. vWF levels at 48 hours
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(3.0 and 3.07 IU/ml) were higher than those patients who did not have an MI (median
2.12, range 0.98 - 2.86 IU/ml; p=0.026) and were associated with low platelet count
(124 and 57 x 109/1) and elevated fibrinogen levels (7.32 and 4.28 g/1). There was no




Haematocrit, platelet count, fibrinogen, PT, aPTT and D-dimer.
Assay Sample Ruptured AAA Non-ruptured AAA p value
(normal range) point median (range) median (range) *
(n=20) (n=10)
Hct A 0.41 (0.33 -0.47) 0.31 (0.13-0.45) <0.001
(0.37 - 0.54) B 0.3 (0.25 - 0.37) 0.29 (0.18-0.44) NS
C 0.3 (0.23 - 0.35) 0.29 (0.18 -0.42) NS
D 0.33 (0.25 - 0.39) 0.33 (0.26 - 0.42) NS
E 0.33 (0.27 - 0.37) 0.31 (0.24-0.41) NS
Platelet count A 182 (40-321) 193 (75 -744) NS
(150-350 x 109/1) B 110(48 - 189) 140(103 -541) 0.007
C 93 (44 - 164) 140 (91 -577) 0.006
D 97(23 - 133) 136(85 -604) 0.007
E 94 (43 - 124) 136(74-435) 0.017
Fibrinogen A 2.8 (1.59 - 6.02) 2.36 (0.46-6.31) NS
(1.5 - 4.0 g/1) B 1.74 (0.72 -5.39) 1.2 (0.36-2.51) 0.02
C 1.56 (0.36- 5.44) 1.08 (0.46- 1.82) NS
D 3.7 (2.5 - 5.44) 2.96(1.13 -4.63) 0.018
E 6.03 (4.79 - 7.47) 5.57 (2.56- 7.32) NS
PT A 12.5 (10.9 - 14.5) 14(9.7- 120) NS
(10.5 - 14.5 s) B 18.1 (14.5-25.5) 20.8(12- 120) NS
C 19.9(14.4-120) 20.1 (10-31.2) NS
D 14.2(12.4-21.4) 15.6(12- 18.6) NS
E 13.1 (11.5- 18.8) 14.6(12.4- 19.3) NS
aPTT A 31.3 (25.4-49.3) 36.8 (27.6-210) NS
(28 - 40 s) B 210(55.9-210) 59.5 (33.8-210) 0.021
C 210(56.8-210) 57.3 (41.7-210) 0.016
D 37.1 (28.6-210) 47.4 (32.1 - 76) NS
E 34.7 (27.9- 51) 37.3 (29.8 - 52.5) NS
D-dimer A 3886 (1236 - 1547 (550- 5334) 0.004
17552)
(630 - 850 ng/ml)
KEY: * = Mann-Whitney U test
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TABLE 9.5
Endothelial cell markers and C-reactive protein.
Assay Sample Ruptured AAA Non-ruptured AAA p vali
(normal range) point median (range) median (range) *
(n=20) (n=10)
vWF A 1.9 (0.47-3.64) 1.4 (0.44-3.6) NS
(0.42 - 1.22 B 0.81 (0.14-2.12) 0.96 (0.3 - 3.06) NS
IU/ml)
C 0.91 (0.21 - 1.7) 0.86 (0.29-2.75) NS
D 1.68(0.8-3.12) 1.89(1.5 -3.99) NS
E 2.13 (0.98 - 3.07) 2.62(1.41 -4.02) NS
sTM A 108 (40 -381) 88 (66 - 555) NS
(< 25ng/ml)
CRP A 7.7 (0.3 - 178.3) 5 (0.3 - 18.6) NS
(< 10 mg/1) B 4(0.3 - 116) 2.4 (0.3 - 13.4) NS
C 4 (0.3 - 114.2) 1.8(0.3-8.2) NS
D 127 (41.8-400) 101.7(41.5 - 180.8) NS
E 165.1 (57.5 -400) 111.2 (90.2 -257.6) NS
KEY: * = Mann-Whitney U test
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9.5 Discussion
The present study is the first to examine the relationship between plasma vWF, sTM and
platelets in patients undergoing ruptured and non-ruptured AAA repair. The principal
findings are that elevated vWF levels are present in approximately 60% of patients with
intact or ruptured AAA pre-operatively, and almost 100% post-operatively.
Furthermore, there is a significant positive association between peri-operative vWF
levels and platelet count in both groups, and increased operative blood loss and aortic
clamp times exacerbate the intra-operative fall in vWF and platelet count. However,
there is no significant difference in peri-operative vWF levels between patients with
ruptured and non-ruptured AAA. This finding significantly reduces the degree of
certainty ascribed to the conclusions of this study.
Elevated plasma vWF levels are associated with an increased thrombotic tendency and
have been reported in patients with peripheral (64,65) and coronary arterial occlusive
disease (66-68). In patients undergoing elective repair of non-ruptured AAA, Yamazumi
et al (260) showed no difference in pre-operative vWF levels compared with control
patients. Gibbs et al (145) demonstrated an early post-operative increase in vWF levels
in association with a procoagulant state in 19 patients undergoing elective aortic surgery
for AAA or occlusive disease. A previous study from this department demonstrated
ultrastructural changes in endothelial cell morphology consistent with endothelial cell
activation in patients with ruptured AAA, but no such changes were observed in non-
ruptured AAA (169). The present study, however, suggests that the endothelium is
activated in the majority of patients with non-ruptured AAA, and that this is of similar
magnitude to that which occurs in patients presenting with ruptured AAA. In keeping
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with the findings of Gibbs et al (145), vWF levels were almost universally elevated at
24 hours in both groups of patients.
Previous work from this department has demonstrated a strong association between pre¬
operative thrombocytopenia and mortality, and immediate post-operative platelet count
and the development of MOF in patients with ruptured AAA (45). Similar but less
dramatic changes in platelet count are observed after elective aortic reconstruction for
AAA and occlusive disease (263). The findings of the present study concur with our
previous findings in that peri-operative PC was significantly lower in non-survivors of
rupture, and low platelet count at 48 hours post-operatively was associated with
prolonged ITU stay. The relationship between early peri-operative thrombocytopenia
and mortality suggests that the changes in platelet count in ruptured AAA may
contribute to, rather than occur as a consequence of, major morbidity and mortality. The
finding that two patients with post-operative MI had high post-operative vWF levels is
support for the relationship between vWF and thrombotic events. In ruptured AAA,
there was no evidence that haemodilution, duration of symptoms or pre-operative
hypothermia had an effect on vWF or platelet count. However, an elevated acute phase
response and increased operative blood loss were associated with reduced peri-operative
vWF and platelet count. These data, combined with the fact that there no significant
difference in vWF levels between patients with ruptured and non-ruptured AAA,
suggest that the stress response to surgery may have contributed to the changes in vWF
and platelet count. As a control group of patients were not included, it is not possible to
clarify this association from the present study.
Patients with non-ruptured AAA had epidural in addition to general anaesthesia and
received intra-operative heparin. Epidural anaesthesia is associated with a reduction in
adreno-cortical system function compared with general anaesthesia, but the effects on
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vWF and platelets are unclear: factor VIII antigen or complex may be reduced (269,270)
or unaffected (271) and platelet function may be reduced (272) or increased (273)
compared with general anaesthesia. In elective aortic surgery, epidural and general
anaesthesia have been shown to have no beneficial effect on peri-operative coagulation
compared with general anaesthesia alone (147). Standard heparin has no effect on
platelet count (274) but inhibits interactions between vWF and platelets (275) and
stimulates vWF-independent platelet aggregation and activation (276,277).
One can speculate that EC activation and injury leads to vWF release. The vWF binds
platelets and initiates the formation of occlusive thrombi at sites of endothelial injury.
The resultant consumption of vWF and platelets secondary to macro- and microvascular
thrombus formation leads to a fall in their circulating levels. This may partly explain the
relationship between thrombocytopenia and poor outcome associated with AAA repair.
Intravenous DDAVP leads to an acute increase in vWF levels with increased platelet
adhesiveness. A randomised trial in patients undergoing elective aortic surgery failed to
demonstrate a significant difference in operative blood loss or transfusion requirement, or
pre- and post-operative bleeding time, platelet count or haematocrit (180). The limited
efficacy of DDAVP in AAA patients may be explained by the finding of naturally
elevated pre- and post-operative vWF levels, and because the proposed mechanism for
the intra-operative fall in vWF is increased consumption secondary to increased platelet
thrombi formation, rather than an actual deficiency of endogenous vWF.
In conclusion, these novel data demonstrate that ruptured and non-ruptured AAA are
associated with peri-operative EC activation. vWF may initiate peri-operative formation
of occlusive platelet thrombi at sites of endothelial injury, thereby contributing to the
poor outcome associated with thrombocytopenia in patients undergoing AAA repair.
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9.6 Summary
• Endothelial cell activation, as demonstrated by elevated vWF levels, is present in
approximately 60% patients with ruptured and non-ruptured AAA pre-operatively,
and almost 100% of patients post-operatively
• There is a significant positive association between peri-operative vWF levels and
platelet count in ruptured and non-ruptured AAA.
• There is a negative correlation between operative blood loss and aortic clamp time
and intra-operative vWF levels and platelet count.
• vWF may contribute to the procoagulant state in patients undergoing AAA repair by
binding platelets initiating the formation of occlusive thrombi at sites of endothelial
injury. The resultant consumption of vWF and platelets secondary to macro- and
microvascular thrombus formation may lead to a fall in their circulating levels, thus
partly explaining the relationship between thrombocytopenia and poor outcome
associated with AAA repair.
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Chapter 10
Haemostasis and myocardial injury in ruptured
and non-ruptured AAA repair
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10.1 Introduction
Cardiac events are a major cause of peri-operative morbidity and mortality in patients
undergoing repair of ruptured and non-ruptured AAA (7,30,44,182). A hypofibrinolytic
state has been demonstrated in patients with peripheral vascular disease (64,104,105)
and may predict cardiovascular events in symptomatic patients (105). There is also
considerable evidence to support a hypofibrinolytic state as a causative factor in the
development of coronary artery disease and acute coronary events (95-100,
102,103,188,189).
We hypothesised that the procoagulant and hypofibrinolytic state which occurs during




To examine the relationship between peri-operative changes in coagulation and
fibrinolysis and myocardial injury in patients undergoing ruptured AAA repair, and to




Ten patients (8 men and 2 women ofmedian age 76, range 71-86, years) who underwent
repair of ruptured infrarenal AAA and nine patients (8 men and 1 woman of median age
69, range 58-80, years) operated for asymptomatic non-ruptured infrarenal AAA were
prospectively studied. These patients were described in Chapter 6. All patients with
rupture had at least one documented episode of hypotension (systolic blood pressure less
than lOOmmHg) prior to surgery. Six patients with rupture had cardiac co-morbidity
including hypertension (n=3), MI (n=2), angina pectoris (n=l) and CCF (n=l). Four
patients with non-ruptured AAA had cardiac co-morbidity including hypertension (n=2),
exertional angina pectoris (n=2) and previous coronary artery bypass grafting (n=l).
Three patients with rupture and four with non-ruptured AAA were taking regular aspirin.
Operative methods
The operations were performed as previously described. Eight patients operated for
rupture had at least one episode of intra-operative hypotension: on induction of
anaesthesia (n=2), before aortic clamping (n=2), during lower torso ischaemia (n=3),
and after aortic declamping (n=5). Four patients received low dose dopamine infusion
(2-5 ug/kg/min), one received adrenaline infusion and one received both dopamine and
adrenaline intra-operatively. Five patients operated for non-ruptured AAA had at least
one episode of intra-operative hypotension: on induction of anaesthesia (n=4), before
aortic clamping (n=2), during lower torso ischaemia (n=2), and after aortic declamping
(n=2). One patient received intra-operative adrenaline infusion.
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Assays ofhaemostatic function andmyocardial injury
Haematocrit, platelet count, fibrinogen, PT, aPTT, PAI activity, t-PA activity and PF
1+2 were assayed. cTn I greater than or equal to 0.5 ng/ml was positive for myocardial
injury. Serum CK was measured if cTn I was positive. CK-MB was measured if total CK
was elevated above the normal range. CK-MB greater than 16U/1 and greater than or
equal to 6% of total CK is positive for MI. Samples were analysed as described above.
Sample collection
Blood for haemostatic markers and haematocrit was sampled before induction of
anaesthesia (sample A), immediately before (sample B) and five minutes (sample C) and
24 hours (sample D) after aortic clamp release. cTn I is detectable 2-6 hours after
myocardial cell injury. Therefore, blood was sampled for markers of myocardial injury
immediately prior to the induction of anaesthesia (sample E), and 6 hours (sample F), 24
hours (sample G) and 48 hours (sample H) after aortic clamp release (Figure 10.1).
Samples were prepared as described above.
Definition ofmajor peri-operative cardiac complications
These were defined as described above, and consisted of acute MI, cardiac failure, and
significant cardiac arrhythmia.
Statistical analysis
The Spearman rank test was used to correlate the levels of haemostatic markers with
cTn I. Where levels of cTn I were below the limit of detection of the assay, no value was




PATHOPHYSIOLOGICAL PHASES IN RUPTURED AAA


























All patients survived to 24 hours after repair and two patients with rupture died in
hospital from pneumonia and CLI on post-operative day 21 (patient 3), and from ARDS
and ARF on post-operative day 10 (patient 9) (Table 10.2). Three patients with non-
rupture and six with ruptured AAA had clinically apparent major post-operative cardiac
complications (Tables 10.1 and 10.2).
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TABLE 10.1







cTn I (ng/ml) / CK-MB (%)
Sample
E F G H
1 N N AF, CCF ND ND ND ND




3 Y Y None ND ND ND ND
4 N N None ND 0.8
ND
ND ND
5 Y Y None ND ND ND ND




7 N Y CCF ND ND 0.7
2
ND
8 N Y None ND ND ND ND
9 N N None ND ND ND ND
KEY: ND = not detected
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TABLE 10.2
Peri-operative cardiac events, cTn I and CK-MB in patients with ruptured AAA.
cTn I (ng/ml) / CK-MB (%)
Patient Cardiac Hypotension Post-op. cardiac Sample
co-morbidity Pre-op. Intra-op. complications E F G H
Y Y Y MI, CCF,AF, ND 25 106 123
cardiac arrest 20 8 6
N Y N CCF ND ND 0.6 ND
ND
Y Y Y AF * ND ND ND ND
N Y Y CCF 1.1 7.4 17 6.3
ND 11 3 3
Y Y Y MI, CCF, AF 1.3 71 110 70
ND 13 5 4
Y Y Y None 3.6 0.9 0.6 ND
ND 4 3 -
N Y Y AF ND ND 2.6 1.0
- - 3 2
Y Y N None ND 28 51 22
- 14 5 5
N Y Y None * ND ND ND ND
10 Y Y Y None 6.8 5.5 2.9 1.6
ND ND 4 ND
KEY: ND = not detected, * = post-operative death
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Assays ofhaemostatic function and myocardial injury
The median (range) values for platelet count, fibrinogen, PT, aPTT and haematocrit are
shown in Table 6.3. The median (range) values for t-PA activity, PAI activity and PF
1+2 are shown in Table 6.4.
In non-ruptured AAA, serum cTn I was detectable in 6 of 36 samples (Figure 10.2).
Serum CK was elevated in 5 of these 6 samples, and CK-MB was greater than 6% of the
total CK in none of these 5 samples (Table 10.1). CTn I was positive for myocardial
injury at one or more sample point in three patients, but CK-MB was positive for MI in
none of the patients. Two of three patients with elevated cTn I had clinically apparent
cardiac events.
In ruptured AAA, serum cTn I was detectable in 24 of 40 samples (Figure 10.3). Serum
CK was elevated in 17 of these 24 samples, and CK-MB was greater than 6% of the
total CK in 5 of these 17 samples (Table 10.2). Four patients had elevated cTn I on
admission to the hospital. These patients were not clinically distinct from patients who
did not have elevated cTn I on admission. CTn I was positive for myocardial injury at
one or more sample point in eight patients, and CK-MB was positive for MI at one or
more sampling point in four. Three of four patients with elevated cTn I and CK-MB had
clinically apparent cardiac events.
In ruptured AAA, cardiac co-morbidity and intra-operative hypotension were not
associated with a significant difference in cTn I levels. There was also no correlation
between cTn I levels and duration of symptoms, operative blood loss or aortic clamp
time. The number of patients with non-ruptured AAA and elevated cTn I were too small
to make valid statistical conclusions.
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FIGURE 10.2
Individual data points for cTn I in non-ruptured AAA repair immediately
before induction of anaesthesia (sample E), and 6 hours (sample F), 24 hours
(sample G) and 48 hours (sample H) after aortic clamp release.















E F G H
218
FIGURE 10.3
Individual data points for cTn I in ruptured AAA repair immediately before
induction of anaesthesia (sample E), and 6 hours (sample F), 24 hours (sample
G) and 48 hours (sample H) after aortic clamp release.
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Relationship between haemostatic markers and cardiac troponin I
There was no significant relationship between platelet count, fibrinogen, PT and aPTT,
and cTn I at any sampling point. There was no significant relationship between t-PA
activity and PF 1+2, and cTn I at any sampling point. There was also no significant
relationship between PAI activity before operation and cTn I at any sampling point.
There was, however, a significant positive correlation between PAI activity immediately
before aortic clamp release and cTn 1 at 6 hours (r= +0.829, p= 0.042), 24 hours (r=
+0.762, p= 0.028) and 48 hours (r= +0.829, p= 0.042) after aortic clamp release; and
PAI activity 5 minutes after aortic clamp release and cTn I at 6 hours (r= +0.943, p=
0.005) and 24 hours (r= +0.881, p= 0.004) after aortic clamp release.
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10.5 Discussion
The principal finding of the present study is that the hypofibrinolytic state which occurs
during ruptured AAA repair is associated with peri-operative myocardial injury as
demonstrated by elevated levels of cTn I.
cTn I is currently the most specific and sensitive marker for myocardial injury (193-197)
and has major advantages over CK-MB and cTnT in patients undergoing major
peripheral vascular surgery: it is entirely cardiospecific, does not accumulate in patients
with renal failure, has not been shown to be released from skeletal muscle, and is
detectable after myocardial ischaemia and minor myocardial injury. Elevated levels may
also be detected in conditions where myocardial necrosis is uncommon such as
myocarditis (278) and myocardial strain which accompanies cardiac dilation and
hypertrophy (279).
Adams and colleagues (194) studied 96 patients undergoing vascular surgery and 12
patients undergoing spinal surgery. Eight of 96 (8.3%) patients undergoing vascular
surgery had abnormal post-operative echocardiographic examinations suggestive ofMI,
and of these all eight had elevated cTn I and six had elevated CK-MB. Of the 100
patients who had normal post-operative echocardiography, one patient had a slightly
elevated cTn I whereas 19 had elevated CK-MB. The authors concluded that cTn I
measurement was very sensitive and specific for peri-operative MI and CK-MB was
associated with a high incidence of false positive results. Of 291 patients who underwent
major vascular surgical procedures (including 61 patients operated for AAA), Lee and
colleagues (280) reported elevated post-operative cTn T in approximately 10% and
clinically apparent cardiac complications in approximately 6%. Metzler and colleagues
(281) measured peri-operative cTn T and cTn I in 67 patients undergoing elective non-
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cardiac surgery, of whom 38 had underwent (undefined) vascular surgical procedures. Of
13 patients with elevated cTn T, 10 were in the vascular surgery group, and eight had
major post-operative cardiac complications (unstable angina, CCF, arrhythmia, MI). In
the present study, cTn I was positive for myocardial injury in 3 of 9 patients with non-
ruptured AAA, but no patient had a CK-MB positive for MI. Two of the patients with
elevated cTn I had cardiac events. In ruptured AAA, 2 of 10 patients had a clinically
apparent MI, four had a positive CK-MB. Eight patients had elevated cTn I, of whom
three had no clinically apparent cardiac complications. Three of four patients with
elevated cTn I and CK-MB had cardiac events. CTn I is a very sensitive marker of
myocardial injury, and, it possible that the elevated levels in the patients with no cardiac
complications may have been due to ischaemia and 'minor' necrosis (280) affecting
areas of the heart which are not crucial for normal cardiac function.
Between 75% and 95% of patients undergoing elective aortic reconstruction have double
or triple vessel coronary artery disease with stenoses greater than 70% (184,185).
Myocardial injury is also associated with a procoagulant state but there is evidence that
peri-operative MI is most often of the non-Q-wave type (190,191) which is secondary to
sustained subendocardial ischaemia. Atherosclerotic plaque rupture with subsequent
occlusive thrombus formation generally results * in Q-wave infarction on
electrocardiography (ECG) (186). Gibbs et al (145) demonstrated an early post¬
operative hypercoagulable state in patients undergoing elective aortic surgery for
aneurysmal and occlusive disease, and were the first to speculate that this may contribute
to coronary artery thrombosis and MI. The present study has confirmed an association
between derangement of intra-operative haemostatic function and myocardial injury.
There was a positive association between PAI activity and cTn I in those patients who
had detectable levels of cTn I, with PAI activity being elevated at least 6 hours before
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cTn I was detected. Some patients had elevated PAI activity with no evidence of
myocardial injury, indicating that the hypofibrinolytic state may be only one of many
contributory factors in the pathophysiology of myocardial injury. Possible mechanisms
contributing to the development of peri-operative myocardial injury and MI in patients
with ruptured AAA include; a hypofibrinolytic state leading to thrombosis in the presence
of a critical coronary artery stenosis or on an unstable coronary artery plaque, both of
which cause mechanical disruption to blood flow; dilation of the left ventricle on aortic
clamping which leads to distortion of an atherosclerotic plaque in the coronary arteries
with subsequent plaque fissure and exposure of procoagulant media (181); and coronary
artery hypoperfusion secondary to hypotension. The risk of cardiac complications
associated with this hypercoagulable state may, therefore, be potentiated by periods of
haemodynamic instability and pre-existing coronary artery disease. In the present study,
however, pre-existing cardiac disease, intra-operative hypotension, operative blood loss
and aortic clamp time had no demonstrable effect on cTn I levels
In conclusion, these data support the hypothesis that the procoagulant state which occurs
during ruptured AAA repair contributes to the development of post-operative myocardial
injury. It is interesting to speculate that the procoagulant and hypofibrinolytic state may
represent both a homeostatic and pathological response; it allows the patient to survive
the initial rupture event and operative repair, but contributes to the development of major
post-operative cardiac complications. By contrast, increased systemic fibrinolysis as
demonstrated in Chapter 8 may be a pathological response to rupture and is associated
with early mortality, usually secondary to coagulopathy and haemorrhage.
In patients undergoing AAA repair, screening for myocardial injury using cTn 1 may be
of value if a) it predicts post-operative cardiac problems such as cardiac failure or
arrhythmias and allows these to be treated prophylactically, and b) allows for therapeutic
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intervention peri-operatively to improve the myocardial perfusion either directly by
emergency coronary angiography and percutaneous transluminal coronary angioplasty or
indirectly by correcting the procoagulant and hypofibrinolytic state. A recent randomised
trial (181) of systemic heparinisation versus no heparinisation during elective AAA
repair demonstrated a significant reduction in the incidence of fatal and non-fatal MI in
those patients who received heparin. The effect of intra-operative heparinisation on




• cTn I demonstrated peri-operative myocardial injury in 33% of patients with non-
ruptured AAA and 80% of patients with ruptured AAA.
• CK-MB was elevated in no patient with non-ruptured AAA, and 40% of patients with
ruptured AAA.
• There was a significant relationship between intra-operative PAI activity and post¬
operative cTn I levels, indicating that there is an association between hypofibrinolytic








Vasoconstriction is the first event in the haemostatic response to vascular injury.
Endothelin (ET)-l is the most potent known vasoconstrictor. Furthermore, there is
evidence that ET stimulates thrombin generation and a local inflammatory response,
which also contribute to intravascular thrombus formation (205-208). ET release may be
pathological (217-222) or homeostatic (222,223). Elevated plasma ET levels have been
demonstrated in number of critical illnesses which may complicate ruptured AAA repair
(208-216). Increased plasma ET levels have been demonstrated in patients undergoing
non-ruptured AAA repair with infrarenal (224,225) and supracoeliac aortic cross-
clamping (226), as well as in one animal model of infrarenal aortic clamping and
subsequent exsanguination (227). To date, however, there are no reports of the ET
response in patients undergoing repair of ruptured AAA.
We hypothesised that haemorrhagic shock, ischaemia and reperfusion would lead to
increased synthesis and secretion of ET which would predispose to the development of
organ failure, one of the principal causes of death in this group ofpatients.
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11.2 Aims
To examine peri-operative changes in plasma levels of big ET-1 and ET-1 in patients
undergoing repair of ruptured AAA, and to examine the relationship between ET levels




Fourteen consecutive patients (13 men and 1 woman of median age 74, range 65-86,
years) who underwent repair of ruptured infrarenal AAA and survived to at least 24
hours after surgery, were prospectively studied. The median (range) delay between the
onset of symptoms of rupture and hospital admission was 5 (3-14) hours. All patients
had at least one documented episode of hypotension (systolic blood pressure less than
lOOmmHg) prior to surgery. Co-morbidity data are shown in Table 11.1.
Operative methods
All patients had retroperitoneal ruptured AAA and none had intraperitoneal rupture. The
operations were performed as previously described. An aorto-aortic graft was inserted in
10 patients, an aorto-bifemoral graft in three, and an aorto-bi-iliac graft in one patient.
Sample collection and assay methods
For estimation of ET-1 and big ET-1, blood was sampled from an indwelling arterial
line before induction of anaesthesia (sample A), immediately before aortic clamp release
(sample B), and five minutes (sample C) and 6 hours (sample D) after aortic clamp
release. For estimation of haematocrit, t-PA and PAI activities and PF 1+2, blood was
sampled before induction of anaesthesia (sample A); immediately before release of the
aortic clamp (sample B); five minutes (sample C) and 24 hours (sample D) after aortic
clamp release. All samples were prepared and assays performed as described above.
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Definitions ofpost-operative organ failure
These were defined as described above.
Statistical analysis
The Mann-Whitney U test, Kruskal-Wallis one-way analysis of variance and Spearman
rank test were used.
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TABLE 11.1






Angina pectoris 2 1
Hypertension 3
Congestive cardiac failure 1
Atrial fibrillation - 1
Stroke 1
Peripheral arterial occlusive disease 1















All patients were admitted to the ITU post-operatively. All patients survived for at least
24 hours post-operatively, but five (36%) died in the post-operative period. Clinical and
operative data for survivors and non-survivors are summarized in Table 11.2 and post¬
operative complications are shown in Table 11.3.
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TABLE 11.2










Duration of symptoms (hr) 4(3 - 14) 6(5 - 12) NS
Serum creatinine (pmol/1) 138 (82 - 176) 115 (77 - 183) NS
Crystalloid and
colloid administration (1)
0.5 (0.2 - 5.5) 0.7 (0.1 - 1.0) NS
Intra-operative
Total operation time (minutes) 140 (75 - 240) 105 (75 -200) NS
Aortic clamp time (minutes) 90 (40- 185) 75 (55 - 135) NS





RCC administration (units) 8(5 - 11) 8(6 - 22) NS
3
FFP administration (units) 2(2-6) 2 (2 - 12) NS
4
Platelet administration (bags) 1(D 1(0-1) NS
KEY; * Mann-Whitney U test, ~ RCC = 300 ml, 3 FFP = 300ml, 4 one bag ofplatelet
transfusion = 4 pooled units (250 ml)
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TABLE 11.3









Respiratory failure 3 4
ARDS - 1
Pneumonia 6 5
Acute Renal Failure 3 5
Coagulopathy 1 2
Sepsis syndrome 1 2





Plasma levels ofbis ET-1, ET-1 and haemostatic markers.
The values of big ET-1 and ET-1 in survivors and non-survivors are shown in Figures
11.1 and 11.2, respectively. The values for haematocrit, t-PA activity, PAI activity and
PF 1+2 are shown in Table 11.4. There was no significant difference in haematocrit or
the levels of haemostatic markers between survivors and non-survivors.
Big ET-1 was above the normal laboratory range at one or more sampling points in all
patients, and ET-1 was above the normal range in all survivors and 4 of 5 non-survivors.
When compared with non-survivors, survivors had significantly higher levels of big ET-
1 at all four sampling points, and significantly higher levels of ET-1 after 5 minutes
reperfusion. When compared with pre-operative levels, there was a significant increase
in big ET-1 levels after 6 hours of reperfusion in survivors. In non-survivors, there was a
significant increase in ET-1 levels between 5 minutes and 6 hours after reperfusion.
There was no relationship between duration of symptoms, operative blood loss or aortic
clamp time and plasma ET-1 and big ET-1 levels at any sampling point. Pre-operative
ET-1 levels were significantly lower in eight patients who subsequently developed ARF
(median 3.72, range 2.76-6.0 pg/ml) than in six patients who did not (median 5.89,
range 3.86-7.23 pg/ml, p=0.02). There was no significant difference in big ET-1 or ET-1




Individual data points for big ET-1 immediately before induction of
anaesthesia (sample A), immediately before release of the aortic clamp,
(sample B), and five minutes (sample C) and 6 hours (sample D) after aortic
clamp release.
Non-survivors are represented by the red squares and survivors by the yellow
circles.
The upper limit of the normal range for big ET-1 (10 - 60 pg/ml) is shown by
the horizontal line.
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FIGURE 11.2
Individual data points for ET-1 immediately before induction of anaesthesia
(sample A), immediately before release of the aortic clamp, (sample B), and
five minutes (sample C) and 6 hours (sample D) after aortic clamp release.
Non-survivors are represented by the red squares and survivors by the yellow
circles.
The upper limit of the normal for ET-1 (1.5 - 4.5 pg/ml) is shown by the
horizontal line. NS = not significant.
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TABLE 11.4
Haematocrit, t-PA activity, PAI activity and PF 1+2 levels.
Assay Normal range Sample Median (range)
Haematocrit 0.37-0.54 A 0.316(0.129-0.367)
B 0.288(0.194-0.439)
C 0.295 (0.183 -0.42)
D 0.329 (0.257 - 0.357)
t-PA activity 0.2 - 2.0 IU/ml A 0.24 (0.06 - 7.9)
B 0.28 (0.08 - 6.4)
C 0.32 (0.09 - 7.3)
D 0.68 (0.15-2.3)
PAI activity < 15 AU/ml A 35.2 (2.6-38.8)
B 38.4 (8.6 - 39.4)
C 37.9 (10.6- 39.4)
D 16.8(5.9-35.3)
PF 1+2 0.4 -1.1 nmol/1 A 6.7(2.4-11.6)
B 6.7(2.0-9.1)
C 6.5 (2.6- 11.4)
D 3.6(1.6- 11.4)
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There were several significant correlations when haemostatic markers were compared
with ET levels. When all patients were examined, there was a significant negative
correlation between PF 1+2 immediately before aortic clamp release and big ET-1 at 5
minutes after aortic clamp release (r= -0.554, p= 0.044). In survivors of rupture, there
was a significant negative correlation between PF 1+2 immediately before (r= -0.695,
p= 0.038) and 5 minutes after aortic clamp release (r= -0.678, p= 0.045) and big ET-1 at
5 minutes after aortic clamp release. The number of patients who did not survive was
too small to make any valid statistical conclusions.
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11.5 Discussion
The present study is the first to examine the relationship between peri-operative ET
levels, organ failure and mortality in patients undergoing ruptured AAA repair. The
principal finding is that, contrary to our original hypothesis, patients who died had
significantly lower peri-operative ET levels than survivors.
Previous studies of the endothelin response to lower torso ischaemia and reperfusion are
few and contradictory. Antonucci et al (224) examined the effect of intra-operative
nifedipine infusion on endothelin-dependent renal vasoconstriction in five patients
undergoing non-ruptured infrarenal AAA repair, and demonstrated a transient but
significant increase in plasma ET-1 and -2 levels at the end of the period of aortic cross-
clamping. The authors concluded that nifedipine prevented the renal vasoconstrictor
response to ET as there was no significant difference in creatinine clearance and
glomerular filtration rate post-operatively compared to pre-operatively. Fukuda et al
(225) measured arterial and iliac vein ET-1 levels in seven patients undergoing elective
aortic aneurysm repair. There was no significant change in arterial ET-1 levels, but a
significant increase in iliac vein ET-1 levels occurred immediately after aortic clamp
release and perfusion of the first limb. Venous ET-1 levels showed a significant
correlation with venous O2 content, pH, pCb, O2 saturation and base excess suggesting
that ET-1 production occurred secondary to lower limb ischaemia. Lintott et al (226)
were the first to attempt to examine the relationship between ET-1 levels and outcome in
21 patients who required supracoeliac and eight who required infrarenal aortic clamping
for repair of non-ruptured aortic aneurysm. Unlike the studies by Antonucci et al and
Fukuda et aU plasma ET-1 was undetectable during the period of aortic clamping and 30
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minutes after aortic declamping. After two hours of reperfusion, ET-1 levels were
significantly higher in patients who subsequently developed ARF after supracoeliac
clamping, and at 8 hours, ET-1 levels were significantly higher in the supracoeliac
clamp group compared with the infrarenal clamp group. In a canine model of infrarenal
aortic clamping, Edwards et al (227) failed to demonstrate a significant increase in
plasma ET-1 levels during ischaemia, but there was a significant increase during
reperfusion and subsequent exsanguination.
In the present study, survivors had increased plasma ET levels during the periods of
lower torso ischaemia and reperfusion. Furthermore, over half of the survivors had
increased ET levels pre-operatively. There was also a significant increase in ET levels
after 6 hours of reperfusion in survivors and non-survivors. The increased physiological
insult of ruptured AAA repair may explain why, unlike previous studies of non-ruptured
AAA repair, elevated ET levels were detected before, during and after operation.
It is interesting to speculate from these data that the ET-dependent vasoconstrictor
response to haemorrhagic shock, ischaemia and reperfusion has a homeostatic and
protective role in ruptured AAA. Patients who manifest a good vasoconstrictor response
(which is partly due to ET) may have a higher probability of survival than those patients
who mount an inferior response. This hypothesis would be in keeping with what the
majority of vascular surgeons know intuitively: that is, intense vasoconstriction (as well
as 'controlled' hypotension, aortic tamponade and the generation of a prothrombotic
state) is one of the principal mechanisms which allows patients with ruptured AAA to
survive to reach hospital and then undergo successful aneurysm repair.
The reasons for low ET levels in non-survivors as well as those patients who developed
ARF are not immediately obvious. Ruptured AAA repair is associated with many factors
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known to stimulate ET synthesis and secretion: intra-operative haemorrhage and
haemodilution, hypoxia and metabolic acidosis, increased sympathetic discharge and
catecholamine release, increased cytokine and endotoxin release, thrombin generation,
and impaired renal excretion. In the present study, there was no apparent difference in
the duration of symptoms of rupture, severity of pre-operative shock, duration of lower
torso ischaemia or peri-operative haematocrit between survivors and non-survivors.
Haynes and colleagues (282) reported a significant, and similarly unexpected, association
between high plasma ET-1 levels and survival in cardiac arrest patients. They proposed
several explanations for their findings: poor peripheral blood flow and local tissue
acidosis may adversely affect production and activity ofET-1, or lead to a local increase
in ET-1 which does not enter the circulation; increased NO production may inhibit ET
production; and reduced pulsatile shear stress in may lead to selective endothelial cell
dysfunction. The low ET levels in non-survivors of ruptured AAA and cardiac arrest
may therefore be an early manifestation of irreversible whole body hypoperfusion.
Data from this and previous chapters demonstrate that survivors and non-survivors of
ruptured AAA repair have evidence of increased thrombin generation, and increased
levels of the endothelial products, t-PA, PAI and vWF. ET is one of the major
contributors to vasoconstriction, the first event in haemostasis, and its release may
stimulate or be stimulated by thrombin generation. In the present study, however, a
negative correlation existed between intra-operative PF 1+2 and ET levels.
These data, together with the fact that increased NO production has been demonstrated
in animal models of infrarenal aortic cross-clamping (232,283), lend support to the
hypothesis that selective endothelial cell dysfunction may lead to downregulation of the
ET response in some patients with ruptured AAA and this may predispose to the
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development of fatal organ dysfunction. The procoagulant state in ruptured AAA repair
may interact with ET production and contribute to the low ET levels in non-survivors.
Impaired ET release may also be a marker of increased NO synthesis which exerts its
injurious effect through the production of oxygen-free radicals. The NO response to
ruptured AAA repair requires investigation.
Although the majority of the current literature concludes that ET release has a
pathological role in critical illness, the findings of the present study do not support the
hypothesis that an increased ET response predisposes to poor outcome in patients
undergoing ruptured AAA repair. By contrast, elevated peri-operative ET levels were
associated with survival. Low ET levels may be an early marker of severe and
irreversible whole body hypoperfusion in this group of patients. Alternatively, increased
circulating ET levels may occur as part of a homeostatic and protective response to
haemorrhage, ischaemia and reperfusion in patients with ruptured AAA. The
measurement of plasma ET levels before and during operation may help to identify




• Patients who died from organ dysfunction after ruptured AAA repair had
significantly lower peri-operative ET levels than survivors.
• Survivors had increased plasma ET levels during the periods of lower torso
ischaemia and reperfusion, and over half had increased levels pre-operatively.
• Increased circulating ET levels present in survivors may occur as part of a
homeostatic and protective response to haemorrhage, ischaemia and reperfusion.
• Low ET levels present in non-survivors may represent an early manifestation of
severe and irreversible whole body hypoperfusion.
• Peri-operatively, elevated ET levels were associated with reduced PF 1+2.
• The measurement of plasma ET levels before and during operation may help to




Soluble TNF receptors and haemostasis in
ruptured and non-ruptured AAA repair
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12.1 Introduction
The pro-inflammatory cytokine, TNF, has been implicated in the systemic inflammatory
response syndrome and MOF (35,228). It also has an important role in haemostasis and
can induce a procoagulant and hypofibrinolytic state by increasing TF expression, vWF
release (53,54) and PAI release while reducing t-PA release (72-75,77,82,83,150).
Binding of TNF to target cells leads to the cleavage and release of TNF receptors into
the circulation as soluble TNF receptors (sTNF-Rs). Circulating TNF is frequently
difficult to demonstrate and it has been suggested that the levels of sTNF-Rs may better
reflect the degree of TNF-induced tissue injury (230,231). Circulating TNF has been
demonstrated in elective and emergency aortic surgery (75.161,162,236-241), and
elevated levels of sTNF-Rs have been detected in patients undergoing repair of non-
ruptured AAA (241,242), and post-operatively in ruptured AAA (241). To date,
however, no study has examined sTNF-R levels during the periods of shock, ischaemia
and early reperfusion which occur in ruptured AAA repair. In an animal model of AAA
repair, administration of exogenous sTNF-R before aortic cross-clamping has been
shown to ameliorate the adverse effects of TNF (232). In humans, however, elevated
levels of endogenous sTNF-Rs are actually associated with MOF and increased
mortality (233-235). While exogenous sTNF-R therapy may have beneficial effects in
elective aortic surgery where endogenous levels are low, it may be ineffective in patients
undergoing ruptured AAA repair if endogenous levels are high.
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12.2 Aims
To examine serial changes in sTNF-Rs occurring during repair of ruptured and non-
ruptured AAA, and to examine the relationship between sTNF-R levels and markers of




Sixteen patients (14 men and 2 women ofmedian age 75, range 65-86, years) operated
for ruptured and 10 patients (8 men and 2 women ofmedian age 69, range 58-80, years)
operated for asymptomatic non-ruptured infrarenal AAA were prospectively studied. In
patients operated for ruptured AAA, the median (range) delay between the onset of
symptoms of rupture and hospital admission was 5 (3-14) hours. All patients had at least
one documented episode of hypotension (systolic blood pressure less than lOOmmHg)
prior to surgery. In patients undergoing operation for asymptomatic non-ruptured AAA,
the median (range) antero-posterior diameter of the aneurysm measured by abdominal
ultrasonography was 6.5 (5.5-8.0) cm. Co-morbidity data are shown in Table 12.1.
Operative methods
Thirteen patients had retroperitoneal rupture and three had retroperitoneal and
intraperitoneal rupture. The operations were performed as previously described. A
dacron tube graft was inserted in 17 patients (12 rupture, 5 non-rupture), an aorto-bi-
iliac graft in five (1 rupture, 4 non-rupture) and aorto-bifemoral graft in four patients (3
rupture, 1 non-rupture).
Sample collection and assay methods
For estimation of serum levels of sTNF-Rs p55 and p75, blood was sampled immediately
prior to the induction of anaesthesia (sample A); immediately before release of the aortic
clamp (sample B); and five minutes (sample C), 6 hours (sample D) and 24 hours
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(sample E) after aortic clamp release. For estimation of t-PA activity, PAI activity, PF
1+2 and vWF levels, blood was sampled immediately prior to the induction of
anaesthesia (sample A); immediately before release of the aortic clamp (sample B); five
minutes (sample C) and 24 hours (sample D) after aortic clamp release. All samples
were prepared and assays were performed as described above.
Definition ofmajor post-operative complications
These were defined as described above.
Statistical analysis
The Mann-Whitney FI test and Kruskall-Wallis one-way analysis of variance were used.
Where levels of sTNF-Rs were below the limit of detection of the assay, the minimum
detection concentration was assigned to that sample and statistical analysis was
performed using this convention.
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TABLE 12.1
Co-morbidity in patients operated for ruptured and non-ruptured AAA.





Angina pectoris 3 2
Coronary artery bypass graft - 1
Hypertension 5 2
Congestive cardiac failure 1
Atrial fibrillation 1
Stroke 2 1
Peripheral arterial occlusive disease 1 2
Venous thrombo-embolism - 1
Chronic obstructive airways disease 2 2










Angiotensin converting enzyme inhibitor 1
Calcium-channel blocker 1





Clinical and operative data for both groups of patients are summarized in Table 12.2.
All patients with ruptured AAA were admitted to the ITU. The median (range) duration
of ITU stay was 3 (0.5 - 24.1) days. The median (range) duration of ventilatory support
was 0.9 (0.4 - 18.8) days and seven patients were ventilated for more than 4 days. All
patients operated for non-ruptured AAA were admitted to the intermediate care unit
post-operatively and no patient was admitted to ITU or required ventilatory support.
Thirteen patients operated for rupture and four operated for non-ruptured AAA
developed major post-operative complications (Table 12.3). Three patients with rupture
and 6 with non-rupture had no post-operative complications. All patients survived to 24
hours after repair. Five (31.2%) patients with ruptured AAA died in hospital. There were
no deaths after repair of non-ruptured AAA.
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TABLE 12.2
Clinical and operative data in patients with ruptured and non-ruptured AAA.
Ruptured Non-ruptured p value
AAA AAA *
median (range) Median (range)
(n=16) (n=10)
Pre-operative
Crystalloid administration (1) 0.5 (0.1 - 4.0)
Colloid administration (1) 0 (0 - 1.5)
Intra-operative
Operation time (mins) 110(70 -250) 160 (85 -285) NS
Total aortic clamp time (mins) 75 (30 -- 180) 75 (30 - 150) NS
Measured blood loss (1) 3.1 (1.0 - 11.0) 2.4 (0.4 -6.0) NS
Crystalloid administration (1) 2.3 (0.5 -6.0) 1.9(1.0 -4.0) NS
Colloid administration (1) 1.5 (0-■2.3) 1.5 (1.0 -4.1) NS
.2
RCC administration (units) 8(5- 22) 4(0- 10) 0.004
3
FFP administration (units) 2 (0- 12) 0(0- 2) 0.0003
4
Platelet administration (bags) 1(0- 1) 0(0- 1) 0.0007
KEY: * = Mann-Whitney U test, RCC = 300 ml, 3 FFP = 300ml, 4 one bag of platelet
transfusion = 4 pooled units (250 ml)
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TABLE 12.3
Post-operative complications and procedures in ruptured and non-ruptured AAA.
Ruptured Non-ruptured
AAA AAA










Respiratory failure 5 0
ARDS 1 0
Acute Renal Failure 6 1 1
Coagulopathy 2 0
Sepsis syndrome 3 0
Colon ischaemia 1 0
Total parenteral nutrition 5 0
Inotropic support
Adrenaline 5 0
Renal dose dopamine 11 0
Re-operation 3 2 1
TOTAL 13/16(81%) 4/10 (40%)
KEY: 1 = 3 of 6 patients who developed ARF received haemofiltration
2
= patient 1 - laparotomy for haemorrhage, femoral thrombectomy, Hartmann's
procedure for colon ischaemia, drainage of infected pelvic haematoma; patient 2
- negative laparotomy for suspected colon ischaemia; patient 3 - bilateral BKA
3
for CLI; = popliteal embolectomy and fasciotomies
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Assays ofsTNF-Rs and haemostatic markers
The median (range) values of sTNF-Rs p55 and p75 are shown in Table 12.4. The
values for t-PA activity, PAI activity, PF 1+2 and vWF are shown in Table 12.5.
Both types of sTNF-R were detectable at one or more sampling points in all patients
with ruptured AAA and 9 of 10 patients with non-ruptured AAA. Five minutes and 24
hours after aortic clamp release, levels of sTNF-R p55 were significantly higher in
patients with ruptured compared with non-ruptured AAA. There was no significant
change in the levels of sTNF-R p55 as a function of time in either group (Figure 12.1).
At all sampling points, levels of sTNF-R p75 were significantly higher in patients with
ruptured compared with non-ruptured AAA, and there was a significant increase in the
levels of sTNF-R p75 during reperfusion in both groups of patients (Figure 12.2). Six
hours after aortic clamp release, levels of sTNF-R p75 were significantly higher in non-
survivors of ruptured AAA compared with survivors and patients operated for non-
ruptured AAA (Figure 12.3). There was no significant difference in levels of sTNF-R
p75 between non-survivors of rupture, survivors of rupture and patients operated for
non-ruptured AAA at any other sampling point. There was also no correlation between
aortic clamp time and sTNF-R levels in ruptured or non-ruptured AAA.
In patients operated for rupture, sTNF-R p55 levels immediately before (p=0.015) and 5
minutes after aortic clamp release (p=0.034) were significantly lower in six patients who
subsequently developed ARF compared with 10 patients who did not. There was no















sTNF-R p55 A 1.3 (0.2-4.9) 0.8(0.2- 1.4) NS
B 1.1 (0.2-2.8) 0.6 (0.2- 1.1) NS
C 1.1 (0.2-3.5) 0.5 (0.2- 1.2) 0.018
D 1.5 (0.3 - 5.3) 0.7 (0.2 - 4.0) NS
E 1.6(0.2-4.4) 0.8(0.2 -2.1) 0.042
Significant differences None None
between samples **
sTNF-R p75 A 4.0 (2.0-14.7) 2.1 (2.0-9.0) 0.028
B 3.3 (2.0-9.1) 2.0 (2.0-2.2) 0.0005
C 3.2 (2.0 - 9.7) 2.0 (2.0-2.2) 0.0013
D 10.0 (2.1 - 18.5) 2.5(2.0-5.9) 0.0009
E 11.1 (2.4-23.6) 2.6 (2.0 - 7.3) 0.0022
Significant differences B - D, B - E, B - D, B - E <0.05
between samples ** C - D, C - E
KEY: * = Mann-Whitney U test, ** = Kruskall-Wallis test
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TABLE 12.5
PF 1 +2, t-PA activity, PAI activity and vWF.
Assay Sample Ruptured Non-ruptured p value
(normal range) point AAA AAA *
median (range) Median (range)
(n=16) (n=10)
PF 1+2 A 6.7(2.4- 11.6) 1.9(0.7-7.1) <0.001
(0.4-1.1 nmol/1) B 6.3 (2.0-9.1) 1.3 (0.9-4.0) <0.001
C 6.5 (2.6- 11.4) O)q00 <0.001
D 3.6(1.6- 11.4) 1.9(1.3-5.6) NS
t-PA activity A 0.24 (0.06 - 7.9) 0.53 (0.14-3.2) NS
(0.2-2.0 IU/ml) B 0.28 (0.08 - 6.4) 1.07 (0.34-4.65) 0.001
C 0.32 (0.09 - 7.3) 1.91 (0.19-5.62) 0.018
D 0.84 (0.15-2.3) 0.46 (0.21 - 1.45) NS
PAI activity A 35.2 (2.6 - 38.8) 6.7(3.2-21.7) 0.001
(less than 15 AU/ml) B 38.3 (8.6 -39.4) 10.1 (2.8-38.9) 0.003
C 37.5 (10.6-39.4) 12.3 (2.2 - 28.7) 0.001
D 13.5 (5.0-35.3) 16.5 (5.7-22.4) NS
vWF A 1.9 (0.48-3.21) 1.4 (0.44-3.6) NS
(0.42 - 1.22 IU/ml) B 0.81 (0.14-2.12) 0.96 (0.3 - 3.06) NS
C 0.88 (0.21 - 1.7) 0.86 (0.29 - 2.75) NS
D 1.68 (0.8-3.12) 1.89 (1.5 -3.99) NS
KEY: * = Mann-Whitney U test
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FIGURE 12.1
Individual data points for sTNF-R p55 immediately before induction of
anaesthesia (sample A), immediately before release of the aortic clamp,
(sample B), and five minutes (sample C), 6 hours (sample D) and 24 hours
(sample E) after aortic clamp release.
Patients with ruptured AAA are represented by the red squares and patients
with non-ruptured AAA by the yellow circles.
The normal range for sTNF-R p55 (< 0.2 ng/ml) is shown by the horizontal
line. NS = not significant
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FIGURE 12.2
Individual data points for sTNF-R p75 immediately before induction of
anaesthesia (sample A), immediately before release of the aortic clamp,
(sample B), and five minutes (sample C), 6 hours (sample D) and 24 hours
(sample E) after aortic clamp release.
Patients with ruptured AAA are represented by the red squares and patients
with non-ruptured AAA by the yellow circles.
The normal range for sTNF-R p75 (< 2 ng/ml) is shown by the horizontal line.
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FIGURE 12.3
Individual data points for sTNF-R p75 at six hours after aortic clamp release in
non-survivors of ruptured AAA compared with survivors and patients operated
for non-ruptured AAA.
Patients with ruptured AAA are represented by the red squares and patients with
non-ruptured AAA by the yellow circles.























There were several significant correlations when haemostatic markers were compared
with sTNF-R levels. When all patients were examined, immediately before aortic clamp
release there was a significant negative correlation between sTNF-R p55 and t-PA
activity (r= -0.535, p= 0.033) and a significant positive correlation between sTNF-R p55
and PAI activity (r= +0.552, p= 0.027). At 24 hours, there was a significant positive
correlation between sTNF-R p75 and t-PA activity (r= +0.639, p= 0.008). Five minutes
after aortic clamp release, there was a significant positive correlation between sTNF-R
p75 and PF 1+2 (r= +0.505, p= 0.046). There was a significant positive correlation
between sTNF-R p55 and vWF pre-operatively (r= +0.589, p= 0.016) and at 24 hours
(r= +0.699, p= 0.003). There was also a significant positive correlation between sTNF-R
p75 and vWF at 5 minutes after aortic clamp release (r= +0.575, p= 0.02). In survivors
of rupture, there was a significant positive correlation between sTNF-R p55 and vWF at
24 hours (r= +0.691, p= 0.019). The number of patients who did not survive was too
small to make any valid statistical analyses.
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12.5 Discussion
The present study has demonstrated, for the first time, that haemorrhagic shock, lower
torso ischaemia and early reperfusion occurring in the course of ruptured AAA repair is
associated with elevated levels of sTNF-Rs p55 and p75, and that elevated levels of
sTNF-R p75 during the period of early reperfusion are associated with increased post¬
operative mortality. Furthermore, sTNF-Rs appeared rapidly after the onset of
haemorrhagic shock and lower torso ischaemia, a finding which may be more indicative
of a direct relationship between sTNF-R levels and increased mortality (284) than in a
previous study where sTNF-Rs p55 and p75 levels were measured daily for 5 days after
operation (241). As circulating TNF is frequently difficult to demonstrate, studies
reporting the time course of TNF release in response to lower extremity ischaemia and
reperfusion are few and contradictory. Animal studies have either demonstrated no
significant increase in TNF levels during ischaemia or reperfusion (163), a transient
increase within minutes of reperfusion due to 'washout' from the lower extremities
(164), or increased levels during ischaemia but not reperfusion (232). Fluman studies
which have included a statistical analysis of the time course of TNF release have failed
to demonstrate a significant increase during early reperfusion in elective aortic
reconstruction (237-239). To date, two studies have examined sTNF-R release before
and after aortic aneurysm repair: Froon and colleagues (241) measured sTNF-R p55 and
p75 levels in 21 patients with ruptured and nine with non-ruptured AAA, and
demonstrated significantly higher levels of both sTNF-Rs in shocked patients and non-
survivors; Soong and colleagues (242) measured sTNF-R p55 levels in 11 patients with
non-ruptured AAA, and demonstrated that levels were lower in four non-survivors but
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that the post-operative increase was significantly greater at 48 hours when compared
with survivors. The present study is the first, therefore, to examine sTNF-R release
before, during and early after ruptured and non-ruptured AAA repair. Although there
was no significant change in sTNF-R p55 levels as a function of time, there was a
significant increase in sTNF-R p75 levels in both groups of patients at 6 and 24 hours
after aortic clamp release.
In contrast to the findings of Froon et al (241), there was no significant positive
association between serum creatinine and sTNF-R levels in the present study. Moreover,
sTNF-R p55 levels before and after aortic clamp release were significantly lower in
patients with rupture who later developed renal failure compared with those who did not.
There was, however, no significant difference in sTNF-R levels among patients with
rupture who did and did not have cardiovascular, respiratory or septic complications.
TNF has been shown to induce a procoagulant and hypofibrinolytic state by increasing
TF expression, vWF release and PAI release while reducing t-PA release. Clotting tests
from femoral and central venous blood have been shown to be similar suggesting that
lower limb ischaemia does not play a direct role in the pathogenesis of haemostatic
derangement (144). Hypoxia combined with reperfusion induces procoagulant activity
in vascular endothelium (166) and this may occur indirectly through the synthesis and
release of cytokines (52-54,72-75,77,82,83,150). There is evidence to suggest that TNF
and IL-1 may be responsible for activation of the fibrinolytic system in both lower torso
ischaemia and endotoxaemia (71,160). In the present study, only sTNF-R p75 was
associated with increased thrombin generation during ruptured AAA repair, as
demonstrated by elevated PF 1+2 levels. Both types of sTNF-R, however, were
associated with increased vWF release in ruptured AAA repair. There was evidence of an
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association between sTNF-R p55 and p75 and a hypofibrinolytic state before and during
operation as demonstrated by a negative correlation with t-PA activity and a positive
correlation with PAI activity. At 24 hours, however, sTNF-R p75 was associated with
increased fibrinolysis, as demonstrated by a positive correlation with t-PA activity.
The association between elevated sTNF-R levels and increased mortality in patients
operated for ruptured AAA is similar to that observed by other investigators in acute
inflammatory conditions or severe injury (233-235). Elevated levels of sTNF-Rs may
indicate that the endogenous pool of sTNF-Rs is replete (233), and this may partly
explain the disappointing results achieved with exogenous sTNF-R p55 and p75 in
patients with sepsis syndrome and septic shock (285). It is not possible to determine
from the present study whether therapeutic intervention with exogenous sTNF-Rs would
ameliorate the adverse effects of TNF in lower extremity ischaemia and ruptured AAA
repair (162-164,241). However, a recent animal study of infrarenal aortic cross-clamping
demonstrated a significant reduction in circulating TNF levels, nitric oxide production
and subsequent lung injury when exogenous sTNF-R p55 was administered before aortic
clamp placement (232). In the present study, endogenous sTNF-R levels were
significantly lower in patients undergoing repair of non-ruptured AAA compared with
those operated for ruptured AAA. One can speculate that exogenous sTNF-R therapy
may ameliorate the adverse effects of TNF in elective aortic surgery where endogenous
levels of sTNF-Rs are low, but may have limited efficacy in patients presenting with
haemorrhagic shock before ruptured AAA repair (233), where the concentrations of
sTNF-Rs observed in the present study would have been sufficient to effectively
antagonise the effects of circulating TNF in vitro (286).
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In conclusion, these data demonstrate that haemorrhagic shock, lower torso ischaemia
and early reperfusion occurring in the course of ruptured AAA repair is associated with
elevated levels of the sTNF-Rs, and that elevated levels of sTNF-R p75 during the period
of early reperfusion are associated with increased mortality. Furthermore, in patients who
survive to 24 hours, elevated levels of sTNF-Rs were associated with increased thrombin
generation, increased vWF release and a hypofibrinolytic state before and during
ruptured AAA repair. Finally, the fact that the endogenous pool of sTNF-Rs may be
replete and elevated endogenous levels are associated with increased mortality suggests
that sTNF-R therapy may have limited efficacy in patients with ruptured AAA.
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12.6 Summary
• Ruptured AAA repair is associated with elevated levels of sTNF-Rs, and elevated
levels of sTNF-R p75 during the period of early reperfusion are associated with
increased post-operative mortality.
• There was no significant change in sTNF-R p55 levels as a function of time, but there
was a significant increase in sTNF-R p75 levels in ruptured and non-ruptured AAA
at 6 and 24 hours after aortic clamp release.
• sTNF-R p55 levels immediately before and after aortic clamp release were
significantly lower in patients with rupture who later developed ARF.
• Before and during ruptured AAA repair, elevated sTNF-R levels were associated with
increased PF 1+2, vWF and PAI activity and reduced t-PA activity in patients who
survive to 24 hours.
• As the endogenous pool of sTNF-Rs may be replete and elevated endogenous levels
are associated with increased mortality, exogenous sTNF-R administration may have





Haemostasis before and after aortic surgery has been the subject of many studies, but
there are few detailed investigations of the peri-operative changes in the coagulation and
fibrinolytic pathways in patients undergoing elective AAA repair, and to our knowledge
no published reports in patients undergoing repair of ruptured AAA.
Thrombotic and haemorrhagic complications such as acute cardiac events, acute renal
failure, respiratory failure, coagulopathy and haemorrhage, lower limb ischaemia, stroke
and pulmonary embolism were confirmed as the major complications contributing to
post-operative mortality in the present study. Despite advances in anaesthesia, surgical
techniques, critical care, centralisation of vascular surgical services and a more
aggressive surgical approach in recent years there was no improvement in the operative
mortality rate or the overall community-based mortality for patients with ruptured AAA
in past two decades.
Ruptured AAA repair was shown to be associated with intense peri-operative thrombin
generation, increased secondary 'physiological' fibrinolysis and inhibition of systemic
fibrinolysis in patients who survived to at least 24 hours after surgery. Prolonged
duration of symptoms of rupture were associated with increased thrombin generation
which suggests that those patients who mount an increased thrombin response may be
more likely to survive long enough to reach hospital. The finding that haemostatic
markers were not significantly different between normotensive and hypotensive patients
with rupture suggests that haemorrhage, rather than hypotension, may be the principal
mechanism which initiates this procoagulant state. Increased operative blood loss was
associated with reduced fibrinogen and platelet count, and prolonged clotting times
while prolonged aortic clamp time was associated with a fall platelet count early after
declamping. In patients with ruptured AAA complicated by peri-operative coagulopathic
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haemorrhage, there was also evidence of increased thrombin generation but, unlike those
who survived to 24 hours post-operatively, increased systemic fibrinolysis was detectable
on admission and/or before aortic declamping in a proportion of patients and this was
associated with an extremely poor prognosis. From these findings, patients with ruptured
AAA may be classified into two categories according to the pattern of haemostatic
derangement. Those who have 'compensated' shock may exhibit thrombin generation
and inhibition of systemic fibrinolysis and are likely to survive to at least 24 hours post¬
operatively. By contrast, those with 'decompensated' shock may exhibit thrombin
generation and increased systemic fibrinolysis and are very likely to die intra-operatively
or in the immediate post-operative period from coagulopathy.
The present study confirmed increased thrombin generation in the majority of patients
undergoing elective repair of non-ruptured AAA. A proportion of patients were also
shown to have evidence of increased systemic fibrinolysis during the period of lower
torso ischaemia and early reperfusion. Increased operative blood loss was not only
associated with reduced fibrinogen and platelet count, prolonged clotting times but also
inhibition of systemic fibrinolysis. The relationship between prolonged aortic clamp time
and a fall in fibrinogen and platelet count and prolonged of clotting times was confirmed
and, for the first time, prolonged clamp time was shown to be associated with increased
inhibition of systemic fibrinolysis.
For the first time, haemostasis was examined in a small cohort of patients presenting as
an emergency with acutely symptomatic non-ruptured AAA. These patients exhibited
reduced thrombin generation, reduced secondary fibrinolysis and increased systemic
fibrinolysis compared with patients with rupture, and increased systemic fibrinolysis
compared with patients with asymptomatic AAA. There were significant differences in
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the markers of coagulation and fibrinolysis between acutely symptomatic patients and
normotensive patients with rupture, suggesting that haemorrhage rather than hypotension
is responsible for the haemostatic changes.
A hypothesis for the findings in patients with acutely symptomatic and ruptured AAA
can be formulated. Impending AAA rupture may be analogous to an aortic dissection
which explains the finding of increased systemic fibrinolysis. When actual AAA rupture
occurs, haemorrhage triggers the procoagulant and hypofibrinolytic state which is both a
homeostatic and pathological response; it acts to minimise local blood loss and allows
the patient to survive the initial rupture event and operative repair, but also triggers
micro- and macrovascular thrombosis and contributes to the development ofmajor post¬
operative complications. By contrast, in patients with severe 'decompensated' shock,
there is a net increase in systemic fibrinolytic activity which appears to be a pathological
response as it is associated with early mortality from coagulopathy and haemorrhage.
The majority of patients with ruptured and non-ruptured AAA had elevated peri¬
operative vWF and sTM levels consistent with endothelial cell activation. These findings
contrast with those from a previous study which demonstrated changes in endothelial
cell morphology consistent with endothelial cell activation in ruptured, but not non-
ruptured, AAA. It is possible that examining changes in endothelial cell morphology is
too insensitive to assess endothelial cell activation in this group of patients. There was a
significant positive association between peri-operative vWF levels and platelet count in
patients undergoing AAA repair and the intra-operative fall in vWF and platelet count
were exacerbated by increased operative blood loss and prolonged aortic clamp time.
One can speculate that endothelial cell activation and injury leads to vWF release which
binds platelets and initiates the formation of occlusive thrombi at sites of endothelial
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injury. The resultant consumption of vWF and platelets secondary to macro- and
microvascular thrombus formation leads to a fall in their circulating levels. This may
explain the relationship between peri-operative thrombocytopenia and poor outcome
previously demonstrated in AAA repair.
The hypothesis that haemostatic derangement would contribute to morbidity and
mortality from haemorrhagic and thrombotic events in ruptured AAA surgery was
confirmed. Life-threatening intra-operative coagulopathy was associated with increased
systemic fibrinolysis. By contrast, major post-operative cardiac events as determined by
cTn I levels were associated with peri-operative inhibition of systemic fibrinolysis which
is consistent with previous studies demonstrating a relationship between myocardial
injury and a procoagulant state. The fact that some patients with elevated PAI activity
had no myocardial injury and pre-existing cardiac disease, intra-operative hypotension,
operative blood loss and aortic clamp time had no demonstrable effect on cTn I levels all
indicate that the procoagulant state is only one of many contributory factors in the
pathophysiology of peri-operative myocardial injury.
Patients who died from organ dysfunction after ruptured AAA repair had significantly
lower peri-operative ET levels compared with survivors. Survivors had increased plasma
ET levels during the periods of lower torso ischaemia and reperfusion, and over half had
increased levels pre-operatively. The elevated peri-operative ET levels present in
survivors were associated with reduced thrombin generation. These findings do not
support the hypothesis that an increased ET response has a pathological role in critical
illness and predisposes to poor outcome in patients undergoing ruptured AAA repair.
The ET-dependent vasoconstrictor response in survivors may occur as part of a
homeostatic and protective response to haemorrhage, ischaemia and reperfusion and the
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low ET levels in non-survivors may be an early manifestation of severe and irreversible
whole body hypoperfusion.
Ischaemia and reperfusion induce procoagulant activity in endothelial cells and this may
occur indirectly through the synthesis and release of cytokines such as TNF. As
circulating TNF is frequently difficult to demonstrate, the levels of sTNF-Rs were
examined. Ruptured AAA repair was associated with elevated levels of sTNF-Rs p55
and p75. Elevated levels of sTNF-R p75 during early reperfusion were associated with
increased mortality in ruptured AAA and similar findings have been observed in other
acute inflammatory conditions and severe injury.
In ruptured AAA, there was a positive association between increased sTNF-R levels and
a procoagulant state as demonstrated by increased thrombin generation and vWF release
and inhibition of systemic fibrinolysis. One can speculate from these data that sTNF-Rs
have an important stimulatory role in the pathophysiology of haemostatic derangement
observed in ruptured AAA.
The findings of this thesis suggest that further study is required to elucidate the
triggering mechanisms for the deranged haemostasis evident in patients with AAA. TF
expression is the stimulus for thrombin generation and has also been reported to be
associated with reduced fibrinolysis. In patients with asymptomatic AAA, no
relationship has been demonstrated between pre-operative TF levels and other markers
of coagulation and fibrinolysis but further investigation is required. The finding of
reduced endothelin levels in non-survivors of ruptured AAA was unexpected but may be
secondary to increased NO synthesis. Currently, there are no reports of the NO response
to ruptured AAA repair.
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The findings of this thesis also suggest that further investigation is required into the
effect of therapeutic intervention on the haemostatic abnormalities which occur in
ruptured AAA repair. Current data do not support the routine use of antifibrinolytic
therapy in ruptured AAA repair, but suggest that peri-operative administration of these
agents as well as of FFP, cryoprecipitate and platelets may prove beneficial if targeted at
the selected group of patients with a hyperfibrinolytic state. The measurement of peri¬
operative fibrinolytic function may help to distinguish patients with hypofibrinolysis from
those with hyperfibrinolysis and further studies are required to assess whether TEG is of
clinical value in this situation.
Cardiac events are the commonest cause of poor outcome in AAA surgery. A large
prospective study of prevention, diagnosis and management of myocardial injury in aortic
surgery would be valuable. Screening for myocardial injury using cTn I may be of value
if a) it predicts post-operative cardiac events and allows these to be treated
prophylactically, and b) allows for peri-operative therapeutic intervention either
indirectly by correcting the procoagulant and hypofibrinolytic state or directly by
emergency percutaneous transluminal coronary angioplasty. Modification of the
hypofibrinolytic state is difficult as currently there are few therapeutic options. In elective
AAA repair, systemic heparinisation has been shown to be associated with a significant
reduction in the incidence of fatal and non-fatal Ml. As ruptured AAA is associated with
increased thrombin generation, it is possible that judicious use of systemically




Clinical correlations in patients operated for ruptured AAA.
r value p value
Duration of symptoms PF 1+2 before operation + 0.717 0.02
Operative blood loss Platelet count at 5 mins post-declamping -0.569 0.027
Operative blood loss Fibrinogen pre-declamping - 0.694 0.026
Operative blood loss Fibrinogen at 5 mins post-declamping -0.75 0.012
Operative blood loss Platelet count at 5 mins post-declamping -0.726 0.018
Operative blood loss PT pre-declamping + 0.823 0.003
Operative blood loss aPTT pre-declamping + 0.787 0.007
Operative blood loss aPTT at 5 mins post-declamping + 0.64 0.046
Operative blood loss vWF at 5 mins post-declamping -0.526 0.03
Aortic clamp time Platelet count at 5 mins post-declamping - 0.574 0.02
vWF pre-op. sTM pre-op. + 0.492 0.032
vWF pre-op. Platelet count pre-op. + 0.477 0.033
vWF pre-declamping Platelet count pre-declamping + 0.467 0.044
vWF at 5 mins post-declamping Platelet count at 5 mins post-declamping + 0.495 0.043
PAI activity pre-declamping cTn I at 6 hrs post-declamping + 0.829 0.042
PAI activity pre-declamping cTn I at 24 hrs post-declamping + 0.762 0.028
PAI activity pre-declamping cTn I at 48 hrs post-declamping + 0.829 0.042
PAI activity at 5 mins post-declamping cTn I at 6 hrs post-declamping + 0.943 0.005
PAI activity at 5 mins post-declamping cTn I at 24 hrs after declamping + 0.881 0.004
PF 1+2 pre-declamping Big ET-1 at 5 mins post-declamping -0.554 0.044
PF 1+2 pre-declamping Big ET-1 at 5 mins post-declamping - 0.695 0.038
PF 1+2 at 5 mins post-declamping Big ET-1 at 5 mins post-declamping -0.678 0.045
sTNF-R p55 pre-op. vWF pre-op. + 0.589 0.016
sTNF-R p55 pre-declamping t-PA activity pre-declamping -0.535 0.033
sTNF-R p55 pre-declamping PAI activity pre-declamping + 0.552 0.027
sTNF-R p55 at 24 hrs post-declamping vWF at 24 hrs post-declamping + 0.699 0.003
sTNF-R p75 at 5 mins post-declamping vWF at 5 mins post-declamping + 0.575 0.02
sTNF-R p75 at 5 mins post-declamping PF 1+2 at 5 mins post-declamping + 0.505 0.046
sTNF-R p75 at 24 hrs post-declamping t-PA activity at 24 hrs post-declamping + 0.639 0.008
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TABLE 13.2
Clinical correlations in patients operated for non-ruptured AAA.
r value p value
Operative blood loss Fibrinogen pre-declamping - 0.678 0.045
Operative blood loss Fibrinogen at 5 mins post-declamping -0.711 0.032
Operative blood loss Platelet count pre-declamping - 0.728 0.026
Operative blood loss PT at 5 mins post-declamping + 0.728 0.026
Operative blood loss t-PA activity at 5 mins post-declamping - 0.753 0.019
Aortic clamp time Fibrinogen pre-declamping -0.812 0.008
Aortic clamp time Fibrinogen at 5 mins post-declamping -0.711 0.032
Aortic clamp time Platelet count pre-declamping - 0.678 0.045
Aortic clamp time PT pre-declamping + 0.72 0.029
Aortic clamp time PT at 5 mins post-declamping + 0.828 0.006
Aortic clamp time t-PA activity pre-declamping -0.837 0.005
Aortic clamp time t-PA activity at 5 mins post-declamping -0.72 0.029
Aortic clamp time PAI activity at 5 mins post-declamping + 0.686 0.041
Aortic clamp time vWF at 5 mins post-declamping - 0.632 0.05
vWF pre-op. Haematocrit pre-op. + 0.721 0.019
vWF pre-op. Platelet count pre-op. + 0.794 0.006
vWF pre-declamping Platelet count pre-declamping + 0.648 0.043
vWF at 5 mins post-declamping Platelet count at 5 mins post-declamping + 0.634 0.048
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Community and hospital outcome from
ruptured abdominal aortic aneurysm
within the catchment area of a regional
vascular surgical service
Donald J. Adam, FRCSE, Irwin V. Mohan, FRCSI, Wesley P. Stuart, FRCSE,
Marion Bain, MFPHM, and Andrew W. Bradbury, BSc, MD, FRCSE,
Edinburgh, Scotland
Objective: The objective of this study was to examine patterns of referral, management,
and outcome of patients with ruptured abdominal aortic aneurysm (RAAA) within the
catchment area of this regional vascular unit (RVU).
Methods: Referral, management, and outcome data regarding 972 consecutive patients
admitted to the hospital or certified deceased in the community because of RAAA
between January 1, 1989, and December 31, 1995, were retrieved from prospectively
gathered computerized national and local databases.
Results: Of 381 (39.2%) patients admitted to this unit, 316 (82.9%) underwent surgery,
and of those, 188 (59.5%) survived. There was no significant difference in overall mor¬
tality between patients who were admitted directly to this unit (152 of 310, 49%) and
those who were transferred from elsewhere (41 of 71, 58%). Surgical patients traveled
significantly farther to the RVU than nonsurgical patients (P < .001), but there was no
significant difference in traveling distance between surgical patients who survived and
those who did not. Of 372 (38%) patients who were admitted to other units and not
transferred, 24 (6.4%) underwent surgery and 14 (3.8%) survived. Of 972 patients, the
overall community mortality from RAAA was 770 (79%).
Conclusion: Transferring patients from outlying units did not appear to prejudice oper¬
ative outcome in this RVU. However, less than half of all RAAA patients were trans¬
ferred, and only a small minority of those not transferred underwent surgery. Although
the overall community mortality from RAAA was similar to that reported in earlier stud¬
ies from other regions and countries where centralization has not occurred, centraliza¬
tion of vascular surgical services may be associated with an inappropriately low opera¬
tion and survival rate for those patients who arc not transferred to the regional center.
The effect of centralization on the community outcome of emergent vascular surgical
conditions requires further investigation. (J Vase Surg 1999;30:922-8.)
It is widely believed that surgical and anesthetic
subspccialization leads to better patient outcomes.
Vascular surgery is no exception, with the reduction
in operative mortality associated with ruptured
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abdominal aortic aneurysm (RAAA) and the
improving results of carotid endartcrectomy being
cited as evidence of the benefits of special exper¬
tise.1'2 As a result of these clinical data as well as
other clinical, political, and economic factors, there
is an increasing tendency in the United Kingdom to
centralize vascular surgical services within regional
vascular units serving populations of over 500,000.2
Since 1983, the Edinburgh Regional Vascular
Surgery Unit (ERVSU) has been the sole provider of
24-hour, 365-day vascular surgical services for a
population of 1.2 million living in an area of approx¬
imately 4,500 square miles in southeast Scotland
(Fig 1). However, to concentrate vascular expertise
within a small number of individuals at limited geo¬
graphical sites inevitably leads to a depletion, or even
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Fig 1. Catchment area of the Edinburgh Regional Vascular Surgery Unit: Lothian, Borders,
and Fife Health Board regions.
an absence, of expertise elsewhere. For example, of
nine hospitals conducting "general" surgery in this
catchment area, only this and one peripheral unit are
staffed by vascular surgeons. In these circumstances,
ensuring equality of access to specialist care may
become increasingly difficult.4 Although specializa¬
tion may improve individual patient outcomes for
specific procedures performed within specialist units,
it is equally important to demonstrate that central¬
ization docs not prejudice the overall community-
based outcome for the underlying condition. In
contrast to North America, where a minority ofAAA
operations are performed for rupture, this patient
group in the ERVSU accounts for no fewer than
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45% of all the AAA repairs performed.s Although
reasons for this are complex, it is clear that there is a
low public awareness of the condition and a low
index of suspicion among physicians such that only a
minority of patients initially seen with RAAA have
previously been diagnosed as having an aortic
aneurysm.6 Therefore, RAAA is a major problem in
the United Kingdom, and decisions on how vascular
services are to be distributed must be based, at least
in part, on consideration of how these unstable,
high-risk patients are most appropriately managed.
The aim of this study, therefore, was to examine for
the first time the patterns of referral, management,
and outcome of patients identified as having RAAA
within the catchment area served by this regional
vascular unit.
METHODS
This prospective study was conducted between
January 1, 1989, and December 31, 1995 (the most
recent year for which complete population data are
available). All residents of the catchment area of the
ERVSU—who were admitted to any hospital in
the catchment area with a diagnosis of RAAA
(International Classification of Diseases ninth revi¬
sion codes 441.3, 441.5, and 441.1, if coded in
addition to 441.3 or 441.5), or who were certified
deceased as a result of RAAA, either in the hospital
or in the community—-were identified through the
Information and Statistics Division of the National
Health Service in Scotland using the Scottish
Morbidity Records 1 (hospital discharge records)
and General Registrar Office (Scotland) mortality
records. Scottish Morbidity Records 1 are linked to
each other, and to the General Registrar Office
(Scotland) mortality records by the Information and
Statistics Division using probability matching,7 and
they provide a patient database that includes hospi¬
tal admission and mortality data. The Lothian
Surgical Audit database was used to identity all resi¬
dents from the catchment area who were admitted
to the ERVSU with RAAA.8 Residents of the catch¬
ment area who were admitted to hospitals outside
the catchment area (n = 32) and residents of other
catchment areas who were admitted to hospitals
within the area (n = 20) were excluded from analy¬
sis. Patterns of referral and management, as well as
outcome data and post-codes (equivalent to ZIP
codes), were retrieved lor each patient.
It was not possible, in most instances, to ascertain
the patient's precise location at the time of rupture, so
it was assumed that rupture had occurred near the
home address rather than at a distant site. Travel dis¬
tance for patients admitted directly to the ERVSU
was, therefore, defined as the distance by land from
the center of the individual's post-code region of res¬
idence to this unit. For those admitted indirectly, trav¬
el distance was defined as the distance from the cen¬
ter of the individual's post-code region of residence to
the referring hospital and then to this unit. All
patients in the study were transferred by land ambu¬
lance. In Scotland, air ambulance is not routinely
available for transfer of patients with RAAA.
There is no written protocol regarding the selec¬
tion ofpatients to be admitted to the ERVSU because
we believe that no written guideline can satisfactorily
cover all eventualities. Rather, we encourage medical
and surgical colleagues to discuss the patient's condi¬
tion by telephone so that each patient is considered
individually. When the condition of a patient with
rupture is discussed with the referring doctor, he or
she is advised against any prehospital fluid resuscita¬
tion; this may lead to an increase in blood pressure
and contribute to the development of coagulopathy
and fatal aortic hemorrhage before the patient reach¬
es the operating room and the aorta is clamped. The
final decision to admit, transfer, or operate on a
patient is made by the oil-call consultant vascular sur¬
geon, based on this unit's considerable experience in
managing'patients with RAAA.9 The Mann-Whitney
(MW) test, x2 test, and Fisher's exact test were used
for statistical analysis.
A probability value of less than .05 was regarded
as statistically significant.
RESULTS
The patterns of referral, management, and out¬
come for 972 patients who were identified as having
RAAA during the 7-year study period are shown in
Fig 2. Two hundred nineteen (22.5%) patients were
certified dead in the community without being
admitted to the hospital, 551 (56.7%) were certified
dead in the hospital, and 202 (20.8%) survived.
Therefore, the community mortality for RAAA was
79% (770 of 972 patients). The diagnosis was con¬
firmed at operation in 340 (35%) patients and at
postmortem examination in 268 (28%). Of the lat¬
ter, 175 died in the community and 93-died in the
hospital without transfer to the F2RVSU. In the
remaining 364 patients, RAAA was diagnosed and
recorded on the death certificate on the basis of clin¬
ical examination or investigation.
Three hundred seventy-two (38%) patients were
admitted to other units within or outside Edinburgh
and were not transferred to the F1RVSU. Of these,
24 (6.4%) patients underwent operation and 14
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Fig 2. Management of 972 patients diagnosed as ruptured abdominal aortic aneurysm in the
catchment area of the Edinburgh Regional Vascular Surgery Unit (ERVSU).
(3.8%) survived. For this group of patients, no data
are available to explain the decisions to transfer, per¬
form surgery, or treat conservatively. Three hundred
eighty-one (39%) patients (304 men, 77 women;
median age, 73 years; range, 46 to 93 years) were
admitted to the ERVSU. Of these, 65 (17%) patients
did not undergo surgery because they were consid¬
ered unfit for surgery on the basis of severe co-mor¬
bidity (ischemic heart disease, stroke, dementia,
renal failure, and carcinoma) or extreme age, their
clinical condition had deteriorated such that they
were considered unfit for repair (unrecordable blood
pressure or loss of consciousness), a decision to
operate was made but death occurred before surgery
could commence, or the offer of operation was
declined.5 Of 316 (83%) patients who underwent
surgery, a graft was inserted in 277 (88%). The over¬
all mortality for all patients admitted to the ERVSU
was 193 of 381 (51%), and the operative mortality
was 128 of 316 (41%). There was no significant dif¬
ference in the overall mortality among patients
transferred from units outside Edinburgh (25 of 43,
58%), those transferred from units within Edinburgh
(16 of 28, 57%), and those admitted directly to the
ERVSU (152 of 310, 49%) (P = .41, y} test).
Overall, 316 surgical patients traveled significantly
farther than 65 nonsurgical patients (P < .001,
MW). There was no significant difference in travel¬
ing distance between 188 (59%) surgical patients
who survived and the 128 who did not (Table I). Of
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Table I. Transfer distance and outcome in 381 patients with ruptured abdominal aortic aneurysm admit¬
ted (directly and indirectly) to the Edinburgh Regional Vascular Surgery Unit
Distance No Operated, Operated, Operative Overall
traveled »f Not graft nograft mortality mortality
(miles) patients operated inserted inserted (%) (%) '
0 - 5 152 41 95 16 44/111 (40) 85/152(56)
5 - 10 74 9 58 7 26/65 (40) 35/74 (47)
10 - 15 48 9 34 5 19/39(49) 28/48 (58)
15-20 44 3 39 2 14/41 (34) 17/44 (39)
20 - 25 32 1 27 4 14/31 (45) 15/32 (47)
25 + 31 2 24 5 11/29 (38) 13/31 (42)
381 65 277 39 128/316 (41) 193/381 (51)
310 patients who were admitted directly to the
ERVSU, 262 who underwent surgery traveled sig¬
nificantly farther than 48 who did not have surgery
(P < .001, MW), and there was no significant differ¬
ence in traveling distance between 160 surgical
patients who survived and 102 (40%) who did not.
DISCUSSION
This is the first study to describe the management
of patients with RAAA within a single region of die
United Kingdom, and to describe the relationship of
traveling distance, surgical intervention rates, and out¬
come. The first principal finding was that there was no
significant difference in traveling distance between the
operated patients who survived and those who did
not; however, patients who did not undergo surgery
traveled significantly shorter distances to the hospital
dian diose who did have surgery. One explanation for
this may be die preselection of "good-risk" patients for
transfer over longer distances. In addition, a propor¬
tion of patients sustaining rupture in the immediate
vicinity of the ERVSU may have been moribund on
arrival and dius did not undergo surgery.
Several studies have attempted to determine
whether traveling distance and transfer time has an
effect on operative mortality in ruptured aortic
aneurysm. Butler and colleagues9 showed no signif¬
icant difference in operative mortality between
patients admitted from the local catchment area (28
of48, 58%) and those transferred from other centers
(13 of 24, 54%). In 183 patients, Fielding et al10
reported no significant difference in operative mor¬
tality between those transferred less than 5 miles (43
of 85, 50.5%) and those transferred farther than 5
miles (39 of 97, 40.2%). Similarly, Barros D'Sa11
demonstrated no significant correlation between
traveling distance and outcome in 187 surgical
patients. Although Yashar et al12 reported a mortal¬
ity rate of 27% for patients undergoing surgery with¬
in 4 hours of onset of symptoms compared with 80%
for those undergoing surgery beyond 4 hours, van
Hceckercn13 was unable to demonstrate a significant
correlation between duration of symptoms and mor¬
tality in 57 surgical patients, and Amundsen et al14
tailed to demonstrate any correlation between trans¬
port time and overall mortality for 114 patients
(including 30 who did not undergo surgery). Meyer
and colleagues15 compared 48 patients admitted to
a community hospital and 49 admitted to a munici¬
pal hospital. They demonstrated that while signifi¬
cantly more patients in stable condition underwent
surgery more than 2 hours after diagnosis in the
community hospital, significantly more patients who
were shocked underwent immediate operation in
the municipal hospital, and consequently mortality
was significantly higher. However, Ouricl and col¬
leagues16 demonstrated no significant difference in
the delay from the onset of symptoms to hospital
arrival for patients admitted to a university or com¬
munity facility, and they found no significant rela¬
tionship between operative mortality and the delay
from hospital arrival to the start of the operation. In
a study of 122 patients, Farooq ct al17 also demon¬
strated no relationship between operative mortality
and duration of symptoms and delay between hospi¬
tal arrival and the start of the operation. Although
more hypotensive patients were operated on within
2 hours of onset of symptoms, this was not associat¬
ed with a significant increase in mortality.
At first sight, these and present data suggest that
centralization does not prejudice the community
outcome for RAAA. However, in this 7-year study,
93% of survivors of RAAA were operated on in the
ERVSU, fewer than 40% were transferred to this
regional vascular unit, and only 6% of those treated
outside this unit underwent operation. The opera¬
tive mortality outside the ERVSU was a very accept¬
able 10 of 24 (42%). However, almost all of these
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Table II. Reported studies estimating the community outcome from ruptured abdom inal aortic aneurysm
Died outside Died in hospital
Author Total number hospital (%) not operated operated Survivors (%)
Armour,'* 1977 25 1 1 (44) 9 1 4 (16)
Ingoldby," 1986 260 158(61) 1 49 52 (20)
Johansson,20 1 986 88 24 (27) 51 8 5 (6)
Mealy,21 1988 265 169(64) 18 48 30 (11)
Thomas,22 1988 183 64 (35) 44 41 34 (19)
Semniens,23 1 998 873 379 (43) 21 1 102 181 (21)
Present study 972 219(23) 413 138 202 (21)
operations were performed in one peripheral hospi¬
tal by two general surgeons with a major vascular
interest. None of the other seven hospitals were
staffed by surgeons with vascular expertise, which
presumably explains the low operation rate outside
the ERVSU and the other peripheral hospital.
The present study and, indeed, all community
studies of 11AAA have limitations. The diagnosis of
RAAA was confirmed by operation or postmortem
examination in only 63% of patients. It is not known
what proportion of patients who were not operated
on were diagnosed as having RAAA in life. It is likely
that there were patients who died suddenly from
RAAA in whom the diagnosis was not made, and per¬
haps there were a few who did not die from rupture
but in whom this was the certified cause of death.
The important question raised by these data is
whether a broader provision of vascular surgical
expertise would have increased the proportion of
patients offered and surviving surgery and whether
this, in turn, would have had a positive impact on the
community survival from the condition. Although
the community outcome from RAAA in this series is
similar to that reported in earlier studies from regions
where centralization has not occurred (Table II),
centralization of vascular surgical services may be
associated with an inappropriately low operation and
survival rate for the majority of patients who arc not
transferred to the regional center.
The reviewers have specifically requested that the
authors discuss whether "rationing" of health care
resources in the United Kingdom may explain what
they describe as the "excessive mortality" observed in
this study. This is a complex issue. However, the
United Kingdom spends significantly less money on
health education and care than North America and
many European countries, and this may have a nega¬
tive impact on the mortality from AAA in several
ways. First, there is low public and physician aware¬
ness of the condition such that only a small propor¬
tion of patients with AAA are diagnosed and treated
before the onset of life-threatening complications.
Second, the absence of "round-the-clock" vascular
surgical expertise in the majority of "local" hospitals
means that, for most patients, the only prospect of
survival lies in transfer to a regional center. Third,
suboptimal transport ofcritically ill patients and a lack
of intensive therapy beds may be relevant to the out¬
come for patients with AAA and many other patient
groups. Present data indicate that the effect of these
factors and the centralization of vascular surgical ser¬
vices on the community outcome of this and other
emergent vascular surgical conditions requires further
investigation.
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Coagulation and fibrinolysis in patients
undergoing operation for ruptured and
nonruptured infrarenal abdominal aortic
aneurysms
Donald J. Adam, FRCSEd, Christopher A. Ludlam, PhD, FRCP, C. Vaughan
Ruckley, ChM, FRCSEd, and Andrew W. Bradbury, BSc, MD, FRCSEd,
Edinburgh, Scotland, United Kingdom
Purpose. Hemorrhage and thrombosis predisposing to myocardial infarction, multiple
organ failure, and thromboembolism account for the majority of the morbidity and
mortality associated with repair of ruptured and nonruptured abdominal aortic
aneurysms (AAAs). The aim of this study was to examine coagulation and fibrinolysis in
patients operated on for ruptured and nonruptured infrarcnal AAAs.
Methods-. Ten patients operated 011 for ruptured and 9 patients operated on for nonrup¬
tured AAAs were studied. Tissue plasminogen activator (t-PA) antigen, thrombin-
antithrombin (TAT), and D-dimcr were measured before induction of anesthesia.
Plasminogen activator inhibitor (PAI) activity, t-PA activity, and prothrombin fragment
(PF) 1+2 were measured before induction of anesthesia, immediately before aortic clamp
release, and 5 minutes and 24 hours after aortic clamp release.
Results: Preopcratively, ruptured AAA was associated with significantly elevated t-PA
antigen (median 15.7 ng/mL, range 9.0 to 22.1 ng/mL versus nonrupture: median
6.6 ng/mL, range 4.7 to 16.4 ng/mL; P < .01, Mann-Whitney test), increased PAI
activity (median 36.5 arbitrary units/mL, range 20.6 to 38.8 arbitrary units/mL ver¬
sus nonrupture: median 8.2 arbitrary units/mL, range 3.2 to 21.7 arbitrary
units/mL; P< .001), reduced t-PA activity (median 0.12 IU/mL, range 0.06 to 0.4
IU/mL versus nonrupture: median 0.49 IU/mL, range 0.14 to 3.2 IU/mL; P< .01),
elevated TAT (median 135.5 pg/L, range 61.2 to 209.4 pg/L versus nonrupture:
median 21.6 pg/L, range 6.6 to 180.4 pg/L; P < .02) and elevated PF 1 + 2 (median
9.0 mnol/L, range 5.4 to 11.6 nmol/L versus nonrupture: median 2.2 nmol/L, range
0.7 to 7.1 nmol/L, P< .001). There was 110 significant difference in preoperative D-
dimer levels (median 3460 ng/mL, range 1236 to 7860 ng/ntL versus nonrupture:
median 1642 ng/mL, range 728 to 5334 ng/mL; P = .07). The differences in PAI
activity, t-PA activity, and PF 1+2 persisted throughout the course of surgery, but
there was no significant difference between the groups at 24 hours.
Conclusion: These novel data demonstrate that ruptured AAA repair is associated with
inhibition of systemic fibrinolysis and intense thrombin generation. Similar changes
are seen in nonruptured AAA but arc of a lesser magnitude. This procoagulant state
may contribute to the microvascular and macrovascular thrombosis that leads to
myocardial infarction, multiple organ failure, and thromboembolism. (J Vase Surg
1999;30:641-50.)
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Fig 1. Overview of extrinsic coagulation and fibrinolytic
systems. Markers studied are shown in boxes. Kxtrinsic
coagulation system: tissue injury, endothelial activation
and injury, and monocyte activation lead to tissue factor
expression, which triggers the extrinsic coagulation cas¬
cade. This leads to conversion of prothrombin to throm¬
bin with release of PF 1+2. Excess thrombin is inactivated
by antithrombin III (main thrombin inhibitor) with for¬
mation of TAT. Fibrinolytic system: endothelial activation
and injury lead to release of t-l'A, which converts plas¬
minogen to the active enzyme plasmin, which, in turn,
leads to breakdown of fibrinogen, fibrin and fibrin clot to
fibrin degradation products such as D-dimer. FA I is the
naturally occurring inhibitor of t-PA and is released from
endothelium, hepatocytes anil platelets.
Repair of ruptured and nonruptured abdominal
aortic aneurysms (AAAs) is associated with an opera¬
tive mortality rate of approximately 35% to 50%'-2
and 5% to 15%,3 respectively. The great majority of
these deaths are due to myocardial infarction, multi¬
ple organ failure, and thromboembolism, all ofwhich
may be related to microvascular and macrovascular
thrombosis developing as a result of a procoagulant
state.T4--4 Perhaps surprisingly, therefore, previous
authors have suggested that supraceliac aortic cross-
clamping and thoracoabdominal aortic aneurysm
repair are associated with increased fibrinolysis,
which may be due to reduced hepatic blood flow.6-7
Furthermore, animal studies suggest that infrarcnal
aortic clamping and isolated lower body ischemia arc-
also associated with elevated levels of fibrinolytic
markers.8 With respect to elective inlrarenal aortic
reconstruction, studies are few and contradictory.912
Although these data have been used to support the
use of antifibrinolytic agents in patients undergoing
operation for ruptured AAA,1-4 careful review of the
literature reveals that the precise nature ot the serial
changes in hemostatic derangement in such patients
has not previously been studied. The aims of this
study were to examine serial markers of thrombin
generation and fibrinolysis during the course of
emergent surgery for ruptured infrarenal AAA and to
compare these with those undergoing elective repair
of nonruptured infrarenal AAA.
METHODS
Patients. Ten patients (8 men and 2 women of
median age 76 years, range 71 to 86 years) operated
on for ruptured and 9 patients (8 men and 1 woman
of median age 69 years, range 58 to 80 years) oper¬
ated on for asymptomatic nonruptured infrarenal
AAA were prospectively studied. Lothian Region
Ethical Committee approval was obtained as was
fully informed written consent from all patients.
In patients operated on for ruptured AAA, the
median (range) delay between the onset of symp¬
toms of rupture and hospital admission was 5 (3 to
14) hours. All patients had at least one documented
episode of hypotension (systolic blood pressure less
than 100 mm Hg) before surgery. In patients under¬
going operation for nonruptured AAA, the median
(range) anteroposterior diameter of the aneurysm
measured by abdominal ultrasound scan was 6.5
(5.5 to 8.0) cm. No patient in either group had a
history of liver disease or was taking oral anticoagu¬
lant medication before admission. Liver function
tests were only available preoperatively in elective
cases and were all normal. Three patients with rup¬
tured AAA and four with nonruptured AAA were
taking regular aspirin before admission.
Operative medtods. Ruptured AAA was defined
by the presence of fresh retroperitoneal blood at oper¬
ation. No patient had intraperitoneal rupture. Patients
with rupture had general anesthesia, and patients with
nonruptured AAA had combined general and epidur¬
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Table I. Assays of coagulation and fibrinolysis




Platelet count ED IA (1.6 nig/ml.) 2.7 SYSMHX NE 8000 150-350 x 109/L
CRP Clot activator 9.0
.




PT ACL 300 10.5-14.5 s
aPTT 28-40 s
TAT Hnzygnost TAT micro; Bchring 1.0-4.1 (.tg/L
Diagnostics
PF 1+2 Sodium citrate (0.106 mol/L) 3.0 EI.ISA Enzygnost PF 1+2 micro; Bchring 0.4-1.1 nmol/L
Diagnostics
D-dimcr Asserachrom D-Di; Diagnostic.! 630-850 ng/mL
Stago, France
t-PA antigen Coaliza t-PA; Chromogcnix, Sweden 1-12 ng/mL
PA! activity Chromogenic assay Coaset PAI; Chromogcnix, Sweden
~
(amidolytic method) < 15 AU/mL
t-PA activity Strong acid citrate (Stabilytc; Coatest t-PA; 0.2-2.0 IU/mL
Biopool, Sweden) 4.5 Chromogcnix, Sweden
EDTA, Ethvlenediaminetetraaceric acid; El.ISA, enzyme-linked immunosorbent assay; AU, arbitrary units.
through a transverse supraumbilical incision with
infrarena! aortic clamping, which is the standard
approach in this institution. No patients required
supraceliac aortic clamping. No patients with rup¬
tured AAA were systemically heparinized. Patients
with nonrupturcd AAA were given an intravenous
bolus of 5000 units heparin immediately before aor¬
tic clamp placement. No patient received protamine
sulfate or mannitol infusion because this is the stan¬
dard policy in this institution. A Dacron tube graft
was inserted in 13 patients (nine with rupture, four
with nonrupture), aortobi-iliac graft in five (one with
rupture, four with nonrupture), and aortobifemoral
graft in one patient with nonruptured AAA.
Markers of thrombin generation and fibrino¬
lysis. The extrinsic coagulation and fibrinolytic sys¬
tems are summarized in Fig 1. Plasma levels of pro¬
thrombin fragment (PF) 1+2 (normal range, 0.4 to
1.1 nmol/L) and thrombin-antithrombin complex
(TAT) (normal range, 1.0 to 4.1 |ig/L) were assayed
as markers of thrombin generation, and tissue plas¬
minogen activator (t-PA) activity (normal range, 0.2
to 2.0 lU/mL), t-PA antigen (normal range, 1 to 12
ng/mL), plasminogen activator inhibitor (PAI)
activity (normal range, less than 15 arbitrary units
[AU]/mL), and fibrin degradation product D-
dimer (normal range, 630 to 850 ng/mL) as mark¬
ers of fibrinolysis. Hematocrit (normal range, 0.37
to 0.54), platelet count (normal range, 150 to 350
x 109/L), fibrinogen (normal range, 1.5 to 4.0
g/L), prothrombin time (PT) (normal range, 10.5
to 14.5 seconds) and activated partial thromboplas¬
tin time (aPTT) (normal range, 28 to 40 seconds),
and C-reactive protein (CRP) (normal range, less
than 10 mg/L) were also measured (Table I).
Sample collection. The sampling points were
chosen to reflect the maximum effect of each of the
three pathophysiologic phases of ruptured AAA
repair (Fig 2). Blood was sampled from an indwelling
radial arterial line immediately before the induction
of anesthesia (sample A), immediately before release
of the aortic clamp (sample B), and 5 minutes (sam¬
ple C) and 24 hours (sample D) after aortic clamp
release. t-PA antigen, D-dimcr and TAT were mea¬
sured at sample point A. Hematocrit, platelet count,
fibrinogen, PT, aPTT, CRP, t-PA activity, PAI activi¬
ty, and PF 1+2 were measured at all four sample
points. Samples were placed immediately on ice and
ccntrifuged within 30 minutes of collection at 3000
revolutions per minute for 30 minutes at 4°C (equiv¬
alent to 1400/7). Plasma and serum were separated
and stored at -70"C for later batch analysis.
Statistical methods. The Mann-Whitnev test
was used to compare groups of patients. Because the
data were not normally distributed, the Spearman
rank test was used to correlate the degree of preop¬
erative hypotension and the operative blood loss with
the levels of hemostatic markers in patients operated
on for ruptured AAA. A probability value of less than
.05 was regarded as statistically significant.
RESULTS
Clinical data. Clinical and operative data for
both groups of patients are summarized in Table II.
During operation, no patients with nonruptured
AAA received inotropic support. Three patients with
644 Adam ct al




















Fig 2. Schematic view of pathophysiology of ruptured
AAA repair. Pathophysiology of ruptured AAA repair can
be divided into three phases. First, there is a period of
whole body hypoperfusion due to hypovolemic shock.
Second, there is a period ofprofound lower body ischemia
after aortic clamp placement. Finally, if repair is successful,



































Fig 3. Individual data points for levels ofTAT, t-PA anti¬
gen, and fibrin degradation product D-dimer immediately
before induction of anesthesia (sample A) in 10 patients
with ruptured AAA (black squares) and 9 patients with
nonruptured AAA (black circles). Normal ranges for TAT
(1.0 to 4.1 jig/L), t-PA antigen (1 to 12 ng/mL), and D-
dimcr (630 to 850 ng/mL) arc shown by horizontal lines.
NS, Not significant.
rupture received adrenaline infusion and five
received dopamine infusion. All patients with rup¬
ture were admitted to the intensive therapy unit
postoperatively for ventilatory support. The median
(range) duration of intensive therapy unit stay was
72 (13 to 244) hours. The median (range) duration
of ventilatory support was 19 (9 to 142) hours. All
patients operated tan for nonruptured AAA were
admitted to the surgical high dependency unit post¬
operatively, and no patient was admitted to the
intensive therapy unit or required ventilatory sup¬
port. Seven patients operated on for rupture and
four operated on for nonruptured AAA developed
major postoperative complications (Table III). All
patients survived to 24 hours after repair. Two
patients with rupture died in hospital of acute respi¬
ratory distress syndrome and acute renal failure on
postoperative day 10 and of pneumonia and critical
lower limb ischemia on postoperative day 2 1. There
were no deaths after repair of nonruptured AAA.
Hematocrit, platelet count, fibrinogen, PT,
aPTT, and CRP. The median (range) values for
hematocrit, the standard tests of hemostasis (platelet
count, PT, aPTT, and fibrinogen) and CRP are
shown in Table IV.
In patients operated on for ruptured AAA, there
was no significant relationship between the degree
of preoperative hypotension and any of the standard
tests of hemostasis. There was, however, a significant
negative correlation between operative blood loss
and fibrinogen level immediately before (r= -0.694,
P = .026) and 5 minutes after aortic clamp release (r
= -0.75, P= .012), and also platelet count 5 minutes
after aortic clamp release (r = -0.726, P = .018); and
a significant positive correlation between operative-
blood loss and PT immediately before aortic clamp
release (r = +0.823, P = .003), and aPTT immedi¬
ately before (r = +0.787, P = .007) and 5 minutes
after aortic clamp release (;•= +0.64, P = .046).
Markers of thrombin generation. Before oper¬
ation, TAT levels were elevated above the normal
range in all patients. Levels were significantly higher
in patients with ruptured AAA (median 135.5 gg/L,
range 61.2 to 209.4 gg/L) than in those with non¬
ruptured AAA (median 21.6 gg/L, range 6.6 to
180.4 gg/L; P < .02, Mann-Whitney test) (Fig 3).
Before and during operation, PF 1+2 levels were also
significantly higher in patients undergoing repair of
ruptured AAA when compared with those undergo¬
ing repair of nonruptured AAA. At 24 hours there
was no significant difference in PF 1+2 levels
between the groups (Table V and Fig 4). There was
no significant relationship between the degree of pre¬
operative hypotension or operative blood loss and
any of the markers of thrombin generation.
Markers of fibrinolysis. Before operation,
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Fig 4. Individual data points for PF 1+2 immediately
before induction of anesthesia (sample A), immediately
before release of aortic clamp (sample B), and 5 minutes
(sample C) and 24 hours (sample D) after aortic clamp
release in 10 patients operated on for ruptured (black
squares) and 9 patients operated on for nonruptured
{bind: circles) infrarenal AAA. Normal range for PF 1+2 is
0.4 to 1.1 nmol/L and is shown by the horizontal line.
NS, Not significant.
Fig 5. Individual data points for t-PA activity immediate¬
ly before induction of anesthesia (sample A), immediately
before release of aortic clamp (sample B), and 5 minutes
(sample C) and 24 hours (sample D) after aortic clamp
release in 10 patients operated on for ruptured (black
squares) and 9 patients operated on for nonruptured
(black circles) infrarenal AAA. Normal range for t-PA activ¬
ity is 0.2 to 2.0 IU/mL and is shown by the horizontal
line. NS, Not significant.
Table II. Clinical and operative data in 10 patients operated on for ruptured and 9 patients operated on
for nonruptured infrarenal AAAs
Ruptured AAA, Nonruptured AAA,
median (ranjje) (n = 10) median (J'anjje) (n = 9) P value*
Preoperative
Crystalloid administration (L) 0.5(0.1-4.0) —
Colloid administration (L) 0(0-1.5) —
Intraoperative
Operation time (min) 105 (70-205) 160 (85-285) NS
Aortic clamp time (min) 60 (30-125) 70 (25-150) NS
Measured blood loss (I.) 2.3 (1.0-6.4) 2.8 (1.0-6.0) NS
Crystalloid administration (I.) 2.0 (0.5-3.5) 2.0 (1.0-4.0) NS
Colloid administration (L.) 1.5 (0-2.3) 2.0 (0.5-3.8) NS
RCC administration (units) 8 (6-11) 4 (0-10) 0.02
FFP administration (units) 2 (0-6) 0 (0-2) NS
Platelet administration (bags/ 1 (0-1) 0(0-1) NS
NS, Not significant; RCC, red cell concentrate (300 mL); FFP, fresh frozen plasma (300 niL).
*Mann-Whitney test.
tOne hag of platelet transfusion = 4 pooled units (250 nil.).
t-PA antigen levels were significantly higher in
patients with ruptured AAA (median 15.7 ng/mL,
range 9.0 to 22.1 ng/mL) compared with those
with nonruptured AAA (median 6.6 ng/mL, range
4.7 to 16.4 ng/mL; P < .005, Mann-Whitney test).
Before operation, there was no significant difference
in the D-dimcr levels between the ruptured AAA
(median 3460 ng/mL, range 1236 to 7860
ng/mL.) and nonruptured AAA group (median
1642 ng/mL, range 728 to 5334 ng/mL; P= .07,
Mann-Whitney test) (Fig 3). Before and during
operation, t-PA activity was significantly lower in
patients undergoing repair of ruptured AAA when
compared with those undergoing repair of nonrup¬
tured AAA (Table V and Fig 5). At 24 hours there
was no significant difference in t-PA activity between
the groups. Before and during operation, PAI activ¬
ity was significantly higher in patients undergoing
repair of ruptured AAA when compared with those
undergoing repair of nonruptured AAA. At 24
646 Adam et al

















































Fig 6. Individual data points for 1'AI activity immediately
before induction of anesthesia (sample A), immediately
before release of aortic clamp (sample B), and 5 minutes
(sample C) and 24 hours (sample D) after aortic clamp
release in 10 patients operated on for ruptured (black
squares) and 9 patients operated on for nonruptured (black
circles) infrarenal AAA. Normal range for PAI activity is less
than 15 AU/mL and is shown by the horizontal line.
NS, Not significant.
hours there was no significant difference in PAI
activity between the groups (Table V and Fig 6).
There was no significant relationship between the
degree of preoperative hypotension or operative
blood loss and any of the markers of fibrinolysis.
Coagulation and fibrinolytic data for two patients
who died after ruptured AAA repair compared with
eight who survived are shown in Table VI.
DISCUSSION
The principal finding of the present study is that
emergency repair of ruptured AAA is associated with
intense thrombin generation (as demonstrated by
elevated TAT and PF 1+2 levels) and inhibition of
systemic fibrinolysis (as demonstrated by elevated t-
PA antigen, reduced t-PA activity, and elevated PAI
activity). This procoaguiant state is present before
surgery, persists throughout the period of operation,
and has largely resolved 24 hours after operation.
Furthermore, similar changes are observed in a pro¬
portion of patients undergoing elective repair of
nonruptured AAA but arc of much less magnitude.
At first sight, these novel findings appear to con¬
tradict a previous study that reported supraccliac
aortic cross-clamping to be associated with increased
fibrinolysis.6 One reason for this apparent discrepan¬
cy may be due to the measurement of t-PA antigen
as opposed to the measurement of t-PA activity. This
failure to measure activity, as well as antigen, in the
present study might have led to the erroneous con-
Table III. Postoperative complications and proce¬
dures in 7 patients operated on for ruptured and 4
patients operated on for nonrupturcd infrarenal AAAs
Ruptured AAA Nonniptitrcd
(n = 7) AAA (n = 4)
Cardiovascular
Atrial fibrillation 3
Congestive cardiac failure 4
Myocardial infarction 1
Stroke I
Lower limb critical ischemia 2




Acute respiratory distress 1
syndrome





Total parenteral nutrition 3
Inotropic support
Adrenaline 3



















'Laparotomy for intra-abdominal hemorrhage, femoral thrombec¬
tomy, Hartmann's procedure for colon ischemia, drainage of
infected pelvic hematoma.
TPopliteal thrombectomy and fasciotomies.
elusion that ruptured AAA was, indeed, associated
with enhanced fibrinolysis. However, it is increas¬
ingly apparent that t-PA antigen levels primarily
reflect the level of inactive circulating t-PA/PAI
complexes. This contention is demonstrated by the
present study, where elevated t-PA antigen is, in fact,
associated with markedly elevated PAI activity and
markedly depressed t-PA activity, consistent with a
procoaguiant state. 14>1S
Given that repair of ruptured aortic aneurysm
and a proportion ofelective aneurysm operations are
associated with a procoaguiant state,y-ll) two impor¬
tant questions need to be addressed.
First, are the presence and the intensity of the
procoaguiant state associated with poor outcome as
a result of microvascular and macrovascular throm¬
botic events? Although the changes in coagulation
and fibrinolysis observed in the present study have
been associated with myocardial injury,14'16"19 mul¬
tiple organ failure,20-21 and stroke22 in other patient
groups, it is not possible to answer this question
directly from the present data for two reasons. Only
data for patients who survived for 24 hours are
included in the present analysis. Data for those who
JOURNAL OH VASCULAR SURGKRY
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Table IV. Hematocrit, platelet count, fibrinogen, PT, aPTT, and CUP in patients operated on for ruptured
and nonruptured AAAs
Ruptured AAA, Nimrnptitrcd AAA,
Assay (normal rantje) Sample point median (ranjje) (n = JO) median (rmijje) (n = 9) P value *
Hematocrit (0.37-0.54) A 0.31 (0.13-0.34) 0.42 (0.33-0.47) .0004
11 0.27 (0.18-0.44) 0.30 (0.25-0.37) NS
C 0.28 (0.22-0.42) 0.30 (0.23-0.35) NS
D 0.34 (0.26-0.42) 0.34 (0.25-0.39) NS
Platelet count (150-350 x 10y/L) A 230 (119-303) 1S2 (75-744) NS
11 120 (81-189) 132 (103-541) NS
C 108 (59-146) 135 (91-577) NS
D 97 (50-133) 127 (85-604) NS
Fibrinogen (1.5-4.0 g/L) A 2.27 (0.86-3.75) 2.80 (1.59-6.02) NS
11 1.12 (0.88-2.51) 1.68 (0.72-5.39) NS
c; 0.97 (0.46-1.82) 1.45 (0.36-5.44) NS
D 3.29 (1.76-4.63) 3.70 (2.50-8.98) NS
PT (10.5-14.5 s) A 14 (11-35) 12 (11-14) .009
11 20 (15-26) 17 (15-26) NS
C 20 (17-31) 20 (14-23) NS
D 16(13-18) 14 (12-21) NS
aPTT (28-40 s) A 32 (28-126) 31 (25-49) NS
11 50 (34-210) 176 (56-240) .006
C 55 (42-210) 210 (79-240) .008
D 39 (32-76) 36 (29-39) .02
CUP (< 10 mg/L) A 6.7 (2.6-178.3) 4.3 (0.3-18.6) NS
11 3.0 (0.9-116) 5.0 (1.1-13.4) NS
C 3.8 (1.9-11.4) 2.0 (1.3-8.2) NS
D 105 (41.8-141.8) 92.4 (41.5-180.8) NS
Sample A, Immediately before induction of anesthesia; sample R, immediately before release of aortic clamp; sample C, 5 minutes after
aortic clamp release; sample D, 24 hours after aortic clamp release; NS, not significant.
*Mann-VVhitney test.
Table V. PF 1+2, t-PA activity, and PAI activity in patients operated on for ruptured and nonruptured AAAs
Ruptured AAA, Nonruptured AAA,
Assay (norma1 ranjjc) Sample point median (ranije) (n = 10) median (ranjjc) (n = 9) P value*
PF 1+2 (0.4-1.1 nmol/L) A 9.0 (5.4-11.6) 2.2 (0.7-7.1) .0008
B 6.7 (3.3-8.9) 1.0 (0.9-4.0) .0003
C 6.5 (4.2-9.6) 2.0 (1.0-4.9) .0007
D 3.5 (1.9-11.4) 1.9 (1.3-5.6) NS
t-PA activity (0.2-2.0 IU/ml.) A 0.12 (0.06-0.43) 0.49 (0.14-3.2) .009
R 0.27 (0.08-0.S) 0.91 (0.34-4.65) .0014
C 0.32 (0.09-4.53) 1.06 (0.19-5.62) .034
D 0.41 (0.15-2.1) 0.46 (0.21-1.45) NS
PAI activity (< 15 AU/mL) A 36.5 (20.6-38.S) 8.2 (3.2-21.7) .0003
15 38.6 (13.0-39.4) 10.8 (2.8-38.9) .0042
C 37.2 (10.6-39.4) 12.6 (2.2-28.7) .0055
D 18.1 (5.0-35.3) 14.7 (5.7-22.3) NS
Sample 4, Immediately before induction of anesthesia; satuple /i, immediately before release of aortic clamp; sample C, 5 minutes after
aortic clamp release; sample D, 24 hours alter aortic clamp release; NS, not significant.
*Man n-Whitney test.
died intraoperatively or within the first 24 hours
after operation are the subject of an ongoing study.
Furthermore, the number of patients and adverse
clinical outcomes is small (Table III). However,
both of the patients with rupture who died had PF
1+2 levels 24 hours alter operation that were con¬
siderably higher than survivors, and one who died
10 days after surgery had very high t-1'A activity and
very low PAI activity (indicating increased systemic
fibrinolysis) during and 24 hours after the operation.
A larger prospective study of the relationship
between hemostatic derangement and outcome in
patients undergoing repair of ruptured and nonrup¬
tured AAAs is currently underway in our institution.
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Table VI. Coagulation and fibrinolytic data for 2 patients who died after ruptured AAA repair compared
with 8 patients who survived
Nonsurvivor Nonsurvival- Survivors, median
Assay (normal ranjjc) Sample point (ARDS, ARF) (pneumonia, C.LI) (raiige) (n = S)
Platelet eount (150-350 x 109/L) A 119 178 249(156-303)
15 81 116 125 (96-189)
c; 66 84 117(59-146)
D 86 72 102 (50-133)
fibrinogen (1.5-4.0 r/L) A 2.18 1.87 2.52 (0.86-3.75)
15 1.2 0.94 1.20 (0.88-2.51)
C 0.77 0.85 1.20 (0.46-1.82)
D 1.87 2.57 3.35 (1.76-4.63)
PT (10.5-14.5 s) A 16 14 14 (11-35)
15 23 18 20 (15-26)
C 27 24 20 (17-31)
n 18 15 16(13-18)
aPIT (28-40 s) A 40 35 30(28-126)
15 120 52 53(34-210)
c 108 210 55(42-123)
D 51 49 39 (32-76)
PF 1+2 (0.4-1.1 nmoI/L) A 10.1 9.3 7.7(5.4-11.6)
15 7.0 8.9 6.2 (3.3-8.4)
C 4.8 9.6 6.5 (4.2-8.0)
D 11.4 4.8 3.4 (1.9-4.4)
t-PA activity (0.2-2.0 IU/mL) A 0.13 0.11 0.17 (0.06-0.43)
15 0.8 0.12 0.27 (0.08-0.41)
C 4.53 0.43 0.28 (0.09-1.27)
D 2.1 0.25 0.41 (0.15-2.08)
PAI activity (< 15 AU/mL) A 31.0 36.4 36.7 (20.6-38.8)
B 13.0 38.9 38.6 (29.4-39.4)
C 10.6 38.2 37.2 (19.4-39.4)
D 5.9 22.2 18.1 (5.0-35.3)
Sample A, Immediately before induction of anesthesia; sample B, immediately before release of aortic clamp; sample C, 5 minutes after
aortic clamp release; sample D, 24 hours after aortic clamp release; ARDS, acute respiratory distress syndrome; ARB, acute renal failure;
CLI, critical lower limb ischemia.
The second question is whether therapeutic inter¬
vention may ameliorate the adverse effects of this pro-
coagulant state and thus improve outcome. Apart
from tire fact that patients in this study with ruptured
AAA sustained a period of preoperative hypovolemic
shock, the most obvious difference between the
groups relates to the use of systemic heparin during
aneurysm repair. The effects ofheparin on tire coagu¬
lation parameters examined in the present study
include slight (5% to 10%) reduction in platelet count
in a small proportion of patients, prolongation of the
aPTT, marginal prolongation of the PT in a small
proportion of patients, elevation of the fibrinogen
level and a reduction in D-dimcr levels due to a reduc¬
tion in fibrin deposition, reduced PF 1+2 due to inhi¬
bition of thrombin generation by antithrombin III,
and increased binding of thrombin to antithrombin
III but no increase in TAT levels. Other than t-PA, no
other fibrinolytic component appears to be affected
by heparin; whereas the majority of clinical and vol¬
unteer studies have shown that repeated administra¬
tion of unfractionated heparin over a number of days
increases t-PA antigen, short-term studies have shown
increases in t-PA activity similar in magnitude to what
might be expected due to diurnal variation and that
may be artifactual.23 Surgeons arc naturally reluctant
to systcmically heparinizc a patient with a ruptured
aortic aneurysm, but these data suggest that after con¬
trol of bleeding by aortic clamping, judicious use of
heparin may reverse the procoagulant state and may,
therefore, improve outcome from thrombotic com¬
plications.24 It is important to note, however, that
patients with ruptured AAA exhibited very elevated
levels of TAT, which indicate that there is already a
considerable, albeit ineffective, attempt by nature to
inhibit thrombin activation. This may limit the effica¬
cy of heparin in this situation. Other possible thera¬
peutic interventions include angiotensin-converting
enzyme inhibitors (which may decrease PAI and
increase t-PA levels) and specific inhibitors of PAI
activity.25 There have been suggestions that patients
with ruptured AAA might benefit from antilibrinolyt-
ic therapy, specifically with aprotonin. However, this
has not been shown to be of therapeutic value in
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reducing blood loss or blood transfusion requirement
in elective infrarenal aortic surgery,13 and the findings
of the present study strongly suggest that such thera¬
py is contraindicated in patients undergoing operation
for ruptured aortic aneurysm.
At the present time, the triggering mechanisms
leading to this procoagulant state are unknown, but, as
it is present before operation in patients with rupture,
it is presumably related to whole body hypoperfusion
as a result of hemorrhagic shock. Although there was
no significant relationship between the degree of pre¬
operative hypotension and any of the coagulation and
fibrinolytic parameters studied, there was a significant
negative correlation between operative blood loss and
fibrinogen level and platelet count during the opera¬
tion, and a significant positive correlation between
operative blood loss and PT and aPTT during the
operation. The finding that certain patients undergo¬
ing elective repair of nonruptured AAA also have ele¬
vated levels ofTAT and PF 1+2 (indicating patholog¬
ic levels of thrombin generation) is difficult to explain
but may be related to the presence of thrombus with¬
in the aneurysm sac.26 Indeed, both we and a number
of previous authors have suggested that patients with
AAA have a low-grade coagulopathy that may make
them particularly sensitive to the effects of hypoten¬
sion and ischemia.5,27,28 Previous work from this
group has demonstrated morphologic evidence of
endothelial cell activation before operation in patients
with ruptured AAA, suggesting that this may be an
early event in this group of patients.29 Tissue factor
expression is associated with thrombin generation and
reduced fibrinolysis,30-31 and its role in the pathophys¬
iology of the hemostatic derangement in patients with
ruptured AAA is currently being investigated.
In conclusion, these novel data demonstrate that
ruptured AAA repair is associated with inhibition of
systemic fibrinolysis and intense thrombin genera¬
tion. This procoagulant state may contribute to
microvascular and macrovascular thrombosis that, in
turn, lead to the common causes of perioperative
morbidity and mortality, namely myocardial infarc¬
tion, multiple organ failure, and thromboembolism.
We thank Pamela Dawson, Department of Haema-
tologv, Royal Infirmary of F.d in burgh, and Wesley Stuart,
Vascular Surgery Unit, Royal Infirmary of Edinburgh, for
technical assistance.
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INVITED COMMENTARY
Regarding "Coagulation and fibrinolysis
in patients undergoing operation for
ruptured and nonruptured infrarenal
abdominal aortic aneurysms"
Kenneth Ouriel, MD, Cleveland, Ohio
The rupture of an abdominal aortic aneurysm is
associated with death in the vast majority of patients
in whom it occurs. One of the most eye-opening
demonstrations of the lethality of the problem is the
population-based report from Malmd in which 88%
of the patients with ruptured aortic aneurysms died,
most ofwhom did not survive to reach the hospital.'
Lowering the rate of mortality would require the
development of a screening program to identify
individuals with aortic aneurysms so that elective
repair could be performed before rupture. The real¬
ity of such an approach is uncertain, and the cost
effectiveness is questionable. As such, the institution
of global methods to identify and repair the great
number of asymptomatic aneurysms is a matter of
public policy and poorly controllable by the vascular
practitioner.
By contrast, vascular surgeons have the potential
to alter patient survival rates for those patients who
arrive at the hospital alive. Anecdotally, it appears
that intraoperative mortality rate has, indeed,
decreased over time, but the chance of surviving
to discharge remains only one in two for these
patients.2 Vascular surgeons and anesthesiologists
have become remarkably effective at getting patients
with ruptured aneurysms through the operation
itself, but the perioperative mortality rate remains
depressingly high. Thrombotic complications pre¬
dominate during the early postoperative period,
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including myocardial infarction, lower extremity and
intestinal ischemia, stroke, and venous thromboem¬
bolism. The frequency of these events must be lim¬
ited if a decrease in the in-hospital mortality rate is
to be achieved.
The work ofAdam and colleagues sheds light on
possible mechanisms to explain the increased inci¬
dence of thrombotic events in patients who undergo
repair of ruptured aortic aneurysms. The crux of
their work is based on the assumption that throm¬
botic events occur as a result of an imbalance
between rhrombogenesis (thrombin generation vs
natural anticoagulant pathways) and endogenous
thrombolysis (plasminogen activation vs plasmino¬
gen activator inhibition and antiplasmin activity).
Elucidation of these mechanisms provides critical
information that can be used to design treatments
directed at the prevention of intravascular thrombo¬
sis, thereby decreasing the rate of associated periop¬
erative thrombotic complications. In this regard, it is
likely that similar mechanisms underlie the patho¬
physiology of thrombotic events after many periph¬
eral vascular procedures, as well as major operative
procedures in general.
There are two major findings of this study, both of
which relate to the development of a hypcrcoagulablc
state before and during the repair of ruptured
aneurysms. First, the investigators detected markers of
intense thrombin generation in these patients, with
elevation of thrombin-antithrombin complexes and
prothrombin fragments 1 and 2. Second, reduced
endogenous tissue plasminogen activator (t-PA) activ¬
ity was seen, explainable by marked elevations in plas¬
minogen activator inhibitor (PAI). The PAI activity
was high enough to account for the diminished t-PA
activity in spite of an increase in the levels of circulat¬
ing t-PA antigen. This apparent paradox is easily
understood when one considers that total t-PA anti¬
gen measures both unbound (active) t-PA as well as
765
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the inactive t-PA bound to inhibitors such as PAI-1.
In fact, the importance of measuring t-PA activity
rather than antigen underlies apparent contradictions
between diis study and a previous investigation ofour
own, where elevations in t-PA antigen were thought
to account for an increased incidence of bleeding after
supraceliac aortic cross clamping.
It is important to note that the present study
compared the levels of markers of coagulation and
fibrinolysis in patients with ruptured versus elective
aneurysm repair. Interesting findings are revealed
when the levels in the elective group are compared
with the normal range. For instance, even the group
of patients who underwent elective aneurysm repair
manifested mild elevations in prothrombin frag¬
ments 1 and 2, indicative of ongoing thrombin gen¬
eration. t-PA and PAI were, however, within the
range of normal before, during, and after operation.
These findings suggest that a procoagulant state is
present at baseline in patients with aneurysms, pri¬
marily related to increased thrombin generation.
This contention, however, may be spurious, related
to an increase in prothrombin fragments in blood
drawn from the arterial lines of patients with
aneurysms rather than the potentially less traumatic
venous sticks used for determining the normal
range. Nevertheless, it corroborates previous work
from a variety of investigators, documenting signifi¬
cant coagulation derangements in patients with
abdominal aortic aneurysms.3'4
There are some potential limitations of the
authors' work. There exist unavoidable demographic,
anatomic, and pharmacologic differences in patients
with ruptured versus non-ruptured aneurysms. P'or
instance, the patients widi ruptured aneurysms may be
older, with an increased frequency of coexistent med¬
ical illnesses. As well, these patients have larger
aneurysms widi a greater amount ofpotentially throm-
bogcnic surface area exposed to blood How. Lasdy, the
pharmacologic profile implemented in patients with
ruptured and non-ruptured aneurysms is quite differ¬
ent, most importantly with respect to the use of
heparin, but also with regard to vasoactive agents, such
as epinephrine and dopamine—agents that can have
significant effects on coagulation, platelet function,
and endothelial physiology.
Despite these potential drawbacks, the present
work represents a carefully designed and well-execut¬
ed study of coagulation and fibrinolytic derangements
in patients with ruptured aortic aneurysms. Although
the observations must be corroborated by subse¬
quent, larger studies, a major value of the present
study resides in the fact that it will generate cog¬
nizance of these hemostatic derangements. Clinical
results can only be improved through the acquisition
of sound research data gained from investigations
such as this. Novel techniques and strategies are, of
necessity, formulated and implemented on the basis of
fundamental research. It is incumbent on lis to assure
a continuing supply of well-trained vascular surgeons
with education sufficient to critique research studies
and, in many cases, design and conduct investigations
themselves. Training of academically inclined vascular
surgeons will ensure adequate growth in the fund of
knowledge relating to vascular disease and, ultimately,
bring about great improvements in patient care and
clinical outcome.
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Hemostatic markers before operation in patients
with acutely symptomatic nonruptured and
ruptured infrarenal abdominal aortic aneurysm
Donald J. Adam, FRCSEd,1 Paul C. Haggart, BSc, AFRCSEd,b Christopher A. Ludlam, PhD, FRCP,c
and Andrew W. Bradbury, BSc, MD, FRCSEd,b Birmingham, United Kingdom
Background: In patients with acutely symptomatic but nonruptured abdominal aortic aneurysm (AAA), emergent repair
is associated with an increased mortality rate as compared with semi-elective repair. Previous results have shown that
ruptured but not asymptomatic AAA repair is associated with intense thrombin generation and inhibition of systemic
fibrinolysis. The purpose of this study was to determine whether circulating markers of coagulation and fibrinolysis
may be used to distinguish acutely symptomatic nonruptured and ruptured AAA.
Methods: A prospective study was performed of 44 patients who underwent emergency AAA repair for suspected rup¬
ture. Platelet count, fibrinogen level, prothrombin time, activated partial thromboplastin time, tissue plasminogen acti¬
vator (t-PA) activity, plasminogen activator inhibitor (PAI) activity, prothrombin fragment (PF) 1+2 level, and D dimer
level were measured before surgery.
Results: When compared with ruptured AAAs (n = 37), acutely symptomatic nonruptured AAAs (n = 7) were associ¬
ated with increased fibrinogen level (P = .033), reduced activated partial thromboplastin time (P = .043), increased t-
PA activity (P = .023), reduced PAI activity (P = .005), reduced PF 1+2 level (P = .001), and reduced D dimer level (P
= .005; all P values determined with Mann-Whitney test). The differences in t-PA activity (P = .01), PAI activity (P =
.004), and PF 1+2 level (P = .01) persisted in patients whose conditions were normotensive. In all patients, a PF 1+2
level of greater than or equal to 2.5 nmol/L was associated with a sensitivity, specificity, and positive and negative pre¬
dictive value for rupture of 89%, 86%, 97%, and 60%, respectively. In patients whose conditions were normotensive, PAI
activity of greater than or equal to 16 AU/ml was associated with a sensitivity, specificity, and positive and negative
predictive value of 83%, 100%, 100%, and 88%, respectively.
Conclusion: These data show that acutely symptomatic nonruptured AAA is associated with increased systemic fibri¬
nolysis (caused by reduced fibrinolytic inhibition) and reduced thrombin generation as compared with rupture.
Preoperative hemostatic markers, particularly PF 1+2 level and PAI activity, may distinguish acutely symptomatic non¬
ruptured from ruptured AAA. (J Vase Surg 2002;35:661-5)
In the United Kingdom, more than 50% of all abdom¬
inal aortic aneurysm (AAA) repairs are performed on an
emergency basis because the surgeon believes, or is unable
to exclude the possibility, that rupture has occurred.
However, in approximately 20% of these patients, the AAA
is found to be intact, and sudden expansion or impending
rupture are presumed to be responsible for the patient's
symptoms.1 The operative mortality rate for this group of
patients is twice that of symptomatic patients in whom
rupture is not suspected and who do not undergo opera¬
tion on an emergency basis.1"4
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At present, acutely symptomatic nonruptured AAAs
are differentiated from ruptured AAAs primarily on the
basis of history and examination, but even the most expe¬
rienced of vascular surgeons cannot always confidently
exclude rupture with clinical assessment alone.5 Many clin¬
icians have advocated the use of emergency computed
tomographic (CT) scanning in this situation, but previous
results from this group have shown that, in cases of true
clinical uncertainty, CT scan has an unacceptably low sen¬
sitivity and specificity.6 Previous results from this group
have also shown that ruptured AAA is. associated with
intense thrombin generation and inhibition of systemic fib¬
rinolysis.7 To date, there are no reports ofhemostatic func¬
tion in patients with acutely symptomatic nonruptured
AAA. We.hypothesised that, because acutely sympto¬
matic nonruptured AAA is not associated with extramural
hemorrhage, this group of patients would not manifest the
same pattern of hemostatic derangement as patients with
rupture. As such, hemostatic variables might aid clinical
decision-making regarding the timing of surgery in
patients with acutely symptomatic nonruptured AAA. The
aims of this study were two-fold. The first aim was the
examination of whether patients who undergo repair of
acutely symptomatic nonruptured AAA exhibited the same
hemostatic derangement as those who underwent opera-
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Big 1. Preoperative tissue plasminogen activator activity in
acutely symptomatic and ruptured abdominal aortic aneurysm.
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Fig 2. Preoperative plasminogen activator inhibitor activity in
acutely symptomatic and ruptured abdominal aortic aneurysm.
Upper limit of healthy range is shown with horizontal lino.
tion for rupture. The second aim was the determination of
the feasibility of hemostatic markers as diagnostic adjuncts.
METHODS
Patients. Forty-four patients who underwent emer¬
gency operation for suspected rupture of infrarenal AAA
were prospectively studied. At operation, 37 patients (33
men and four women; median age, 74 years; range, 63 to
87 years) were found to have ruptured AAAs and seven
men (median age, 68 years; range, 65 to 74 years) had
nonruptured AAAs. Thirty-one patients widi rupture had
at least one documented episode of hypotension (systolic
blood pressure, <100 mm Hg) before surgery. Seven
patients with acutely symptomatic nonruptured AAAs and
six patients with rupture were not hypotensive before
surgery. The clinical data for both groups of patients are
shown in Table I. Rupture was defined by the presence of
fresh retroperitoneal or intraperitoneal blood in the pres¬
ence of an aortic aneurysm with no other identifiable
cause for the findings. In patients with acutely sympto¬
matic nonruptured AAAs, sudden expansion or impending
rupture were presumed to be responsible for the clinical
findings because there were no other identifiable causes.
Table I. Clinical data for patients with acutely sympto¬





























Stroke 4 . -
Peripheral arterial occlusive disease 2 -
Venous thromboembolism - 1
Chronic obstructive airways disease 6 -











Angiotensin-converting enzyme 6 1
inhibitor
Calcium-channel blocker 4 1
Beta-adrenoceptor blocker 1 1
Bronchodilator 6 -
AAA, Abdominal aortic aneurysm; M, male; F, female; BP, blood pressure.
Sample collection. Blood was sampled from an
indwelling arterial line immediately before the induction
of anesthesia. No patients underwent a blood transfusion
before blood sampling. The samples were placed immedi¬
ately on ice and centrifuged within 30 minutes of collec¬
tion at 3000 revolutions per minute for 30 minutes at4°C
(equivalent to 1400^). Plasma was separated and stored at
-70°C for later batch analysis.
Markers of thrombin generation and fibrinolysis.
Platelet count, fibrinogen level, prothrombin time (PT),
and activated partial thromboplastin time (aPTT) were
measured in the routine hematology laboratory. Plasma
prothrombin fragment (PF) 1+2 (healthy range, 0.4 to
1.1 nmol/L) was assayed as a marker of thrombin gener¬
ation. Plasma tissue plasminogen activator (t-PA) activity
(healthy range, 0.2 to 2.0 IIJ/mL) and plasminogen acti¬
vator inhibitor (PAI) activity (healthy range, <15
AU/mL) 'were assayed as markers of primary systemic fi¬
brinolysis. D dimer (healthy range, 630 to 850 ng/mL)
was assayed as a marker of secondary fibrinolysis. The
healthy range for each hemostatic marker was determined
by the manufacturer of the assay. Details of the commer-
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Symptomatic Rupture Symptomatic Rupture
Pig 3. Preoperative prothrombin fragment 1+2 level in acutely Pig 4. Preoperative D dimer level in acutely symptomatic and
symptomatic and ruptured abdominal aortic aneurysm. Upper ruptured abdominal aortic aneurysm. Upper and lower limits of
and lower limits of healthy range are shown with horizontal lines. healthy range are shown with horizontal lines.
Table II. Fibrinogen, platelet count, prothrombin time, and activated partial thromboplastin time in patients who
underwent operation for acutely symptomatic nonruptured and ruptured abdominal aortic aneurysm (median; range)
Assay Healthy range Ruptured AAA (n - 37) Nonruptured AAA (n = 7) lvalue'





Platelet count 150 - 350 x 109/L 178 x 109/L
(40 - 360 x 109/L)
183 x 109/L
(75 - 292 x 109/L)
NS
PT 10.5 - 14.5 seconds 14.3 seconds
(9 - 126 seconds)
11.8 seconds
(10 - 100 seconds)
NS
aPTT 28 - 40 seconds 33 seconds
(26 - 210 seconds)
29 seconds
(26 - 36 seconds)
.043
"P value determined with Mann-Whitney test.
AAA, Abdominal aortic aneurysm; PT, prothrombin time; &PTT, activated partial thromboplastin time.
daily available assays of coagulation and fibrinolysis have
been described in a previous report.7
Statistical methods. The Mann-Whitney test was
used for the comparison of groups ofpatients. A probabil¬
ity value of less than .05 was regarded as statistically sig¬
nificant. The sensitivity, specificity, and positive and
negative predictive values of each assay (alone and in com¬
bination) for the diagnosis of ruptured AAA as compared
with operative findings were determined.
RESULTS
Clinical data. There were no deaths after repair of
acutely symptomatic nonruptured AAA. The inhospital
mortality rate for repair of ruptured AAA was 16 of 37
patients (43%): seven patients died during surgery or
within 24 hours of repair, and nine patients died in the late
postoperative period. There were no deaths among the six
patients with ruptured AAAs whose conditions were nor-
motexasive before surgery.
Markers of fibrinolysis and thrombin generation.
The median and range values for preoperative platelet
count, fibrinogen level, PT, and aPTT are shown in Table
II. The median and range values for preoperative t-PA
activity, PAI activity, PF 1+2, and D dimer levels are
shown in Table III. When compared with ruptured AAA,
acutely symptomatic nonruptured AAA was associated
with significantly higher fibrinogen level (P = .033),
reduced aPTT (P = .043), increased t-PA activity (P =
.023; Fig 1), reduced PAI activity (P = .005; Fig 2),
reduced PF 1+2 level (P = .001;.Fig 3), and reduced D
dimer level (P = .005; Fig 4).
When the seven normotensive patients with acutely
symptomatic nonruptured AAA were compared with the
six normotensive patients with rupture, .there was no sig¬
nificant difference in platelet count, fibrinogen level, PT,
aPTT, or D dimer level. However, the differences in t-PA
activity (nonruptured: median, 1.7 IU/mL; range, 0.75
to 3.2 IU/mL; versus ruptured: median, 0.22 IU/mL;
range, 0.11 to 1.0 IU/mL; P = .01), PA activity (non¬
ruptured: median, 6.3 AU/mL; range, 3.2 to 15.4
AU/mL; versus ruptured: median, 30.3 AU/mL; range,
12.1 to 37.6 AU/mL; P= .004), and PF 1+2 level (non¬
ruptured: median, 2.1 nmol/L; range, 1.1 to 5.2 nmol/L;
versus ruptured: median, 5.3 nmol/L; range, 2.5 to 6.8
nmol/L; P = .01) were maintained.
In ruptured AAA, there was no significant difference
in any of the markers between patients with hypotensive
and normotensive conditions or between patients with
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Table III. Tissue plasminogen activator activity, plasminogen activator inhibitor activity, prothrombin fragment 1+2
level, and D dimer level in patients who underwent operation for acutely symptomatic nonruptured and ruptured
abdominal aortic aneurysm (median; range)
Ruptured AAA Nonruptured AAA P
Assay Healthy range (n = 37) (n = 7) value *
t-PA activity 0.2 - 2.0 IU/mL 0.28 IU/mL
(0.06 - 9.6 IU/mL)
1.7 IU/mL
(0.75 - 3.2 IU/mL)
.023
PAI activity <15 AU/mL 31 AU/mL




PF 1+2 level 0.4-1.1 nmol/L 6.4 nmol/L
(1.1 - 13.3 nmol/L)
2.1 nmol/L
(1.1 - 5.2 nmol/L)
.001
D dimcr level 630 - 850 ng/mL 4108 ng/mL
(155 - 25,947 ng/mL)
1633 ng/mL
(753 - 3014 ng/mL)
.005
"P value determined with Mann-Whitney test.
AAA, Abdominal aortic aneurysm; t-PA, tissue plasminogen activator; PAI, plasminogen activator inhibitor; PF, prothrombin fragment.
retroperitoneal or intraperitoneal hemorrhage. Non-
survivors had significantly lower platelet counts (nonsur¬
vivors: median, 126 x 109/L; range, 40 to 321 x 109/L;
versus survivors: median, 224 x 109/L; range, 97 to 360
x 109/L; P= .005), lower fibrinogen levels (nonsurvivors:
median, 2.03 g/L; range, 0.46 to 6.31 g/L; versus sur¬
vivors: median, 2.8 g/L; range, 0.86 to 5.9 g/L; P =
.007), and prolonged aPTT (nonsurvivors: median, 39
seconds; range, 28 to 210 seconds; versus survivors:
median, 31 seconds; range, 26 to 142 seconds; P = .01) as
compared with survivors. There was no significant differ¬
ence in t-PA activity, PAI activity, or PF 1+2 level between
survivors and nonsurvivors, but D dimer level was signifi¬
cantly higher in nonsurvivors (P = .046).
When all patients were examined, PF 1+2 level was the
most accurate assay for distinguishing nonruptured from
ruptured AAA. With the upper limit of the healthy labo¬
ratory range for PF 1+2 level as a diagnostic cut-off (>1.1
nmol/L), the test had a high sensitivity (36 of 37; 97%)
and positive predictive value (36 of 41; 88%) but low
specificity (1 of 7; 14%) and negative predictive value (1 of
2; 50%) for the diagnosis of ruptured AAA. When the cut¬
off for PF 1+2 was increased to greater than or equal to
2.5 nmol/L, the test had a high sensitivity (33 of 37;
89%), specificity (6 of 7; 86%) and positive predictive value
(33 of 34; 97%), but low negative predictive value (6 of
10; 60%). When only patients with normotensive condi¬
tions were examined, PAI activity was the most accurate
assay for distinguishing acutely symptomatic nonruptured
from ruptured AAA. PAI activity higher than the healthy
range (>15 AU/mL) had a high sensitivity (5 of 6; 83%)
and specificity (6 of 7; 86%) and a high positive (5 of 6;
83%) and negative predictive value (6 of 7; 86%) for the
diagnosis of rupture. When the cut-off for PAI activity was
increased to greater than or equal to 16 AU/mL, the sen¬
sitivity and specificity was 5 of 6 (83%) and 7 of 7 (100%)
and the positive and negative predictive values were 5 of 5
(100%) and 7 of 8 (88%), respectively.
DISCUSSION
Hemostatic derangement is central to the thrombotic
and hemorrhagic complications that are responsible for the
considerable majority of the major morbidity and mortality
associated with aortic aneurysm surgery.7"9 Before surgery,
asymptomatic AAA is associated with increased thrombin
generation10"13 and essentially healthy systemic fibrinolytic
activity in most cases,14"16 although a proportion of cases
show increased systemic fibrinolysis.7 By contrast, hypoten¬
sive patients with ruptured AAA have evidence of increased
thrombin generation and inhibition of systemic nbrinofy-
sis.7 The findings of this study corroborate the finding of a
previous report,7 provide further insight into the patho¬
physiology of hemostasis associated with ruptured AAA,
and reveal novel data regarding hemostasis in patients with
acutely symptomatic nonruptured AAA..
The principal finding of this study is that acutely
symptomatic nonruptured AAA is associated with increased
primary systemic fibrinolysis, reduced secondary fibrinoly¬
sis, and reduced thrombin generation as compared with
ruptured AAA. The lower t-PA activity in ruptured AAA
may be caused by increased inhibition of systemic fibrinol¬
ysis (as shown with elevated PAI activity), a finding that
was not present in the patients with acutely symptomatic
nonruptured AAA. D dimer is a marker of secondary fi¬
brinolysis, which occurs in response to thrombus forma¬
tion and acts to restore microvascular patency. D dimer
and PF 1+2 levels were elevated in both groups ofpatients
but to a greater extent in the ruptured AAA group.
These differences in coagulation and fibrinolysis were
also observed when the normotensive patients with acutely
symptomatic nonruptured AAA were compared with nor¬
motensive patients with rupture. No such differences were
present when normotensive and hypotensive patients with
ruptured AAA were compared. These findings suggest that
hemorrhage rather than hypotension may be one of die
principal mechanisms that triggers the generalized proco-
agulant state in patients with ruptured AAA.
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The findings of this study may be explained if one con¬
siders that sudden expansion or impending rupture of an
aortic aneurysm is analogous to an aortic dissection.
Fibrinolytic gene expression and focal fibrinolytic activity
have been shown within the aortic wall of patients with
asymptomatic AAA,17-18 and aortic adventitia is associated
with elevated fibrinolytic activator activity.19"21 Sudden
expansion leads to bloodflow in the marginal thrombus
adjacent to the diseased aortic wall, and as the surface area
of aortic adventitia exposed to blood flow increases, there
is increased local and systemic fibrinolysis.19 Aneurysm
rupture and subsequent hemorrhage trigger a procoagu-
lant and hypofibrinolytic state that acts to minimize local
blood loss but has die detrimental effect of stimulating
microvascular and macrovascular thrombosis.
Many clinicians have advocated the use of emergency
CT scanning to differentiate acutely symptomatic nonrup-
tured AAA from rupture. Although these early studies
reported acceptable diagnostic accuracy, the conclusions
were limited by the fact that a significant proportion of
patients did not undergo operation and thus CT scan find¬
ings could not be correlated with operative findings.6
Previous results from this group have shown that, in
cases of true clinical uncertainty, CT scanning has an unac-
ceptably low sensitivity and specificity of 79% and 77%,
respectively, in patients with hemodynamically stable con¬
ditions.6 There are no data to show that advances in CT
technology have been associated with improved diagnos¬
tic accuracy in this clinical situation.
In this study, there was no significant difference in
platelet count, fibrinogen level, PT, aPTT, or D dimer
level between normotensive patients with nonruptured
and ruptured AAA. There were, however, significant dif¬
ferences in t-PA activity, PAI activity, and PF 1+2 level.
Furthermore, preoperative PAI activity greater than or
equal to 16 AU/mL was more accurate than our experi¬
ence with emergency CT scanning in these patients with
hemodynamically stable conditions. Although the mea¬
surement of PAI activity may distinguish acutely sympto¬
matic nonruptured AAA from ruptured AAA, currently,
the time taken to prepare tire plasma and perform the
assay (approximately 2 hours) precludes its use as a diag¬
nostic adjunct. The small numbers ofpatients studied with
nonruptured AAA do not allow the authors to reach
strong conclusions or make firm clinical recommendations.
However, should a rapid assay for PAI activity become avail¬
able, then it may be ofvalue in distinguishing rupture from
nonrupture in normotensive patients who are seen with
acutely symptomatic aneurysms.
In conclusion, these novel data show that patients
with acutely symptomatic nonruptured AAAs do not man¬
ifest the same pattern of hemostatic derangement evident
in patients with rupture. Preoperative PAI activity higher
than the healthy range was more accurate than our expe¬
rience with CT scanning in patients who were hemody¬
namically stable with suspected ruptured AAAs.
We thank Pamela Dawson, Department of Haematol-
ogy, Royal Infirmary ofEdinburgh, for technical assistance.
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Plasma endothelin levels and outcome in patients
undergoing repair of ruptured infrarenal
abdominal aortic aneurysm
Donald J. Adam, FRCSEd,■> Stephen M. Evans, BSc, FRCSEd,' David J. Webb, MD, FRCl',b and
Andrew W. Bradbury, BSc, MD, FRCSEd,c Edinburgh and Birmingham, United Kingdom
Background: Eiidothclin-1 (ET-1) is die most potent known vasoconstrictor. Elevated plasma levels have been demon¬
strated in patients with myocardial infarction, cardiogenic and septic shock, and respiratory, heart, and kidney failure,
as well as in those undergoing elective abdominal aortic aneurysm (AAA) repair. However, cndothclin levels have not
previously been examined in patients undergoing repair of ruptured AAA. Wc hypothesized that hemorrhagic shock,
lower torso ischemia, and rcpcrfusion associated with ruptured AAA repair lead to increased synthesis and secretion of
ET-1, which, in turn, predispose to organ failure, one of the principal causes of death in this condition.
Methods: Fourteen patients were studied. Plasma levels of big ET-1 and ET-1 were measured immediately before oper¬
ation and immediately before, 5 minutes, and 6 hours after aortic clamp release.
Results: All patients survived for at least 24 hours after operation. Big ET-1 levels were above the normal range at
one or more sample points in all patients, and the ET-1 levels were above the normal range in all survivors and four
of five nonsurvivors. Five patients who died of organ failure had significantly lower big ET-1 levels at all sample
points and significantly lower ET-1 levels after 5 minutes of rcpcrfusion when compared with survivors. Preoperative
ET-1 levels were significantly lower in eight patients who subsequently developed kidney failure than in six patients
who did not.
Conclusion: Contrary to our original hypothesis, these novel data demonstrate that patients with ruptured AAA in
whom fatal postoperative organ failure develops have significantly lower perioperative cndothclin levels than survivors.
(J Vase Surg 2001;33:1242-6.)
Endothclin-1 (ET-1) is the most potent known vaso¬
constrictor. It is principally secreted abluminally from vas¬
cular endothelial cells but may enter the circulation if
concentrations are high at the endothelial cells-vascular
smooth muscle interface.1 ET-1 leads to vasoconstriction
in resistance vessels, especially the coronary, cerebral, and
renal circulation, by acting on ETA receptors in vascular
smooth muscle cells, and ETjj receptors on vascular
smooth muscle and endothelial cells. Big ET-1 is the
immediate precursor of ET-1, and its conversion to bio¬
logically active ET-1 by endothclin-convcrting enzymes
occurs mainly in the vessel wall.2-3 Big ET-1 is detectable
in the plasma for considerably longer than ET-1,4 and
increased plasma levels of big ET-1 are considered to rep¬
resent increased ET-1 generation. Elevated plasma
endothelin levels may form part of a homcostatic response
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to maintain systemic blood pressure5 and have been
demonstrated in critically ill patients with myocardial
infarction,6 cardiogenic shock,7 septic shock,3 adult respi¬
ratory distress syndrome,9 heart failure,10-11 and acute kid¬
ney failure.12 To date, several animal and human studies of
septic shock have suggested that endothclin release may be
pathologic1318 or homcostatic.18-19 Increased plasma
endothclin levels have been demonstrated in patients
undergoing nonrupturcd abdominal aortic aneurysm
(AAA) repair with infrarenal20-21 and supraccliac aortic
cross-clamping,22 as well as in one animal model of
infrarenal aortic clamping and subsequent exsanguina-
tion.23 To date, however, there arc no reports of the
endothclin response in patients undergoing repair of rup¬
tured AAA. The aim of this study was to examine, for the
first time, perioperative changes in plasma levels of big ET-
1 and ET-1 in patients undergoing repair of ruptured
AAA. We hypothesized that hemorrhagic shock, ischemia,
and rcpcrfusion would lead to increased synthesis and
secretion of endothelin, which would predispose to the
development of organ failure, one of the principal causes
of death in this group of patients.
METHODS
Patients. Fourteen consecutive patients (13 men and
1 woman of median age 74 years; range, 65-86) who
underwent repair of ruptured infrarenal AAA and survived
to at least 24 hours after surgery were prospectively stud¬
ied. Lothian Research Ethics Committee approval was
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Fig 1. Individual data points for big ET-1 immediately before
induction of anesthesia (sample A), immediately before release of
aortic clamp, (sample B), and 5 minutes (sample C), and 6 hours
(sample D) after aortic clamp release in 14 patients who under¬
went operation for ruptured AAA. Survivors (n = 9) are repre¬
sented by black squares and nonsurvivors (n = 5) by black circles.
Normal laboratory range for big ET-1 (10-60 pg/mL) is shown
by parallel horizontal lines. Mann-Whitney U test was used to test
whether medians of samples in survivors and nonsurvivors were
significantly different from each other at each sample point. A P
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Fig 2. Individual data points for ET-1 immediately before induc¬
tion of anesthesia (sample A), immediately before release of aor¬
tic clamp, (sample B), and 5 minutes (sample C), and 6 hours
(sample D) after aortic clamp release in 14 patients who under¬
went operation for ruptured AAA. Survivors (n = 9) are repre¬
sented by black squares and nonsurvivors (n = 5) by black circles.
Normal laboratory range for ET-1 (1.5-4.5 pg/mL) is shown by
parallel horizontal lines. Mann-Whitney U test was used to test
whether medians of samples in survivors and nonsurvivors were
significantly different from each other at each sample point. A P
value less than .05 was regarded as statistically significant. NS,
Not significant.
obtained. The median (range) delay between the onset of
symptoms of rupture and hospital admission was 5 (3-14)
hours. All patients had at least one documented episode of
hypotension (systolic blood pressure <100 mm Hg)
before surgery.
Operative methods. Ruptured AAA was defined by
the presence of fresh retroperitoneal blood at operation.
No patient had intraperitoneal rupture. All patients under¬
went AAA repair under general anesthesia through a trans¬
verse supraumbilical incision with infrarenal aortic
cross-clamping. No patient required suprarenal aortic
clamping. An aortoaortic graft was inserted in 10 patients,
an aortobifemoral graft in three, and an aortobiiliac graft
in one patient.
Sample collection and assay methods. Blood (8.2
mL) was obtained from an indwelling radial arterial line
and placed into ethylenediamine tetra-acetic acid (2.7 mL)
for estimation of hematocrit, and lithium heparin (5.5
mL) for estimation of big ET-1 and ET-1. Blood was sam¬
pled immediately before the induction of anesthesia (sam¬
ple A), immediately before aortic clamp release (sample
B), and 5 minutes (sample C) and 6 hours (sample D)
after aortic clamp release. Samples were placed immedi¬
ately on ice and spun in a centrifuge within 30 minutes of
collection at 1400// for 30 minutes at 4°C. Plasma was
separated and stored at -70°C for later batch analysis.
Hematocrit was estimated in the routine hematology
laboratory with the fully automated Sysmex NE 8000 ana¬
lyzer (Sysmex, Milton Keynes, UK). Plasma immunoreac-
tive big ET-1 and ET-1 concentrations were measured by
use of an acetic acid extraction technique24 and a modified
commercial radioimmunoassay with rabbit antihuman big
ET-1 or ET-1 (Peninsula Laboratories Europe, St Helens,
UK). Sample extract was incubated with either big ET-1
or ET-1 antibody for 24 hours at 4°C. After incubation,
125-labeled big ET-1 (Peninsula Laboratories Europe) or
ET-1 (NEN Life Science Products, Boston, Mass) was
added, and incubation was continued for an additional 20
minutes at 4°C. Complexes were precipitated with
Amerlex donkey antirabbit antibody (Amersham Life
Sciences Limited, UK) and counted for radioactivity. The
lower limits of detection for the big ET-1 and ET-1 assays
are 1 pg/mL and 0.25 pg/mL, respectively. The normal
laboratory range for big ET-1 is 10 to 60 pg/niL, and for
ET-1 1.5 to 4.5 pg/mL.
Definitions of postoperative organ failure. Cardiac
failure was defined as arrhythmia requiring pharmacologic
treatment to maintain cardiovascular stability and/or sus¬
tained periods of hypotension (mean arterial pressure < 60
mm Hg) requiring fluid resuscitation and inotropic sup¬
port. Respiratory failure was defined as hypoxia requiring
mechanical ventilatory support for more than 4 days.
Kidney failure was defined as elevated serum creatinine
level greater than or equal to 250 pmol/L and/or the
requirement for renal replacement therapy. Disseminated
intravascular coagulation was defined as clinical evidence
of hemorrhage accompanied by laboratory evidence of
thrombocytopenia, prolonged clotting times, hypofibrino-
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Table I. Clinical and operative data
Survivors (11 - 9) Nousiirviviirs (n = 5)
Median Range Median Range P valiti
Preoperative
Duration of symptoms (h) 4 (3-14) 6 (5-12) NS
Serum creatinine level (gmol/L) 138 (82-176) 115 (77-183) NS
Intravenous fluid administration before clamping (L) 0.5 (0.2-5.5) 0.7 (0.1-1.0) NS
Intraoperative
Total operation time (min) 140 (75-240) 105 (75-200) NS
Aortic clamp time (min) 90 (40-185) 75 (55-135) NS
Measured blood loss (L) 4.0 (1.0-6.4) 3.3 (1.5-11.0) NS
Crystalloid and colloid administration (L) 3.4 (1.5-8.0) 3.8 (3.5-5.0) NS
pREC administration (units) 8 (5-11) 8 (6-22) NS
FFP administration (units) 2 (2-6) 2 (2-12) NS
Platelet administration (bags)f 1 (1) 1 (0-1) NS
pRUC, Packed red blood cells (300 mL); Fl:l\ fresh frozen plasma (300 mL).
"Mann-Whitney U test.
"fOnc bag of platelet transfusion = 4 pooled units (250 mL).
gcncmia, and elevated levels of fibrin/fibrinogen degrada¬
tion products.
Statistical methods. The Mann-Whitney U test was
used to test whether the medians of samples in survivors
and nonsurvivors were significantly different from each
other and to examine whether there was a difference in
levels between patients who had postoperative organ fail¬
ure compared with patients who did not. The Kruskal-
Wallis one-way analysis of variance was used to examine
whether assay levels changed significantly over the four
sampling points in survivors and nonsurvivors. A P value
of less than .05 was regarded as statistically significant.
RESULTS
Clinical data. All patients were admitted to the
intensive therapy unit after operation. All patients survived
for at least 24 hours after operation, but five (36%) died in
the postoperative period. Clinical and operative data for
survivors and nonsurvivors arc summarized in Table I, and
postoperative complications arc shown in Table II.
Plasma levels of big ET-1 and ET-1. There was no
significant difference in hematocrit between survivors and
nonsurvivors at any of the sample points. The values of big
ET-1 and ET-1 in survivors and nonsurvivors are shown in
Figs 1 and 2, respectively. The big ET-1 level was above
the normal laboratory range at one or more sampling
points in all patients, and the ET-1 level was above the
normal range in all survivors and four of five nonsurvivors.
When compared with nonsurvivors, survivors had signifi¬
cantly higher levels of big ET-1 at all four sampling points
and significantly higher levels of ET-1 after 5 minutes'
rcpcrfusion than nonsurvivors. When compared with pre¬
operative levels, there was a significant increase in big ET-
1 levels after 6 hours of rcpcrfusion in survivors. In
nonsurvivors, there was a significant increase in ET-1 lev¬
els between 5 minutes and 6 hours after rcpcrfusion.
Preoperative ET-1 levels were significantly lower in eight
patients who subsequently had kidney failure (median,
3.72; range, 2.76-6.0 pg/mL) than in six patients who did
not (median, 5.89; range, 3.86-7.23 pg/mL; P = .02).
There was no significant difference in big ET-1 or ET-1
levels between patients who did and did not have cardiac
failure, respiratory failure, or disseminated intravascular
coagulation.
DISCUSSION
This study is the first to examine the relationship
between perioperative endothclin levels, organ failure, and
death in patients undergoing ruptured AAA repair. The
principal finding is that, contrary to our original hypothe¬
sis, patients who died had significantly lower perioperative
endothclin levels than survivors.
Previous studies of the endothclin response to lower
torso ischemia and rcpcrfusion arc few and contradictory.
Antonucci et al2" examined the effect of intraoperative
nifedipine infusion on cndothclin-dependcnt renal vaso¬
constriction in five patients undergoing nonrupturcd
infrarcnal AAA repair and demonstrated a transient but
significant increase in plasma ET-1 and -2 levels at the end
of the period of aortic cross-clamping. The authors con-
eluded that nifedipine prevented the renal vasoconstrictor
response to endothclin because there was no significant
difference in creatinine clearance and glomerular filtration
rate after operation compared with before operation.
Fukuda et ai21 measured arterial and iliac vein ET-1 levels
in seven patients undergoing elective aortic aneurysm
repair. There was no significant change in arterial ET-1
levels, but a significant increase in iliac vein ET-1 levels
occurred immediately after aortic clamp release and perfu¬
sion of the first limb. Venous ET-1 levels showed a signif¬
icant correlation with venous 02 content, pFI, partial
pressure of oxygen 02, 02 saturation, and base excess sug¬
gesting that ET-1 production occurred because of lower
limb ischemia. Lintott et al22 were the first to attempt to
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examine the relationship between ET-1 levels and out-
eome in 21 patients who required supraceliae and eight
who required infrarenal aortic clamping for repair of
nonruptured aortic aneurysm. Unlike the studies by
Antonucci et ai2() and Fukuda et al,21 plasma ET-1 was
undetectable during the period of aortic clamping and 30
minutes after aortic declamping. After 2 hours of rcperfu-
sion, ET-1 levels were significantly higher in patients in
whom acute kidney failure developed after supraceliac
clamping, and at 8 hours, ET-1 levels were significantly
higher in the supraceliae clamp group compared with the
infrarenal clamp group. In a canine model of infrarenal
aortic clamping, Edwards et al2-' failed to demonstrate a
significant increase in plasma ET-1 levels during hind limb
ischemia, but there was a significant increase during reper-
fusion and subsequent exsanguination.
In this study, survivors had increased plasma endothe-
lin levels during the periods of lower torso ischemia and
reperfusion. Furthermore, more than halfof the survivors
had increased endothelin levels before operation. There-
was also a significant increase in endothelin levels after 6
hours of reperfusion in survivors and nonsurvivors. The
increased physiological insult of emergency ruptured AAA
repair may explain why, unlike previous studies of nonrup¬
tured AAA repair, elevated endothelin levels were detected
before, during, and after operation.
It is interesting to speculate from these data that the
F.T-dependent vasoconstrictor response to hemorrhagic
shock, ischemia, and reperfusion has a homcostatic and
protective role in ruptured AAA, in that patients who
manifest a good vasoconstrictor response (which is partly
due to endothelin) have a higher probability of survival
than those patients whose response is inferior. This
hypothesis would be in keeping with what most vascular
surgeons know intuitively: that is, intense vasoconstriction
(as well as "controlled" hypotension, aortic tamponade,
and the generation of a prothrombotic state) is one of the
principal mechanisms that allows patients with ruptured
AAA to reach the hospital in better clinical condition and
then undergo successful aneurysm repair.
The reasons for low endothelin levels in nonsurvivors,
as well as those patients in whom acute kidney failure-
developed, are not immediately obvious because ruptured
AAA repair is associated with many factors known to stim¬
ulate endothelin synthesis and secretion: intraoperative
hemorrhage and hemodilution, hypoxia, and metabolic
acidosis, increased sympathetic discharge and cate¬
cholamine release, increased cytokine and endotoxin
release, thrombin generation, and impaired renal excre¬
tion. In this study, there was no apparent difference in the
duration of symptoms of rupture, severity of preoperative
shock, duration of lower torso ischemia or perioperative-
hematocrit between survivors and nonsurvivors. Most
patients received renal-dose dopamine in the perioperative
period, but, unlike nifedipine, this has not been shown to
reduce plasma endothelin levels or maintain glomerular fil¬
tration rate in patients undergoing major aortic surgery.25
Havnes et al26 reported a significant, and similarly
Table II. Postoperative complications
Survivors Nonsurvivals



















unexpected, association between high plasma ET-1 levels
and survival in patients with cardiac arrest. They proposed
several explanations for their findings: poor peripheral
blood flow and local tissue acidosis may adversely affect
production and activity of ET-1, or lead to a local increase
in ET-1 that does not enter the circulation; increased
nitric oxide production may inhibit endothelin produc¬
tion; and reduced pulsatile shear stress may lead to selec¬
tive endothelial cell dysfunction. The low endothelin lex-els
demonstrated in nonsurvivors of ruptured AAA and car¬
diac arrest26 may therefore be an early manifestation of
irreversible whole body hypoperfusion. Studies from this
department have shown that survivors and nonsurvivors of
ruptured AAA repair have elevated plasma levels of the
endothelial products, tissue plasminogen activator and
plasminogen activator inhibitor.27 These and present data
lend support to the hypothesis that selective endothelial
cell dysfunction may lead to downregulation of the
endothelin response in some patients with ruptured AAA,
and this may predispose to the development of fatal organ
dysfunction.
Although most of the current literature concludes
that endothelin release has a pathologic role in critical
illness,13'18 the findings of this study do not support the
hypothesis that an increased endothelin response predis¬
poses to poor outcome in patients undergoing ruptured
AAA repair. Rv contrast, elevated perioperative endothelin
levels were associated with survival. Increased circulating
endothelin levels may occur as part of a homcostatic and
protective response to hemorrhage, ischemia, and reperfu¬
sion in patients with ruptured AAA, or alternatively, low
endothelin levels may be an early marker of severe and irre¬
versible whole bods- hypoperfusion in this group ofpatients.
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Elevated levels of soluble tumor necrosis
factor receptors are associated with
increased mortality rates in patients who
undergo operation for ruptured
abdominal aortic aneurysm
Donald J. Adam, FRCSEd, Amanda J. Lee, PhD, C. Vaughan Rucklcy, ChM,
FRCSEd, Andrew W. Bradbury, BSc, MD, FRCSEd, and James A. Ross, PhD,
Edin.hu rjjfj, Scotiand
Purpose: Elevated levels of soluble tumor necrosis factor receptors (sTNF-Rs) arc associ¬
ated with multiple organ failure and increased mortality rates in critically ill patients.
Paradoxically, experimental data suggest exogenous sTNF-Rs may improve outcome in
patients who undergo elective abdominal aortic aneurysm (AAA) repair. This study
examines, for the first time, changes in sTNF-R levels during repair of ruptured and
nonrupturcd AAA.
Methods: Sixteen patients who underwent surgical procedures for ruptured AAA and 10
patients who underwent surgical procedures for nonrupturcd AAA were studied. Levels
of sTNF-Rs p55 and p75 were measured before the operation and immediately before
and 5 minutes, 6 hours, and 24 hours after aortic clamp release.
Results: When compared with nonrupturcd AAA, levels of sTNF-R p55 were signifi¬
cantly higher in ruptured AAA 5 minutes (P < .02) and 24 hours after aortic clamp
release (P < .05). Levels of sTNF-R p75 were significantly higher in ruptured AAA
before (P < .05), during (P< .001), and after the surgical procedure (P < .01). Six hours
after aortic clamp release, sTNF-R p75 levels were significantly higher in nonsurvivors
of ruptured AAA when compared with survivors (P < .05) and patients who underwent
surgical procedures for nonrupturcd AAA (P < .01).
Conclusion: Ruptured AAA repair is associated with increased sTNF-R expression.
Furthermore, elevated levels of sTNF-R p75 arc associated with increased postoperative
mortality rates. (J Vase Surg 2000;31:514-9.)
The proinflammatory cytokine, tumor necrosis
factor (TNF), has been implicated in the pathophysio¬
logic features of the systemic inflammatory response
syndrome and multiple organ failure.1'2 TNF acts by
binding to target cells at specific TNF receptors (TNF-
Rs) of 55 kDa and 75 kDa molecular mass (p55 and
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p75), respectively.3'4 The binding of TNF leads to
cleavage of these receptors from target cells and their
release into the circulation as soluble TNF receptors
(sTNF-Rs),s and it has been suggested that the levels
of sTNF-Rs may reflect the degree of TNF-induced
tissue injury.6'7 The finding that high concentrations
of sTNF-Rs act as endogenous TNF antagonists and
that low concentrations may slow down TNF clear¬
ance, so prolonging its activity,7 has led to the sugges¬
tion that the administration of exogenous sTNF-Rs
may ameliorate the effects of TNF.
Circulating TNF has been demonstrated in elec¬
tive and emergency aortic surgery,8"16 and elevated
levels of sTNF-Rs have been detected in patients
who undergo repair of nonrupturcd abdominal aor¬
tic aneurysm (AAA) 16-17 and after the operation in
patients with ruptured AAA.16 To date, however, no
study has examined the levels of sTNF-Rs during the
periods of hemorrhagic shock, lower torso ischemia,
514
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and early repcrfusion, which occur in ruptured AAA
repair. This is clinically relevant because, although
experimental data suggest that the administration of
exogenous sTNF-R before aortic crossclamping is
associated with a reduction in circulating TNF and
subsequent lung injury in an animal model,18
human studies have shown that elevated levels of
endogenous sTNF-Rs are actually associated with
the development of multiple organ failure and
increased mortality rates in sepsis,19 pancreatitis,20
and multiple trauma.21 Although exogenous sTNF-
11 therapy may ameliorate the adverse effects ofTNF
in elective aortic surgery in which endogenous levels
are low, it may be ineffective if endogenous levels are
high in patients who undergo ruptured AAA
repair.19 The aims of this study were to examine ser¬
ial changes in sTNF-Rs occurring during emergency
repair of ruptured infrarenal AAA and to compare
the findings with patients who undergo elective
repair of nonruptured AAA.
METHODS
Patients. Sixteen patients (14 men and 2
women; median age, 75 years; range, 65-86 years)
who underwent operation for ruptured infrarenal
AAA and 10 patients (eight men and two women;
median age, 69 years; range, 58-80 years) who
underwent operation for asymptomatic nonruptured
infrarenal AAA were prospectively studied. Lothian
Region Ethical Committee approval and fully
informed written consent from all patients were
obtained. In patients who underwent operation for
ruptured AAA, the median delay between the onset
of symptoms of rupture and hospital admission was
5 hours (range, 3-14 hours). All patients had at least
one documented episode of hypotension (systolic
blood pressure less than 100 mm Hg) before the
surgical procedure. In patients who underwent an
operation for asymptomatic nonruptured AAA, the
median anteroposterior diameter of the aneurysm
measured by abdominal ultrasonography was 6.5 cm
(range, 5.5-8.0 cm).
Operative methods. Ruptured AAA was defined
as the presence of fresh retroperitoneal blood at the
time of the operation. Three patients had retroperi¬
toneal and intraperitoneal rupture. Patients with rup¬
ture were given general anaesthesia, and patients with
nonruptured AAA were given combined general and
epidural anesthesia. All patients underwent AAA
repair through a transverse supraumbilical incision
with infrarenal aortic clamping. A Dacron tube graft
was inserted in 17 patients (12 patients with rupture,
5 patients with nonrupture), aortobi-iliac graft in five
(one patient with rupture, four patients with nonrup¬
ture) and aortobifemoral graft in four patients (three
patients with rupture, one patient with nonrupture).
Aortic clamp time was defined as the time between
aortic clamp placement and the completion of the dis¬
tal anastomosis for patients who underwent tube graft
repair and the completion of the first and second dis¬
tal anastomoses for patients who underwent repair
with a bifurcated graft.
Sample collection. The pathophysiology of
ruptured AAA repair can be divided into three phas¬
es. First, there is a period ofwhole-body hypoperfu¬
sion as the result of hypovolemic shock. Second,
there is a period of profound lower body ischemia
after aortic clamp placement. Finally, if repair is suc¬
cessful, there is a period of repcrfusion. The sam¬
pling points were chosen to reflect the maximum
effect of each of the three pathophysiologic phases
of ruptured AAA repair. Blood was sampled from an
indwelling arterial line immediately before the
induction of anesthesia (sample A); immediately
before release of the aortic clamp (sample B); and 5
minutes (sample C), 6 hours (sample D), and 24
hours (sample E) after aortic clamp release. For
patients who underwent repair with a bifurcated
graft, sampling points C, D, and E were relative to
repcrfusion of the first limb. Blood (9 mL) was col¬
lected into a clot activator for the estimation of
serum levels sTNF-Rs p55 and p75. Samples were
placed immediately on ice and centrifuged within 30
minutes ofcollection at 3000 revolutions per minute
for 30 minutes at 4°C (equivalent to 1400/7). Serum
was separated and stored at -70°C for later batch
analysis.
Assays of soluble TNF receptors p55 and
p75. Scrum levels of sTNF-Rs p55 and p75 were
detected by enzvme-linked immunosorbent assay,
with monoclonal and polyclonal anti-sTNF-R p55
and p75 antibodies (donated by Dr W. A. Butirman,
Maastricht, The Netherlands).22 Purified sTNF-R
p55 and p75 were used to construct standard
curves. The lower limit of detection of the sTNF-R
p55 assay was 0.2 lig/mL and of the sTNF-R p75
assay was 2 ng/mL.
Statistical methods. The Mann-Whitney U
test was used to test whether the medians of two
samples were significantly different from each other
and to examine whether there was a difference in
assay levels between patients with ruptured AAA
who had (1) one or more cardiovascular complica¬
tions, (2) one or more respiratory complications,
(3) sepsis syndrome, or (4) renal failure compared
with patients who did not have these complications.
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Table I. Operative patient data
Ruptured AAA median (range) Nonrtiptured AAA median (range)
(n =16) (u =10) P value"
Preoperative
Crystalloid administration (L) 0.5 (0.1-4.0) — —
Colloid administration (I.) 0 (0-1.5) — —
ltraopcrativc
Operation time (rnin) 1 10 (70-250) 160 (85-285) N5
Total aortic clamp time (mill) 75 (30-180) 75 (30-150) NS
Tube graft (mitt) 69 (35-ISO) 77 (45-120) —
Bifurcate graft: first limb (min) 95(32-130) 68 (38-90) —
Bifurcate graft: second limb (min) 1 13(42-140) 71 (52-110) —
Measured blood loss (L) 3.1 (1.0-11.0) 2.4 (0.4-6.0) NS
Crystalloid administration (L) 2.3 (0.5-6.0) 1.9 (1.0-4.0) NS
Colloid administration (L) 1.5 (0-2.3) 1.5 (1.0-4.1) NS
Packed red blood cell administration (units)! 8 (5-22) 4 (0-10) .004
l-'rcsh frozen plasma administration (units)! 2(0-12) 0 (0-2) .0003
Platelet administration (bags)f 1 (0-1) 0(0-1) .0007
'Mann-Whitney Utest.
1300 ml..
+Onc bag of platelet transfusion = 4 pooled units (250 niL).
NS, Not significant.
The Krnskall-Wallis one-way analysis of variance was
used to examine whether assay levels changed sig¬
nificantly over the five sampling points in the rup¬
tured and nonruptured AAA groups separately. In
addition, the differences between the average rank¬
ings were examined to determine whether they
exceeded a precalculated critical value.25 In patients
who underwent operations for ruptured AAA,
Spearman's rank correlation was calculated between
the assay levels and the following clinicopathologic
variables: duration of symptoms before hospital
admission, volume of preoperative fluid resuscita¬
tion, preoperative serum creatinine level, operative
blood loss, volume of intraoperative fluid resuscita¬
tion (crystalloid and colloid and packed red blood
cells), and aortic crossclamp time. Multiple regres¬
sion was used to examine the independent effect of
these variables and the assay levels at each of the five
sampling points. Age and sex had forced entry, and
a forward-stepping procedure was used. A probabil¬
ity value ofless than .05 was regarded as statistical¬
ly significant. When levels of sTNF-lls were below
the limit of detection of the assay, the minimum
detection concentration was assigned to that sam¬
ple, and statistical analysis was performed with this
convention.20
RESULTS
Clinical data. Operative data for both groups of
patients are summarized in Table I. All patients with
ruptured AAA were admitted to the Intensive Care
Unit (ICU) for postoperative care and ventilatory
support. The median duration of ICU stay was 3
days (range, 0.5-24.1 days). The median duration of
ventilatory support was 0.9 days (range, 0.4-18.8
days), and seven patients received ventilatory sup¬
port for more than 4 days. All patients who under¬
went operations for nonruptured AAA were admit¬
ted to the intermediate care unit after the operation,
and no patient was admitted to the ICU or required
ventilatory support. Major postoperative complica¬
tions developed in 13 patients who underwent oper¬
ation for rupture and in 4 patients who underwent
operation for nonruptured AAA (Table II). Three
patients with rupture and six patients with nonrup-
ture had no postoperative complications. All patients
survived to 24 hours after repair. Five patients
(31.2%) with ruptured AAA died in the hospital.
There were no deaths after the repair of nonrup¬
tured AAA.
Assays of soluble TNF receptors p55 and
p75. The median values for sTNF-Rs p55 and p75
are shown in Table III. Both types of sTNF-R were
detectable at one or more sampling points in all
patients with ruptured AAA and in 9 of 10 patients
with nonruptured AAA.
Five minutes and 24 hours after aortic clamp
release, levels of sTNF-R p55 were significantly
higher in patients with ruptured compared with
nonrupturcd AAA. There was no significant change
in the levels of sTNF-R p55 as a function of time in
either group.
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Ac all sampling points, levels of sTNF-R p75
were significantly higher in patients with ruptured
compared with nonruptured AAA, and there was a
significant increase in the levels of sTNF-R p75 dur¬
ing reperfusion in both groups of patients (Table
III). Six hours after aortic clamp release, levels of
sTNF-R p75 were significantly higher in nonsur-
vivors of ruptured AAA (median, 14.6 ng/mL;
range, 9.7-18.0 ng/mL) compared with survivors
(median, 6.3 ng/mL; range, 2.1-18.5 ng/mL; P =
.036) and patients who underwent operation for
nonruptured AAA (median, 2.5 ng/mL; range, 2.0-
5.9 ng/mL; P= .002). There was no significant dif¬
ference in levels of sTNF-R p75 between nonsur-
vivors of rupture, survivors of rupture, and patients
who underwent operation for nonruptured AAA at
any other sampling point.
In patients who underwent operation for rup¬
ture, sTNF-R p55 levels immediately before (P =
.015) and 5 minutes after aortic clamp release (P-
.034) were significantly lower in six patients who
subsequently experienced the development of renal
failure compared with 10 patients who did not.
There was not a significant difference in sTNF-R
p75 levels among patients who did and did not have
cardiovascular complications, respiratory complica¬
tions, sepsis syndrome, or renal failure.
In patients who underwent operation for rup¬
ture, Spearman's rank test demonstrated a signifi¬
cant negative association between aortic crossclamp
time and sTNF-R p55 level immediately before aor¬
tic clamp release (r- -0.53), volume of preoperative
fluid resuscitation and sTNF-R p75 level at 24 hours
(r = -0.52), and volume of intraoperative packed red
blood cells and sTNF-R p75 level after 5 minutes of
reperfusion (r = -0.55). After adjustment for age
and sex, multiple regression analysis demonstrated
an independent association between aortic cross¬
clamp time and sTNF-R p55 level immediately
before (P = .028) and 5 minutes after aortic clamp
release (P = .028), volume of intraoperative crystal¬
loid and colloid resuscitation and sTNF-R p55 level
at 6 hours after aortic clamp release (P= .013), and
volume of preoperative fluid resuscitation and
sTNF-R p75 level at 5 minutes after aortic clamp
release (P= .008).
DISCUSSION
The present study has demonstrated, for the first
time, that hemorrhagic shock, lower torso ischemia,
and early reperfusion occurring in the course of rup¬
tured AAA repair are associated with elevated levels
ofsTNF-Rs p55 and p75 and that elevated levels of
Table II. Postoperative complications
R it[Hit red Nonruptured
AAA (n = 16) AAA (n = 10)
Cardiovascular
Atrial fibrillation 5 I
Congestive cardiac failure 5 2
Myocardial infarction 1 0
Stroke 2 0
I.ou'cr limb critical ischemia 3 1




Respiratory failure 5 0
Acute respiratory distress 1 0
syndrome
Acute renal failure 6* 1
Disseminated intravascular 2 0
coagulopathy
Sepsis syndrome 3 0
Colon ischemia 1 0
Total parenteral nutrition 5 0
Inotropic support
Adrenaline- 5 0
Renal dose dopamine 11 0
Reoperation 3t If
Total 13/16(81%) 4/10 (40%)
*Threc of six patients who experienced the development of acute
renal failure received hemoliltration.
|Patient 1, laparotomy for hemorrhage, femoral thrombectomy,
Hartmann's procedure for colon ischemia, drainage of infected
pelvic hematoma; patient 2, negative laparotomy for suspected
colon ischemia; patient 3, bilateral below knee amputations for
critical limb ischemia.
XPopliteal thrombectomy and fasciotomies.
sTNF-R p75 during the period of early reperfusion
are associated with increased postoperative mortality
rates. Furthermore, sTNF-Rs appeared rapidly after
the onset of hemorrhagic shock and lower torso
ischemia,24 a finding that is more indicative of a
direct relationship between sTNF-R levels and
increased mortality rates than in a previous study
where sTNF-Rs p55 and p75 levels were measured
daily for 5 days after operation.16
Studies that report the time course ofTNF and
sTNF-R release in response to lower extremity
ischemia and reperfusion are few and contradictory.
Animal studies have either demonstrated no signifi¬
cant increase in TNF levels during ischemia or reper¬
fusion,27 a transient increase within minutes of reper¬
fusion as the result of washout from the lower
extremities,28 or increased levels during ischemia but
not repcrfusion.18 Human studies that have included
a statistical analysis of the time course ofTNF release
have failed to demonstrate a significant increase dur¬
ing early reperfusion in elective aortic rcconstruc-
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tion.12"14 To date, two studies have examined sTNF-
R release before and after aortic aneurysm repair.
Froon et al16 measured sTNF-Rp55 and p75 levels in
21 patients with ruptured AAA and 9 patients with
nonruptured AAA and demonstrated significantly
higher levels of both sTNF-Rs in shocked patients
and nonsurvivors; Soong et al17 measured sTNF-R
p55 levels in 11 patients with nonruptured AAA and
demonstrated that levels were lower in four nonsur¬
vivors but that the postoperative increase was signifi¬
cantly greater at 48 hours when compared with sur¬
vivors. The present study is the first therefore to
examine sTNF-R release before, during, and early
after ruptured and nonruptured AAA repair.
Although there was no significant change in sTNF-R
p55 levels as a function of time, there was a significant
increase in sTNF-R p75 levels in both groups of
patients at 6 and 24 hours after aortic clamp release.
In contrast to the findings of Froon et al,'6 there
was no significant positive association between serum
creatinine and sTNF-R levels in the present study.
Moreover, sTNF-R p55 levels immediately before
and after aortic clamp release were significantly lower
in patients with ruptured AAA who later developed
renal failure compared with those patients who did
not. There was, however, no significant difference in
sTNF-R levels among patients with rupture who did
and did not have cardiovascular, respiratory, or septic
complications.
The association between elevated sTNF-R levels
and increased mortality rates in patients who under¬
went operation for ruptured AAA is similar to that
observed by other investigators in acute inflamma¬
tory conditions or severe injury.19 21 Elevated lev¬
els of sTNF-Rs may indicate that the endogenous
pool of sTNF-Rs is replete19 and this may partly
explain the disappointing results achieved with
exogenous sTNF-R p55 and p75 in patients with
sepsis syndrome and septic shock.25-26 It is not pos¬
sible to determine from the present study whether
therapeutic intervention with exogenous sTNF-Rs
would ameliorate the adverse effects of TNF in
lower extremity ischemia and ruptured AAA
repair.10'16-27-28 However, a recent animal study of
infrarcnal aortic crossclamping demonstrated a sig¬
nificant reduction in circulating TNF levels, nitric
oxide production, and subsequent lung injury when
exogenous sTNF-R p55 was administered before
aortic clamp placement.18 In the present study,
endogenous sTNF-R levels were significantly lower
in patients who underwent repair of nonruptured
AAA compared with those who underwent opera¬
tion for ruptured AAA. One can speculate that
exogenous sTNF-R therapy may ameliorate the
adverse effects of TNF in elective aortic surgery
where endogenous levels of sTNF-Rs are low but
may have limited efficacy in patients with hemor¬
rhagic shock before ruptured AAA repair,19 in which
the concentrations of sTNF-Rs observed in the pre¬
sent study would have been sufficient to effectively
antagonize the ef fects of circulating TNF in vitro.29
In conclusion, these data demonstrate that hem¬
orrhagic shock, lower torso ischemia, and early
repcrfusion that occur in the course of ruptured
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AAA repair are associated with elevated levels of" the
sTNF-lls and that elevated levels of sTNF-R p75
during the period of early reperfusion are associated
with increased mortality rates. The fact that the
endogenous pool of sTNF-lls may be replete and
that elevated endogenous levels are associated with
increased mortality rates suggests that sTNF-R ther¬
apy may have limited efficacy in patients who under¬
go ruptured AAA repair.
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